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Abstract 
 Intrinsically disordered proteins (IDPs) and intrinsically disordered protein regions 
(IDPRs) exist as interconverting conformational ensembles, without a single fixed three-
dimensional structure in vivo. The focus in the literature up to this point has been primarily 
on IDPs that are mostly or entirely disordered. Therefore, we have an incomplete 
understanding of the incidence and functional relevance of IDPRs in proteins that have regions 
of both order and disorder. This work explores these populations, by examining IDPRs in the 
Protein Data Bank (PDB) and in enzymes. By applying disorder prediction methods combined 
with an analysis of missing regions in crystal structure data, this work shows that enzymes 
have a similar incidence and length of IDPRs as do non-enzymes, and that these IDPRs are 
correlated with functions related to macromolecular metabolism, signaling, and regulation. 
Furthermore, extensive analyses of missing regions with conflicting information between 
multiple structures in the PDB show that, rather than experimental artifacts, this ambiguity 
most likely arises due to partially or conditionally disordered regions. This work documents 
the first proteome level study of protein intrinsic disorder in enzyme populations and 
demonstrates a novel way of analyzing missing regions in the PDB. Furthermore, an extensive 
literature search as part of this work provides information for 1127 IDPs with experimental 
evidence documented in the literature, 96 of which are enzymes. The results contained 
herein present a new model of the protein universe, where disorder is directed by evolution 
in both non-enzymes and enzymes to make the most of limited proteomes in complex 
organisms through complicated signaling networks and tightly controlled regulation.  
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1. Introduction to Intrinsically Disordered Proteins 
 
Note to reader 
 Portions of this chapter have been previously published in RSC Advances, 2016 
6(14):11513-11521, and have been reproduced with permission from the Royal Society of 
Chemistry.  
1.1 The Dominant Paradigms in Protein Science 
The dominant paradigms in protein science were, in many ways, shaped by the earliest 
experiments in the field. Those early experiments were constrained by many of the same 
limitations we have today. Can this protein be purified? Does it have consistency and 
simplicity in its function? Ultimately, the measures of success in the dominant methods of 
experimentation can direct scientific thought regarding what is most important in the study 
of proteins. As an example, early protein studies in the nineteenth century revolved around 
the easily obtained and easily crystallized protein hemoglobin. Myosin, also easily available 
and identified around the same time as hemoglobin, was largely ignored because it was not 
crystalline. Because of this, it would be another 100 years before we understood Myosin at 
even the most basic level. [1] 
Jacob Berzelius coined the term “catalysis” in 1836 [2], amidst intense interest in 
enzymes, which at that point had not yet been shown to be proteins. Emil Fischer 
demonstrated enzyme specificity, and established his seminal lock and key model in 1894 [3], 
a model that still dominates our understanding of enzyme catalysis today. Interestingly, 
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Fischer also proposed that proteins would prove to have a maximum size of 4000 amino acids 
in length [1], demonstrating the intuitive, and incorrect, speculations that follow from a 
strict adherence to the lock and key model. Experimental confirmation of the structure-
function relationship continued with early X-ray crystal studies of enzymes such as lysozyme 
[4] and ribonuclease-S [5], followed by Anfinsen’s demonstration that RNase A could be re-
natured with an accompanying restoration of function [6]. It is undeniable that the success of 
these early experiments helped to shape dominant ideas of well-behaved protein behavior, 
where well-behaved was synonymous with well-structured, with one singular function, and 
one mechanism of action. 
In many ways, these early experiments represented canonical examples of how 
proteins should be, which all further experiments were then held against. Therefore, protein 
behaviors that ran counter to the expected results were considered anomalies. That a protein 
could take an extended form with minimal residual structure was well understood due to 
numerous denaturation experiments. However, it was assumed that the native and functional 
state of a protein must have a stable structure. Therefore, results that ran counter to this 
assumption were typically considered a problem with the experiment or the experimenter, 
and not a result of the intrinsic properties of the protein. As these anomalies accumulated to 
the point where they could no longer be ignored, these problem proteins and problem regions 
were often seen as functionally irrelevant, and in many cases, removed before 
experimentation. 
1.2 Defining Intrinsically Disordered Proteins 
Even while the structure-function paradigm was strengthened in protein science, 
examples of intrinsically disordered proteins (IDPs) regularly appeared in the literature. 
Prompted by the increased application of optical rotary dispersion in the 1950s and 1960s to 
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the investigation of protein structure, Jirgensons suggested a classification scheme that 
included a category called “disordered.” [7] By this time phosphvitin [7], casein [8], and 
histones [9] had been shown to have unusual structural properties. In 1971, it was proposed 
that two regions of missing electron density in the X-ray crystal structure of staphylococcus 
nuclease were “disordered” [10] as well. However, as more IDPs were uncovered, a wider 
variety of terms were applied to describe the phenomenon. Tau was initially referred to as 
“natively denatured” [11], while alpha-synuclein was called “natively unfolded” [12]. Early 
reviews and theoretical work in the field used various terms as well, such as “intrinsically 
unstructured” [13], “natively disordered” [14] and “loopy” [15], among others. Vague terms 
such as “flexible” [16] and “mobile” [17] have a long history of hiding in the literature as 
well. In fact, until about 2005, the four most common terms “intrinsically disordered,” 
“intrinsically unstructured,” “natively disordered,” and “natively unfolded,” were all used 
about equally in the literature (Figure 1) [18]. However, after that time, due in part to a 
concerted effort in the field to use consistent terminology, the term “intrinsically disordered” 
became the predominant and agreed upon term.  
The field of un-structural biology has arisen to try to explain all cases of proteins that 
fall outside of the structure-function paradigm, and it is necessarily broad in scope because of 
this. Therefore, just as there have been challenges in reaching a consensus on terminology, 
there have also been similar challenges in defining protein intrinsic disorder. However, 
despite these challenges, several common definitions have emerged. 
Different definitions of IDPs emphasize different experimental and theoretical 
perspectives. An IDP may be described as having little or no ordered secondary or tertiary 
structure. This definition emphasizes an IDP’s difference from proteins as understood by the 
tools of structural biology. An IDP may also be described as under-folded, or as failing to fold 
independently. This definition emphasizes that an IDP may have the same physical properties 
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as the unfolded state or as a folding intermediate of an ordered protein, such as random coil, 
molten globule, or pre-molten globule. Finally, it has become increasingly common to focus 
on the ensemble nature of IDPs when defining them. This places IDPs in the context of 
behavior that can increasingly be measured by NMR. The properties of IDPs are typically 
described as being present in vivo, in vitro, or under functional conditions. This is to 
emphasize that IDPs display their structural properties in a functional, native state. 
 
 
Figure 1. The usage of IDP terminology in PubMed abstracts. The occurrence of each IDP term was 
counted for each year in abstracts of articles in PubMed associated with 1127 known IDPs.  
 
It is interesting to note that all of these definitions do not place disordered proteins in 
a single opposite position from ordered proteins, but instead place ordered and disordered 
proteins at different points on a continuum. This is clearer, when we understand that both 
ordered and disordered proteins have movement at the atomic level and about their 
Ramachandran angles. However, in ordered proteins this motion is sufficiently small that a 
consensus position can be inferred. On the other hand, an intrinsically disordered protein has 
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movement that precludes the collapse into a single point, both at the ensemble and 
individual protein level. 
From these definitions, one can extrapolate a theoretical definition based on theories 
of protein folding. If a protein folds into its lowest energy conformation, then we can define 
an IDP as a protein that does not have a single global minimum in conformational space [19] 
or alternately, IDPs can be described as having a relatively flat free energy surface [20]. 
Unfortunately, this theoretical definition cannot currently be characterized experimentally 
for structured or disordered proteins.  
Finally, it is necessary to distinguish proteins that are mostly or fully disordered from 
proteins with isolated regions of disorder. The term IDP is used to refer to proteins that are 
fully disordered, or contain long, defining regions of disorder. In contrast, when a protein is 
mostly structured but displays some regions of disorder, it is said to have intrinsically 
disordered protein regions (IDPRs). Proteins that contain a mix of ordered and disordered 
regions are also called hybrid proteins. In this work, I will attempt to distinguish IDPs from 
proteins with IDPRs, however for brevity the term IDP(s) will be used when referring to a set 
of proteins with varying levels of disorder, or when the disordered properties of a particular 
protein are being emphasized.  
1.3 The Subtler Side of Disorder 
 In much the same way that protein science has been shaped by the dominant 
experimental methods, so too has the field which specializes in studying protein intrinsic 
disorder. Early measurements of protein intrinsic disorder were obtained by low-resolution 
methods such as optical rotary dispersion and circular dichroism. These methods cannot 
measure individual regions of disorder, but only the structural properties over the whole 
protein. X-ray crystallography can indicate small regions of possible disorder by their absence 
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in the resolved three-dimensional structure, but cannot establish the cause. Therefore the 
early emphasis in the field was on proteins that are mostly or fully disordered in vitro or in 
vivo, such as Myelin Basic Protein [21], alpha-synuclein [12], MAP2 [22], and tau [11]. 
Aside from the experimental challenges, there are additional reasons why the IDP 
literature has remained focused on highly and consistently disordered proteins. Acceptance of 
the relevance, and even the existence of IDPs and IDPRs has not yet solidified in the 
literature. Discussions of IDPs in textbooks are still largely absent, with a few exceptions in 
the last five years [23]. The citation aggregator PubMed did not add “intrinsically disordered 
proteins” to its MeSH (Medical Subject Headings) terms until 2014. The number of papers in 
the body of literature covering IDPs that actually use IDP terminology is still a fraction of a 
percent (Figure 2).  
 
Figure 2. The fraction of PubMed IDs using IDP terminology by year. The fraction for each year is 
calculated by the number of PubMed IDs associated with IDPs that use IDP language, divided by the 
total number of PMIDs associated with the IDP proteins in the set. High confidence IDPs are those that 
have an extensive amount of experimental evidence verifying that the protein is intrinsically 
disordered. 
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Despite this, the rise of NMR and sequence-based bioinformatics methods has greatly 
expanded the experimental and theoretical literature on the topic of IDPs [23]. We now have 
the experimental tools to begin to characterize subtler categories of disorder, such as 
conditional disorder and partial disorder. A protein that is conditionally disordered is either 
ordered or disordered based on the environmental context or interaction partner. It is a term 
that encompasses both disorder-to-order transitions and transient (or cryptic) disorder, which 
is functionally relevant disorder that arises from structured regions (order-to-disorder) [24]. 
Furthermore, an increasing number of examples of small, but important IDPRs are appearing 
in the literature as can be seen in Figure 3 (red square).  
 
Figure 3. The fraction of predicted disorder versus the fraction of PubMed IDs that use IDP 
language. Each blue dot represents a protein. The percent predicted disorder is plotted against the 
fraction of PubMed IDs that use intrinsic disorder language divided by all PubMed IDs associated with 
that protein search term. For each fraction of predicted disorder interval (0-10%, 10-20%, etc.), the 
fraction of the total proteins in that interval is plotted in red. The mean of the fraction of disorder 
PubMed IDs is plotted for each fraction of disorder interval in black. 
1.4 The Line Between Order and Disorder 
The emphasis in this work is on populations of proteins that display the properties of 
both structure and disorder, specifically proteins that have been at least partially 
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crystallized, and enzymes, which will have a structured catalytic region in most cases. While 
structure and disorder are often treated as binary states, they actually sit on a continuum. 
This work concerns proteins that exist in the middle of the structure-disorder continuum, 
therefore it is useful to identify the conceptual line between a structured and disordered 
protein or protein region, and explore why it is necessary to use the tools and language of 
disorder when structure is present.  
When attempting to semantically separate structure from disorder, it becomes clear 
that neither the term “structured” nor “disordered” is precisely correct. All proteins have 
some movement, and no protein is completely chaotic. Because these are conceptual 
frameworks that do not point to precise biological realities, the tools of structural or un-
structural biology should be applied when most useful to solve the problem. The separating 
line between order and disorder is therefore drawn not by theoretical descriptions, but by 
practical considerations. 
When a protein can no longer be adequately described by a single three-dimensional 
structure or a series of snapshots in three dimensions, then the language of disorder has now 
become useful. IDPs are defined by conformational uncertainty, and are typically 
characterized by a combination of sequence level features and a description of the overall 
shape, i.e. extended, random coil, molten globule, or pre-molten globule. Additionally, an 
IDP that changes shape must also be described using the axis of time, and it is along this axis 
that structural biology and un-structural biology most acutely diverge. The introduction of a 
time variable greatly increases the possibilities when describing IDPs and IDPRs, and it is also 
change over time that allows us to describe the mechanisms that IDPs may employ and the 
advantages imparted by disorder. 
As an example, short segments of disorder are commonly observed in the form of 
hinges that move a domain in a controlled way, or loops that have an open and closed 
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conformation, such as the WPD loop in the bacterial protein tyrosine phosphatase YopH [25]. 
While these regions are technically disordered, the ability to describe the movement as a 
series of structural snapshots, typically places these dynamic movements within the realm of 
structural biology. However, other small disordered segments called Molecular Recognition 
Features (MoRFs) [26], which undergo a contextual transition between disorder and order 
upon binding, have a function that is defined by the presence of disorder and the transition to 
an ordered state, and not by a specifically defined three-dimensional structure. Therefore, 
even despite their short lengths and disorder-order transitions, MoRFs fall within the realm of 
un-structural biology. 
Furthermore, whether a protein is considered to be an IDP or to have an IDPR is largely 
determined by the functional significance assigned to the disorder. Disordered regions that 
have no known function are often considered to be functionally neutral sequence noise. An a 
priori assumption that a disordered region is function-neutral can create circular support for 
itself if this region is removed before experimentation, therefore the identification of 
disorder specific functions is of critical importance.  
1.5 The Mechanisms of Disorder 
A great deal of experimental and theoretical work has been done in order to 
illuminate how IDPs and IDPRs fit within a functional protein universe. When viewed within 
the context of finely regulated interaction and signaling networks, where proteins may need 
to display multiple context dependent behaviors, the advantages of disorder begin to become 
clear. While many historical examples of the functional properties of IDPs and IDPRs have 
come from studies of non-enzymes, an increasing number of more recent studies have shown 
that these functional advantages are also demonstrable in enzymes. 
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1.5.1 Entropy 
Entropic functions make use of the advantages inherent in dynamic movement within a 
disordered protein chain. Entropic chains can provide precise spacing between functional 
domains, creating a less restricted search space, maintaining separation between domains, or 
creating the opportunity for two or more domains to interact with each other, or with 
another partner. Two enzymes with kinase domains demonstrate the utility of a disordered 
interdomain linker. The kinase Yck2 has a long disordered interdomain linker that allows the 
kinase domain and a conserved C-terminal peptide (CCTP) domain to interact with two 
separate Akr1 domains simultaneously [27], while a disordered interdomain linker in 
Phototropin 2 becomes elongated when exposed to blue light irradiation, preventing the LOV2 
domain from making contact with and activating the kinase domain [28] (Figure 4). 
Additionally, there are non-enzyme examples of entropic clock functions, such as the voltage-
gated potassium channel of nerve axons which uses a ball and chain mechanism to inactivate 
the channel [29]. Entropic bristles use entropy to fill space as is seen in the gating of the 
nuclear pore complex through the repulsion caused by disordered nucleoporins [30]. 
 
 
Figure 4. Entropic chain functions. A) Yck2 (in blue) uses a disordered interdomain linker to bind to 
two separate domains on Akr1 (in orange). B) The disordered interdomain linker in Phototropin 2 (in 
green) becomes elongated when irradiated with blue light, causing the activating LOV2 domain to 
separate from the kinase domain. 
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1.5.2 Accessibility 
Posttranslational modification (PTM) requires site accessibility, so it is therefore not 
surprising that many PTM sites are embedded in disordered regions, which can provide a large 
surface area with a limited number of residues. Phosphorylation sites in particular have been 
shown to be enriched in disordered residues [31]. Most well-known IDPs have phosphorylation 
sites, and they have been demonstrated in the IDPRs of enzymes as well. For example, the 
intrinsically disordered Cap region of both Abl and Arg non-receptor tyrosine kinases is rich in 
phosphorylation sites that regulate multiple domains [32].  
Site accessibility is also required for proteolytic processing that generates protein 
fragments with altered activity. For example, the phosphatase calcineurin contains an 
intrinsically disordered regulatory domain that is susceptible to proteolytic cleavage in vitro 
[33] and in vivo [34] that significantly increases its activity.  
1.5.3 Plasticity 
Some of the most striking functional advantages of IDPs and IDPRs come from their 
ability to contextually change due to binding or environmental cues. IDPs and IDPRs may 
change shape in response to interactions with proteins, nucleic acids, and other ligands, 
allowing them to specifically bind a wide variety of partners. For example, the disordered 
loop near the active site of Mitochondrial 2,4-Dienoyl-CoA reductase allows this enzyme to 
accommodate a wide range of fatty acids [35]. Protein Kinase R has two intrinsically 
disordered interdomain regions that may allow it to effectively dimerize when interacting 
with a RNA activators of varying size and shape [36]. Plasticity may also be helpful in 
identifying and negotiating disordered regions in substrates, and appears to play an important 
role in ubiquitination pathways. For instance, E3 ubiquitin ligases that bind both substrates 
and E2 ubiquitin conjugating enzymes, are significantly more disordered than those that 
engage in single interactions [37]. 
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1.6 Biological Functions  
The biophysical mechanisms used by disordered regions are disproportionately 
connected to particular biological roles, such as signaling and molecular and cellular 
regulation [38]. This is not surprising, considering the ability of disordered regions to change 
over time and to adapt based on the environmental context. 
1.6.1 Signaling  
Signaling pathways provide a way for complicated biological systems to coordinate 
physiological activities and responses. Signaling pathways can usually be described as a linear 
cascade of interactions that triggers some kind of change in the cell. Frequently PTMs such as 
phosphorylation play a key role in this, and disorder frequently plays a role both in the 
accessibility of PTM sites, and the activity of kinases [39]. Key sequence signals may be 
encoded in disordered sequences, such as in sulfhydryl oxidase ALR which has an IDPR that 
acts as a mitochondrial targeting signal in the cytosol and a recognition site in the disulfide 
relay system of the intermembrane space [40]. Receptors, which are often a starting point for 
a signaling cascade, may have IDPRs that expose phosphorylation sites or bind to signaling 
molecules as is seen in the receptor tyrosine-protein kinase ErbB2 [41].  
1.6.2 Regulation 
 IDPs are frequently involved in regulation at the cellular level through involvement in 
gene transcription [42] and protein degradation [37, 43], and at the protein level, through 
allosteric effects or PTMs that result in the masking and unmasking of interaction sites. As an 
example, phosphorylation of the IDP 4E-BP2 acts as a regulatory switch by inducing a 
disorder-order transition and preventing binding with eIF4E [44]. Conversely, regulation of 
glucokinase is facilitated by an order-disorder transition that causes a time-delay when 
glucose is low [45].  
13 
 
 IDPs are also abundant in protein degradation pathways. There are a number of E3 
ubiquitin-protein ligases which have long stretches of disorder that appear to mediate 
interactions with a variety of mostly disordered substrates [37]. For example, San1 is an E3 
ubiquitin-protein ligase which has extended disorder in its N and C terminal substrate binding 
regions. Interestingly, San1 avoids auto-ubiquitination through the absence of lysines in its 
disordered binding regions [46]. Ubiquitin-independent protein degradation pathways also 
involve disordered protein regions. The enzymes thymidylate synthase and ornithine 
decarboxylase both contain IDPRs that appear to contain the sole requirements for ubiquitin 
independent degradation [43].  
1.7 Disorder and Protein Evolution 
 The evolution of protein coding regions in genomes presents a fundamental mystery. 
The human genome, the genome of the flowering plant Arabidopsis thaliana, and the genome 
of the protozoa Tetrahyma are all estimated to have approximately 27,000 - 29,000 protein 
coding regions. On the other hand, Danio rerio (zebrafish) and Mus musculus have close to 
40,000 protein coding regions each [47]. It is clear that protein coding regions do not scale 
linearly with organismic complexity. One compelling explanation for this is that protein 
intrinsic disorder combined with alternative splicing facilitates tightly regulated and context 
specific multi-functional behavior that allows more complicated organisms to make the most 
of a limited genome [42, 48]. 
 There are several pieces of evidence to support a hypothesis of evolutionarily directed 
functional disorder. Bioinformatics analyses show that eukaryotes are more disordered than 
prokaryotes [49], natural sequences are more disordered than random sequences even with 
the same amino acid composition [50], and disorder within natural sequences is non-random 
in its patterns [51]. Disordered regions tend to evolve more rapidly while maintaining their 
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physiological functions [52], therefore, functional disorder may provide an advantage by 
buffering a genome against mutations. Finally, it can be argued that complex signaling 
networks and finely tuned regulatory mechanisms are themselves a response to organismic 
complexity, therefore the overrepresentation of IDPs and IDPRs in signaling and regulation 
also supports the hypothesis of the directed evolution of disorder in genomes. Interestingly, 
some protists have more disorder than multicellular eukaryotes, suggesting there may be an 
optimal amount of disorder for an organism that is partly based on lifestyle [49]. 
1.8 The Tools of the Un-Structural Biologist  
 The work herein focuses on computational analysis, however these results sit upon a 
foundation of decades of experimental work. The study of IDPs and IDPRs requires a large 
number of experimental and computational methods, and typically the results of these 
experiments combine together to form a picture of the disorder properties over the protein 
and the proteome (Figure 5).  
 
Figure 5. Experimental and Bioinformatics techniques work together to describe the properties of 
disorder in proteomes and proteins. 
 
1.8.1 Experimental techniques 
 1.8.1.1 X-Ray crystallography. It is somewhat surprising that X-ray crystal structures 
provide one of the largest datasets of experimentally indicated IDPRs, considering that X-ray 
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crystallography is one of the primary tools of structural biology. However, missing regions in 
X-ray crystal structures are often caused by IDPRs. The challenge with using this data, 
however, is that missing regions are an imperfect indication of protein intrinsic disorder, as 
there are multiple possible explanations for a missing region, including experimental artifacts 
or annotation errors (for more on this, see Chapter 2). Furthermore, authentic IDPRs 
identified in X-ray crystal structures will be non-representative in terms of the size of the 
region and the amino acid composition, due to their emergence from a very structured set of 
proteins. The decision to use X-ray crystal structure data as an indication of disorder, must 
therefore be made by balancing the usefulness of a large amount of data against the 
imperfections in the data.  
 1.8.1.2 Nuclear Magnetic Resonance. Nuclear Magnetic Resonance (NMR) is arguably 
the current best experimental technique for identifying protein intrinsic disorder and 
conformational ensembles. The key differences that make NMR superior to X-ray 
crystallography for identifying IDPs are that NMR does not require crystallization and NMR can 
provide direct observation of disorder instead of simply indicating a lack of structure. 
However, there are limitations in the size of the protein that restrict the applicability of 
NMR, and the amount of NMR data is still significantly less than the amount of X-ray crystal 
structure data.  
 Identifying IDPs and IDPRs using NMR can be accomplished through several different 
approaches. A collapsed heteronuclear single quantum coherence spectroscopy (HSQC) NMR 
spectrum will indicate disorder over the entire protein, whereas a dispersed spectrum will 
indicate a structured protein. NMR techniques can also be used to generate conformational 
ensembles and multiple methods can be employed to measure the differences between 
ensembles [53, 54]. Additionally, chemical shift and 15N (1H) Nuclear Overhauser Effect (NOE) 
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data can provide flexibility information without the requirement for any structural models 
[55].  
 1.8.1.3 Combining experimental techniques. The number of experimental 
techniques that can be used to study IDPs is extensive, and in fact multiple books [56, 57] and 
reviews [58, 59] have been dedicated to this topic. In practice, multiple techniques of varying 
resolution are typically employed and the aggregated evidence is used to create models of 
the disordered regions. These include low-resolution spectroscopic techniques such as circular 
dichroism, optical rotary dispersion, Fourier-transform infrared spectroscopy, and deep-UV 
resonance Raman spectroscopy. Additionally, the level of protein compaction can be 
measured by small angle X-ray scattering, small angle neutron scattering, gel-filtration, and 
viscometry. The properties of individual protein molecules can help identify ensemble 
properties and can be obtained via high speed atomic force microscopy (AFM), and single-
molecule fluorescence resonance energy transfer (SM-FRET). 
1.8.2 Bioinformatics analysis 
 Bioinformatics tools and analysis have played a large part in the study of IDPs and the 
establishing of the field. The tools used to study IDPs typically focus on extracting information 
from protein sequences, however genome studies focusing on the evolution of IDPs and the 
enrichment of splicing sites in disordered regions are common as well [60, 61]. Several recent 
reviews have been written focusing on different aspects of bioinformatics analyses of IDPs 
such as the discovery of degenerate motifs in IDPs [62], predicting function in IDPs [63], and 
the prediction of IDPs by protein sequence [64]. Indeed, the computational tools used to 
analyze IDPs and IDPRs are as vast as the experimental tools. Therefore, a brief introduction 
will be provided here of the methods used in this work.  
 1.8.2.1 Sequence characteristics. Because of the lack of a stable three-dimensional 
structure, the computational study of IDPs and IDPRs is predominantly dependent on primary 
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sequence information. Anfinsen’s dogma suggests that the three-dimensional structure of a 
protein is encoded into the primary sequence [65], however the accurate prediction of the 
folded structure from primary sequence remains elusive. Tools to predict disorder from 
primary sequence have been much more successful, however. This is intuitive from the 
perspective of entropy. A three-dimensional structure has only one form that it can take, 
whereas the conformational fluctuations that can define a disordered protein are nearly 
infinite in their possibilities within steric limitations, therefore predictors of disorder require 
less information than predictors of structure. 
 IDPs have distinct sequence characteristics that facilitate the identification of disorder 
from sequence. IDPs are enriched in specific disorder promoting residues, such as alanine, 
glycine, serine, proline, glutamine, glutamic acid, lysine and arginine, and they are depleted 
in the order promoting residues isoleucine, valine, leucine, phenylalanine, cysteine, 
tryptophan, tyrosine, and asparagine  [66, 67]. These residues are roughly correlated with 
flexibility [68] and hydrophobicity scales [69] (Figure 6). 
 
Figure 6. Amino acid scales and disorder and order promoting residues. Top) Ranking of the 20 
amino acids by the Kyte-Doolittle hydrophobicity scale from most to least hydrophobic. Bottom) 
Ranking of the amino acids from most to least flexible by Vihinen’s flexibility scale. 
 
 Low complexity regions are often disordered, and disordered regions are often 
enriched in low complexity motifs. However, neither disorder nor low complexity necessarily 
implies the other [70]. Disordered regions tend to have lower sequence conservation in 
families, however there are also well conserved disordered domains [71]. Furthermore, in 
poorly conserved disordered regions, the chemical composition is often preserved [72, 73].  
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 1.8.2.2 Disorder prediction. The distinct sequence features that are present in IDPs 
and IDPRs allow the construction of sequence based rules that can facilitate high performance 
disorder prediction. Over 70 predictors of disorder have been created since 1997 [73, 74]. A 
favorable balance between true positives (TP) / true negatives (TN) and false positives (FP) / 
false negatives (FN) is the objective, and this is typically expressed by the Matthews 
Correlation Coefficient (MCC).  
𝑀𝐶𝐶 =
𝑇𝑃 ∗ 𝑇𝑁 − 𝐹𝑃 ∗ 𝐹𝑁
√(𝑇𝑃 + 𝐹𝑃)(𝑇𝑁 + 𝐹𝑃)(𝑇𝑃 + 𝐹𝑁)(𝑇𝑁 + 𝐹𝑁)
 
 The Critical Assessment of protein Structure Prediction (CASP) competition judges 
disorder predictors based on as yet unpublished disordered regions, which are usually 
obtained from missing regions in newly published X-ray crystal structures [75]. The highest 
ranking predictors in the CASP experiment have an MCC of approximately 0.5 and these 
results are usually achieved by slower predictors that use multiple sequence alignments along 
with sequence based features such as amino acid composition and the physicochemical 
properties of the amino acids. These slow but high performing predictors, such as Protein 
DisOrder prediction System (PrDOS) [76], Sequence based Prediction with Integrated Neural 
network for Disordered residues (SPINE-D) [77], and DISOPRED3 [78] are best for small 
datasets and single protein prediction. Large datasets, however, require the use of faster 
predictors that can be run on a local computer, such as Espritz [79], and IUPred [80, 81]. 
 Disorder predictors must be trained and tested on datasets of experimentally 
indicated disordered residues. These datasets commonly come from Disprot [82], X-ray crystal 
structures in the PDB [83], or NMR data. Most disorder predictors will give a per-residue 
disorder score between 0.0 and 1.0, and the generally agreed upon threshold for disorder is 
greater than or equal to a score of 0.5. Some disorder predictors, such as SLIDER [84] or 
RAPID [85], will provide fast prediction for complete proteomes, by calculating a single score 
across the entire protein. Other predictors may provide a score that is calibrated differently, 
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such as DynaMine which produces scores in the form of backbone N-H S2 order parameter 
values [55, 86]. When using DynaMine, a score below 0.7 is considered flexible. 
 Meta-predictors, which combine the outputs from multiple single predictors are also 
common, such as PONDR-FIT [87] and MetaDisorder [88]. A consensus of multiple predictors 
can provide improved results [89], as it will theoretically reduce the bias inherent in single 
predictors that were trained on limited datasets. However, despite a modest improvement 
through consensus methods, disorder prediction based on currently available datasets has 
likely hit a bottleneck in terms of the maximum possible MCC scores.  
This limitation arises in part due to the imperfections in the testing and training sets 
for the development of disorder prediction. Experimental indications of disorder are gathered 
over a wide range of experimental techniques, including low resolution techniques such as 
circular dichroism which may not provide accurate estimates of the exact disordered 
residues, X-ray crystallography, which only provides an indication of disorder, but may be 
caused by other factors, and NMR, which requires significant, and therefore variable 
interpretation in order to assign disorder. A second issue, which further compounds this, is 
the presence of conditionally and partially disordered regions, which may be assigned as 
ordered or disordered, depending on the experiment. Finally, it is likely that there are 
different flavors of disorder [90] with different sequence based markers, yet a clear 
classification scheme has not yet been created.  
Disorder prediction should be employed in analysis with an appropriate awareness of 
the inherent level of error. However, despite these considerations, disorder prediction still 
provides a way to separate unique sequence regions that indicate a propensity towards 
disorder, and provides a useful level of biological accuracy, especially at the proteome level. 
While individual residues may not be assigned correctly in all cases, disorder prediction still 
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provides an illuminating look into the propensity of the protein to be solvent exposed, to 
undergo dynamic transitions, or to be destabilized by environmental factors.  
 1.8.2.3 Classification of function. There appears to be a relationship between 
biophysical function, cellular function, and sequence characteristics, however the 
identification and development of these relationships is still in its early stages [91]. 
Therefore, a major task in bioinformatics is to attach biological sequence information to 
physical behavior, biological functions, and cellular response. Functional classification based 
on sequence requires two sets of information. The first is sequence based features. These 
may be disorder prediction scores, calculations based on the physicochemical features, or 
amino acid motifs. The second set of information is functional annotation. Gene Ontology 
(GO) term assignments are one of the primary sources of annotations related to cellular 
components, biological processes, and molecular functions [92]. GO terms can be assigned 
based on experimental evidence, or can be inferred based on homology. Additionally, Enzyme 
Commission (EC) numbers provide a useful annotation protocol when classifying enzymes [93]. 
EC numbers are assigned based on the chemical reaction that is catalyzed by the enzyme. 
Similar to GO terms, EC designations can be made based on direct experimental evidence or 
can be inferred through sequence homology.  
1.8.2.4 Proteome level studies. The early assumption in protein science was that 
protein intrinsic disorder represented an unusual and isolated phenomenon. In fact, it can be 
argued that this assumption is still held by many researchers today [18]. Therefore, the 
application of disorder prediction to whole proteomes has been critical to establishing the 
ubiquity and relevance of protein intrinsic disorder while the tools for large scale 
experimental identification are still nascent. Despite differences in the disorder predictors 
used, the proteomes they have been applied to, and the different measures applied,  the 
consensus is that eukaryotes tend to have more predicted disorder than prokaryotes or 
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archaea [49], and within eukaryotic proteomes especially, intrinsic disorder is exceptionally 
common [94]. For instance, Ward et al. found that 2.0% of archaean, 4.2% of eubacterial and 
33.0% of eukaryotic proteins had disordered regions greater than 30 residues in length [95]. 
Estimates of the average fraction of disorder for eukaryotic proteomes tends to be between 
20-30%, while prokaryotes tend to be closer to 5-10%, however there is significant variation 
and overlap in disorder prediction between the taxa [49, 94]. 
1.9 Protein Intrinsic Disorder and Disease 
 In 2008, Uversky et al. introduced the disorder in disorders (D2) concept, and showed 
that proteins with IDPRs greater than thirty residues in length are overrepresented in proteins 
involved with signaling, cancer, neurodegenerative diseases, cardiovascular diseases, and 
diabetes [96]. While this relationship may suggest innate pathogenicity in IDPs and IDPRs, 
studies suggest instead that IDPs and proteins with IDPRs perform tightly regulated [97] and 
necessary functions, many of which depend on the lack of a three-dimensional structure [98]. 
However, as is the case in structured proteins, genetic, environmental, or systemic 
perturbations can make IDPRs and IDPRs susceptible to misfolding and misregulation.  
 Some of the most well-known examples of disease related IDPs are implicated in 
neurodegeneration, such as tau, alpha-synuclein, beta amyloid, and prion protein [99]. 
Flexibility in these proteins can facilitate perturbations into misfolded, aggregated states, 
and therefore the disease state is directly related to a structural transition facilitated by the 
disordered properties of the protein. However, there are also a myriad of potential roles that 
IDPs and IDPRs can play in disease processes. The pathogenic behavior of an IDP or protein 
with an IDPR may be triggered by genetic factors such as pathogenic mutations, alternative 
transcription, or aberrant splicing, or non-genetic factors such as altered protein expression 
levels, PTMs, or aberrant cleavage. These cellular changes may result in misfolding, loss of 
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normal function, gain of toxic function, protein aggregation, misidentification, misregulation, 
or missignaling (reviewed in [100] and [96]).  
 While uncommon, there are some interesting examples of disease associated enzyme 
IDPs in the literature. For instance, virulence factors with catalytic domains may utilize long 
IDPRs to translocate or avoid host defense systems. The adenylate cyclase toxin in Bordetella 
pertussis provides an interesting example of this phenomenon. The adenylate cyclase toxin 
contains a Repeat in ToXin (RTX) motif, which is intrinsically disordered in the absence of 
calcium inside the bacterial cell. This allows the enzyme to translocate the catalytic domain 
across the narrow type 1 secretion channel, and then transition to a globular structure when 
exposed to the calcium gradient on the bacterial cell wall [101] (Figure 7). 
 
Figure 7 A schematic representation of the secretion of adenylate cyclase toxin through the type 1 
secretion system. Reprinted under the creative commons license from Sotomayor-Pérez AC, Ladant D, 
Chenal A: Disorder-to-order transition in the CyaA toxin RTX domain: implications for toxin secretion. 
Toxins (Basel) 2015, 7(1):1-20 
 
The human acetylcholinesterase variant, AChE-R, provides an interesting counter point 
to IDPR associated pathology. The AChE-R variant has an intrinsically disordered C-terminus, 
and the presence of this disordered region appears to provide neuroprotective effects in 
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Alzheimer’s disease as compared to the AChE-S variant, which has a helical C-terminus, and 
appears to accelerate the formation of amyloid fibrils [102]. It is likely that many examples of 
enzymes with IDPRs that are involved in disease processes in both pathogenic and protective 
capacities will emerge with the increased acceptance of the functional roles that IDPRs in 
enzymes may play. 
1.10 Protein Intrinsic Disorder and Drug Design and Discovery 
 The enrichment of long IDPRs in proteins associated with disease processes presents a 
rich source of potential drug targets, however there are several challenges in drug design and 
discovery when IDPRs are targets. Secure binding to a small molecule requires stabilization in 
the binding site, and this may not be possible in all IDPRs. However, functional IDPRs will 
often take on transient structure due to binding or environmental factors which suggests that 
inducible structure may be possible in many cases. In proteins that are mostly disordered in 
their native state, the disorder can be understood as a population of many interconverting 
conformations, with the potential to stabilize a single non-pathogenic conformation. The 
investigation of natural compounds with known effects on IDPs can provide a powerful route 
to discovery. For instance, the consumption of coffee appears to provide some protection 
against the development of Parkinson’s disease. A study on the effects of caffeine on alpha-
synuclein aggregation showed that caffeine modifies the conformation of the monomer form, 
thus accelerating the aggregation of a less toxic species [103] (Figure 8).  
 Drug design and discovery in IDPRs may be more akin to navigating a handshake than 
placing a lock in a key, however many of the principles of design and discovery are still the 
same. When stabilizing binding partners are not known, a clear challenge is the absence of a 
priori knowledge of the three-dimensional structure for in silico screening or rational drug 
design of favorable compounds. This challenge is not insurmountable however, as blind 
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exploratory assays are standard in drug discovery, and the presence of an IDPR should not 
prohibit these kinds of screens. Instead, the biggest challenge in drug discovery for IDPRs may 
be the standard practice of the exclusion of IDPRs before drug screens. 
 
Figure 8 A schematic representation of the effects of caffeine on the aggregation properties of 
alpha-synuclein. Reprinted with permission from Kardani J, Roy I: Understanding Caffeine's Role in 
Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease. ACS 
Chem Neurosci 2015, 6(9):1613-1625. Copyright 2015 American Chemical Society.  
 
1.10.1 The story of PTP1B 
 The phosphatase PTP1B (Figure 9) provides an illustrative example of delayed drug 
discovery for an IDPR due to the consistent truncation of the region before drug screens. The 
catalytic region of PTP1B, encompassing residues 1-321 was purified in 1988 from the human 
placenta [104], and in 1990 the full length form of 435 residues was uncovered through cDNA 
cloning [105]. Despite knowledge of the full length form, and an early demonstration of its 
role in the regulation of PTP1B [106], studies on PTP1B between 1990 and 2014 focused 
almost exclusively on the originally purified form encompassing residues 1-321, therefore 
ignoring the disordered C-terminal region. PTP1B became an attractive therapeutic target due 
to its involvement in multiple signaling pathways, including those implicated in obesity and 
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diabetes [107], however the development of a small molecule inhibitor for the catalytic 
domain of PTP1B was frustrated by the highly charged nature of the catalytic site [108], and 
the practice of testing inhibitors against the truncated form. It was not until 2014 that MSI-
1436, a known inhibitor of PTP1B in vivo [109], was screened against the full length form, and 
found to be an effective inhibitor [110].  
 
Figure 9 A representative ensemble of 100 conformers for PTP1B. Reprinted with permission from 
Macmillan Publishers Ltd: Nature Chemical Biology. Krishnan N, Koveal D, Miller DH, Xue B, Akshinthala 
SD, Kragelj J, Jensen MR, Gauss CM, Page R, Blackledge M et al: Targeting the disordered C terminus of 
PTP1B with an allosteric inhibitor. Nat Chem Biol 2014, 10(7):558-566 copyright 2014. 
 
 The C-terminal region of PTP1B is intrinsically disordered, moving within a wide range 
of three-dimensional space (Figure 9). However, as is often the case in IDPRs, there is 
residual secondary structure in the form of two small alpha helical regions. The most 
peripheral of these alpha helical regions provides one anchor point for MSI-1436, while the 
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second anchor point is found close to the catalytic domain. Upon binding to these two 
regions, PTP1B becomes more compact, and Vmax is decreased. While MSI-1436 provides a 
small amount of inhibition of the truncated form of the enzyme, the primary biding site is 
between residues 367 and 394, and therefore this region is required to observe the full 
strength of the inhibition. To our knowledge, this was the first drug screen against the full 
length form, therefore it is possible that MSI-1436 or other effective inhibitors had been tried 
and discarded previously. 
 The story of PTP1B demonstrates that it is sometimes assumptions about the lack of 
functional relevance of IDPRs in enzymes that creates one of the largest obstacles to 
understanding and utilizing these regions in disease intervention. 
1.11 The Field of Protein Intrinsic Disorder 
 An un-structural biologist specializes in the tools and techniques used to study IDPs. 
Furthermore, a specialist in the field of IDPs must be aware of individual proteins identified 
as IDPs and the body of experimental, proteomic and bioinformatics literature validating the 
existence of disorder in these proteins. Due to the broad scope of the material covered by the 
field of protein intrinsic disorder, and the nascence and relative obscurity of the field, there 
are a number of researchers who focus almost exclusively on the study of IDPs from various 
perspectives.  
The field of protein intrinsic disorder represents a powerful example of the productive 
relationship between experimental and bioinformatics techniques (Figure 5). For example, an 
experimentalist who notices unusual structural behavior in their protein, may employ the use 
of disorder prediction to assess the propensity of their protein towards disorder. Using this 
information as a guide, they can target their research towards those regions predicted to be 
intrinsically disordered, and apply the appropriate experimental techniques. This 
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experimental data yields information, which can then be used to revise and improve the 
prediction of disorder in other proteins, to extrapolate evolutionary information for the 
protein family, or to predict function or biophysical mechanism. However, the number of 
researchers who specialize in the study of specific proteins that are intrinsically disordered, 
and who also embrace the language of disorder to describe these properties, is remarkably 
small (Figure 10), demonstrating that the tools and language of protein intrinsic disorder has 
not propagated far beyond those who specialize in studying IDPs. 
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Figure 10. The number of papers per author for the search term in PubMed, plotted against the 
fraction of those papers that use IDP terminology. Each point represents an author on one or more 
papers associated with the given search term. The darker the dot, the larger the concentration of 
authors at that point. Blue dots are authors who have an IDP paper in the field in question (alpha-
synuclein or tau, in this case), while the red dots are authors who have an IDP paper in the field in 
question and also have an IDP paper in a different field. The fraction of IDP papers is the number of 
papers by that author that use IDP terminology divided by all papers for that author and search term. 
The following search terms were used: (A) (Top) “alpha synuclein” (B) (Bottom) “tau AND (protein OR 
Alzheimer's OR tauopathies OR neuronal)”. 
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1.12 Intrinsic Disorder Where You Least Expect It 
 As this new paradigm of un-structural biology becomes more accepted, it becomes 
clear that the disciplines of structural and un-structural biology can work in tandem to 
explain the dynamics of a protein over time. The line between order and disorder is a 
practical line, and the language and tools of protein intrinsic disorder become necessary when 
a protein or protein region can no longer be described in three-dimensions. The acceptance of 
the presence and functional relevance of protein intrinsic disorder, however, remains 
relatively low, especially in protein populations that are expected to be structured. 
Therefore, this introduction highlights several challenges:  
 There is a focus in the IDP literature on mostly or fully disordered proteins, and an 
incomplete understanding of the diverse mechanisms and functions employed by 
proteins that have regions of both order and disorder. 
 The development and validation of disorder prediction depends on experimental 
datasets of missing regions from the PDB, however it is not always clear what the 
cause and nature of the missing region is. 
 There is an increasing number of enzymes with experimentally measured IDPRs in the 
literature, but no proteome level studies up to this point. 
 There is limited acceptance of the language of protein intrinsic disorder outside of 
those who specialize in studying IDPs. 
 Drug design and discovery frequently focuses on the truncated form of the protein, 
potentially resulting in missed opportunities. 
 This work has direct relevance to applications in human health and disease by 
addressing the question of how likely IDPRs are to occur in canonically structured protein 
classes and whether and how these regions are functionally significant.  
The original research contained within this work has the following main results: 
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 Ambiguous missing regions in the PDB are likely to indicate varying levels of 
conditional and partial disorder instead of static disorder. 
 Enzymes have a similar incidence and length of IDPRs as non-enzymes. 
 Enzymes implicated in macromolecular metabolism, signaling, and regulation are 
enriched in long IDPRs. 
 Protein intrinsic disorder scales with organismic complexity in both enzymes and non-
enzymes. 
 There is a non-random retention of disorder in enzymes, suggesting that disorder in 
enzymes is not sequence noise, and probably has evolutionarily directed functional 
relevance in most cases. 
Furthermore, the following resources have been developed and compiled for this work: 
 1127 experimentally identified IDPs and proteins with IDPRs, and their supporting 
literature, hand curated through an extensive literature search. 
 96 enzymes with experimentally verified regions of protein intrinsic disorder and their 
supporting literature. 
 A publicly available method for compiling ambiguous regions and missing regions in the 
PDB, implemented in the programming language Python [111]. 
This work has a direct bearing on the design of experiments targeted towards intervention 
in human disease. By highlighting “Disorder Where You Least Expect It” this work will 
contribute to the ideological expansion of the field of protein intrinsic disorder so that it is 
increasingly seen as an integrated toolset in the study of proteins.  
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2. Intrinsic Disorder in the Protein Data Bank 
Note to reader 
 Portions of this chapter have been previously published in Protein Sci 2016, 25(3):676-
688, and have been reproduced with permission from John Wiley & Sons publishing.  
2.1 Background 
2.1.1 The Protein Data Bank 
 The Protein Data Bank (PDB) is the foremost archive of three-dimensional structural 
information for proteins and nucleic acids. The PDB has experienced impressive growth since 
its creation in 1971, and as of July 2015, there were over 110,000 entries. PDB structures are 
obtained primarily by X-ray crystallography (89% of structures) and nuclear magnetic 
resonance (10% of structures), with a small number of structures obtained by electron 
microscopy and other methods. In this study, we have focused on the missing residues from X-
ray crystal structures where multiple PDB structures representing the same sequence are 
available.  
2.1.2 Missing regions in the PDB 
 Missing residues in a three-dimensional crystal structure occur due to regions of low or 
poorly defined electron density that cannot be resolved into a single point in space. 
Oftentimes, this is due to dynamic atomic movement resulting in non-coherent X-ray 
scattering, and therefore it is not surprising that these missing regions were some of the first 
to be called “disordered” by the scientific community [10]. However, it is important to note 
that this early use of the word was meant to encompass a wide range of structural 
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possibilities. A missing region in the electron density map of a crystal structure indicates the 
lack of a single stable structure, but it is not a direct measure of the cause. This “disorder” 
was divided roughly by Bennett in 1984 into dynamic and static disorder [112] (Figure 11). 
Dynamic disorder, he proposed, was caused by continual motion in the protein, whereas static 
disorder encompassed all other possibilities, such as multiple stable conformations or crystal 
packing imperfections. In 1998, Garner et al. introduced the term domain wobble to describe 
missing regions that result from cooperative movements of a structurally intact unit, which 
are typically facilitated by a small flexible hinge [113]. They also differentiated these 
regions, along with structural ensembles, from intrinsic disorder.  
 
Figure 11 Missing regions in X-ray crystal structures can have many causes. 
 
 A precise definition of intrinsic disorder in the PDB is further complicated by the 
presence of conditionally (dis)ordered regions [114] and partially disordered regions, 
introduced in section 1.3. Conditionally disordered regions are intrinsically disordered under 
some conditions and structured under others. This most often manifests as a disorder-to-order 
transition upon binding, which is often facilitated by molecular recognition features (MoRFs) 
[26]. There are also many examples of proteins that have transient or cryptic disorder, which 
is functionally relevant disorder that arises only under certain conditions [24]. Partially 
disordered or semi-disordered [115] regions display intermediate amounts of highly flexible, 
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residual, and/or transient secondary structure. Both conditional disorder and partial disorder 
are difficult to detect experimentally and predictively. 
 It has long been understood that not all missing regions in X-ray crystal structures are 
intrinsically disordered. Static disorder, wobbly/mobile domains, packing imperfections, and 
missing regions that arise from experimental conditions would not be considered intrinsically 
disordered. Therefore, for the sake of clarity, we will refer to protein regions with missing 
electron density as missing regions and consider these as distinct from, but often correlated 
with, IDPRs. 
2.1.3 B-factors 
 The B-factor (also called a temperature factor) of an atomic coordinate in a PDB file, 
describes the average displacement of atoms from their mean position in a crystal structure. 
Therefore, the B-factor is usually interpreted as an indication of local flexibility in a protein 
or the degree of solvent accessibility, but it can also be correlated with crystallographic 
resolution and crystal-packing contacts [116]. In addition to variable interpretations, the B-
factors themselves can be highly variable and may require normalization for proper 
interpretation [116]. Due to the lack of a consistent definition for B-factor values, disorder 
prediction methods are not usually trained using B-factor data, and B-factor data is not 
typically used as an indication of disorder, with the exception of the prediction of loops with 
high B-factors by the disorder predictor Disembl [117]. High B-factors were used to determine 
Vihinen’s flexibility scale, which roughly correlates with disorder promoting residues (Figure 
6) [68], and is commonly used to display the biased composition of disordered regions. 
Radivojac et al. studied the characteristics of high B-factor regions, low B-factor regions, and 
missing regions and found that high B-factor regions were similar to short missing regions, 
with some differences in the amino acid compositions [118]. In practice, missing regions 
provide a better indication of intrinsic disorder in X-ray crystal structure data than do B-
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factors, and therefore we have focused exclusively on the measurement of missing regions for 
this study. 
2.1.4 Missing regions and the development of disorder prediction 
 Bioinformatics tools, introduced in section 1.8.2, have played a large part in 
establishing the field of intrinsic disorder, and in the study of IDPs/IDPRs, particularly at the 
proteome level, where high-throughput experimental methods to recognize intrinsic disorder 
are lacking. In order to help fill this gap, over 70 in silico predictors of intrinsic disorder have 
been developed [73, 74] (introduced in section 1.8.2.2). Predictors of intrinsic disorder 
typically use sequence-based features to predict the likelihood that a particular residue or 
region is intrinsically disordered. The experimental identification of IDPRs often requires a 
consensus of methods that may leave some uncertainty as to the nature of the disorder and 
the precise location. Therefore, the development of datasets of known intrinsically 
disordered regions that can be used to train predictors is a slow and arduous process. DisProt 
[82] provides the largest and most well-known database of experimentally verified 
intrinsically disordered regions. However, at 694 entries (as of July 2015), its coverage is 
infinitesimal compared to the predicted amount of intrinsic disorder in various proteomes, 
and it is unlikely to be fully representative. Several groups have compiled NMR-based datasets 
as well [55, 79]; however, the largest dataset of experimentally indicated IDPRs continues to 
come from X-ray crystal structures in the PDB. 
 While one can address the problem of scarce experimental data by using missing 
regions as an indication of disorder, missing electron density is also a weaker indication of an 
IDPR than NMR or a consensus of multiple methods. Therefore, the use of data from the PDB 
for training and testing predictors introduces some uncertainty. It is likely that noise in the 
training and testing sets for disorder predictors is currently the largest bottleneck to 
increased accuracy. For instance, the Critical Assessment of protein Structure Prediction 
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(CASP) competition, which measures the accuracy of disorder predictors, uses missing regions 
in newly published X-ray crystal structures to measure the accuracy of competing predictors, 
despite the acknowledgement that these missing regions could arise for multiple reasons, 
including annotation errors [75]. Disorder predictors are often refined for best performance 
against CASP datasets, but this does not necessarily mean that they are best optimized to 
predict in vivo intrinsic disorder. The fidelity of datasets of IDPRs is of upmost importance; 
therefore, it is critical that we continue to examine the best ways to extract genuine intrinsic 
disorder data from the PDB. 
2.1.5 Previous studies 
 Several studies have examined intrinsic disorder in the PDB [119-123]. Of particular 
interest to us were the ambiguous or dual personality fragments, defined in 2007 by Le Gall 
[119] and Zhang [120], respectively. These are regions in PDB chains where multiple 
structures of the same sequence show a conflict between missing and observed assignments. 
The PDB currently contains nearly three times as many entries as it did in 2007, when Le Gall 
and Zhang published their works. With this expanded source data, we were able to further 
investigate these ambiguous regions by preparing a large dataset that consists only of UniProt 
sequences that have at least two structures (PDB chains) available. Furthermore, using 
precompiled information from the PDB providing per-residue assignments of missing residues 
and secondary structure has allowed us to simplify this analysis and provide an easy-to-use 
method for proteomics studies that make use of PDB data. 
2.2 Results 
2.2.1 A new method for the characterization of missing regions 
 PDB files contain coordinates for a molecular structure (usually a protein) in three-
dimensional space. A single file may have one structure, or it may contain multiple 
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homogenous or heterogeneous structures in complex.  Each structure is assigned a chain 
identifier, and in this study, we call these individual structures PDB chains, to distinguish 
them from the PDB file, which may contain multiple chains. In most cases, some or all of a 
PDB chain can be mapped to a UniProt identifier [124], which provides sequence information 
for the entire protein. However, it is often the case that the PDB chain does not contain the 
entire UniProt sequence, or it may happen that a single PDB chain contains mappings to 
multiple UniProt identifiers, or has additional non-mapped residues. Therefore, we treat the 
PDB file, the PDB chain, and the UniProt identifier as three separate entities.  A PDB file may 
be mapped to multiple PDB chains, a single UniProt identifier may be mapped to multiple PDB 
chains and multiple PDB files, and multiple UniProt identifiers may be mapped to a single PDB 
chain.  
 Our base dataset consists of PDB chains that contain identical sequence residues in at 
least some portion of the chain, where those residues can be mapped to all or part of a 
UniProt identifier. A PDB chain is a single contiguous peptide or protein in a PDB file, where 
some PDB files may contain multiple heterologous or homologous chains in complex. We have 
developed a method that allows us to classify missing regions in these PDB chains according to 
the pattern the missing residues display when those chains disagree. Our method employs the 
following steps, which are outlined in Figure 12:  
1. Create a representative sequence for each PDB chain composed of missing residues, 
uncharacterized residues, and secondary structure information.  
2. Create a representation of the UniProt sequence by compiling information over all PDB 
chains and recording only observed, missing, and uncharacterized assignments. 
3. For each missing region in the UniProt sequence, assign a category (conserved, 
contained, conflicting, overlapping, or discarded), established by the pattern of 
missing residues between PDB chains. 
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We used the following definitions for a single-residue column across multiple PDB chains: 
 Uncharacterized: No PDB chain has an observed or missing residue in this position.   
 Characterized: At least one PDB chain has an observed or missing residue in this 
position. 
 Observed: At least one PDB chain has an observed residue in this position, and no 
PDB chains have a missing residue in this position.  
 Missing residue: At least one PDB chain has a missing residue in this position. 
 Missing region: There are at least three contiguous missing residues from the 
composite of all structures. 
The missing region categories were assigned based on the following criteria, and in the 
following order: 
 Conserved: The contiguous missing residues are present in all PDB chains.  
 Conflicting: At least one PDB chain was completely observed in the missing region. 
 Contained: At least one PDB chain had the full length of the missing region, and all 
other regions were the same length or contained within (but not completely 
conserved). 
 Overlapping: The missing regions overlap or are contiguous, but no one structure 
has a missing region that contains all others. 
If there was a missing region in only one structure and there was not a fully characterized 
region in any of the other structures, the missing region was discarded because we felt this 
left insufficient information for comparison. 
 Our final dataset consisted of 19153 UniProt entries, representing 54937 PDB files and 
147800 PDB chains. 5% of the residues were missing and 34% of the residues were 
uncharacterized, which means they were not crystallized in the experiment. Therefore, it is 
not surprising that the set of PDB chains was significantly shorter overall than the 
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corresponding set of UniProt sequences. The shortest PDB chain was 4 residues in length, and 
the longest PDB chain was 4187 residues in length, with an average length of 250 residues 
across all PDB chains. The shortest UniProt sequence was 7 residues in length, and the longest 
was 7737 residues in length, with an average length of 419 residues (Figure 13). 
 
 
Figure 12 The classification scheme for PDB sequence regions used in this study. 
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Figure 13 The distribution of protein lengths for the PDB chains used in this study compared to the 
distribution of lengths for the corresponding UniProt entries. 
2.2.2 Ambiguous regions have greater secondary structure variation 
 Ambiguous regions, by definition, are missing regions that have observed residues in 
some of their associated PDB chains. Therefore, we were able to compare the difference in 
the secondary structure assignments between the observed portions of the ambiguous regions 
and the fully observed regions in our dataset. Secondary structure assignments are provided 
in a single file by the PDB (available at http://www.rcsb.org/pdb/files/ss_dis.txt) and are 
calculated by the DSSP (Define Secondary Structure of Proteins) program [83]. These are not 
secondary structure predictions, but rather they are calculated by rigorously defined 
geometrical restraints based on the three-dimensional structure of the protein [125]. When 
no defined geometrical restraints are met, the secondary structure for that residue position is 
left blank by DSSP. These irregular assignments are not devoid of information, however, 
because the lack of assignment indicates that these regions have low curvature and lack 
hydrogen-bonded structure [125]. We assigned the letter P to these residues and found that 
they were very highly represented in ambiguous regions. In addition to irregular assignments 
(P), ambiguous regions are also enriched in hydrogen-bonded turns (T) and bends (S), while 
observed regions are enriched in alpha helices (H) and beta sheets (E) (Figure 14(A)). A list of 
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secondary structure, missing residue, and uncharacterized assignments and their 
abbreviations is provided in Table 1. 
Table 1 Secondary structure abbreviations. 
P = low curvature without H-bonded structure 
H = α-helix 
B = residue in isolated β-bridge 
E = extended strand, participates in β ladder 
G = 3-helix (310 helix) 
I = 5 helix (π-helix) 
T = hydrogen bonded turn 
S = bend 
- = uncharacterized 
X = not observed (missing) 
 
 Ambiguous regions are more likely to have secondary structure variation between 
different PDB chains in a single-residue column (Figure 14(B, C, D)). Figure 14(B) shows the 
top 10 most common secondary structure combinations (including those columns with only 
one secondary structure assignment) in an ambiguous residue column position. Surprisingly, 
the combination of P and S is actually more common than a beta sheet assignment. The pairs 
PS, PE, ST, and PH all commonly occur in the same residue position between multiple 
structures in ambiguous regions. This suggests that between the different PDB chains in an 
ambiguous region, recognizable secondary structure elements are relaxing to the point where 
they no longer have a recognized secondary structure type. Figure 14(C) shows the Shannon 
entropy of the secondary structure within residue columns of observed and ambiguous 
regions. The Shannon entropy measures the amount of information within a text string, and 
therefore it increases in proportion to the variety and relative proportion of secondary 
structure assignments in a single-residue position [126]. Nearly 90% of the observed regions 
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had only 1 secondary structure assignment in a residue column, and over 40% of the 
ambiguous regions had at least 2 different secondary structure assignments (Figure 14(C, D)).  
 
Figure 14 Analysis of secondary structure in observed vs. missing regions. (A)  The relative fraction 
of secondary structure assignments on a per-residue basis across all PDB structures with 
uncharacterized and missing residues removed.  (B) The 10 highest-occurring secondary structure 
combinations in ambiguous region columns and the relative fraction in ambiguous and observed residue 
columns. (C) The cumulative distribution of Shannon entropy by secondary structure in residue 
columns. (D) The number of unique secondary structure elements per residue column. 
 
Therefore, results described in this section suggest that:  
 Ambiguous regions have greater variation in the secondary structure between 
multiple PDB files of the same sequence than observed regions.  
 Irregular secondary structure, which has low curvature, is highly represented in 
ambiguous regions. 
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2.2.3 Different types of missing regions have distinct characteristics 
 The missing regions in this study are defined as an all-or-nothing composite of the 
missing residues amongst all PDB chains associated with a particular UniProt ID. 73% 
(13194/19153) of the UniProt IDs in our set had a missing region of at least 3 residues in 
length, with an average of 2.3 (31531/13914) regions per UniProt ID within that set. Each 
missing region was assigned a category, depending on the pattern of missing residues between 
PDB chains mapped to the same UniProt ID. The quantities of each region sorted by category 
are provided in Table 2. 62% of the missing regions were less than 10 residues in length, with 
distinctive differences in the length distribution between each missing region type (Figure 
15(A)). Conflicting regions, which have at least one PDB chain that is completely observed, 
were the shortest on average, and also occurred most often (77%) between multiple files 
(Figure 15(D)). The overlapping pattern was the longest on average, and was quite rare, with 
only 1708 examples in our set. Overlapping patterns are composed of 53% uncharacterized 
residues, yet occur only slightly more often on the ends of the protein (Figure 15(B)). 
Additionally, 76% are produced between different PDB files (Figure 15(D)), in a similar 
proportion to the conflicting regions. This suggests that the overlapping pattern may often be 
an artifact of variable truncation of the PDB chain between multiple files and rarely a 
“naturally occurring” pattern.  
 Contained regions, where at least one PDB chain has a longest missing region that 
encompasses all others, were more than 2.5 times as likely to occur as completely conserved 
regions, and were the most commonly occurring pattern overall. While contained and 
conserved regions have similar amino acid compositions (Figure 16), they come from very 
different file combinations. Conserved regions arise from multiple PDB chains within the same 
file 67% of the time, far more often than any other pattern. It is likely that many of these are 
symmetric oligomers, and the identical missing regions arise from identical environmental 
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conditions and interaction circumstances. Conserved regions are rarely seen in situations 
where PDB chains are pulled from both complex files and monomer files (4%, 208 regions) 
(Figure 15(D)). This suggests that full conservation of a missing region may be somewhat 
delicate, and when different environmental factors are present, including different or absent 
binding partners, the missing region may take on variable lengths, as seen in the contained 
pattern.  
 None of the ambiguous region types display the same secondary structure composition 
as the observed regions (Figure 14(A), Figure 15(C)). The vast majority of the residues in the 
contained regions are missing (Figure 15(C), inset). However, when residues were observed in 
the contained regions, almost 50% of the secondary structure assignments were irregular (P), 
indicating low curvature in these regions. The conflicting regions have fewer missing residues, 
and therefore more assigned secondary structure, but do not show an increase in helical 
regions (H) or beta sheets (E), as might be expected if experimental artifacts caused the 
conflicting regions. Instead, where secondary structure is assigned, conflicting regions show 
more turns (T) and bends (S).  
 Figure 16 displays the amino acid composition of each missing region type versus 
sequence residues from the observed regions. It is displayed using Vihinen’s [68] flexibility 
index, which sorts amino acids from least to most flexible. It is clear that all missing region 
types display a composition bias away from globularity and towards flexibility. The 
differences between the missing region types scale roughly with conserved being the most 
biased and conflicting being the least (Figure 16). Both conserved and contained regions show 
a high bias towards Methionine, which is likely due to their increased likelihood of occurring 
in the N terminus (Figure 15(B)). All the missing region types show a remarkably similar amino 
acid bias to DisProt. However, there are some differences, such as a reduced amount of 
Proline in the missing regions compared to DisProt.  
44 
 
Table 2 Characterization of the datasets analyzed in this study. 
Missing Region Type  Number of Regions Number of Residues 
Conserved  4744 55040 
Contained (ambiguous)  12088 178277 
Conflicting (ambiguous)  11848 102410 
Overlapping (ambiguous)  1708 42837 
Discarded  1143 15845 
 
 
Figure 15 Analysis of sequence and PDB file characteristics sorted by missing region type. (A) The 
cumulative length distribution of missing regions by missing region type. (B) The fraction of regions 
occurring at different locations along the length of the full protein sequence. The full sequence is 
divided into 10 sections, and the missing region location is defined as the midpoint of the missing 
region.  (C) The relative secondary structure composition, excluding uncharacterized and missing 
residues. (Inset) The fraction of residues that are not uncharacterized or missing and are therefore 
assigned a secondary structure or are irregular. (D) The fraction of missing regions occurring in 
different PDB file combinations. Mult. Files refers to PDB chains attached to a single UniProt ID that 
were obtained from more than one PDB file. Mult. Files Monomers refers to missing regions obtained 
from PDB files containing only one PDB chain. Mult. Files Mixed refers to missing regions that are 
obtained from multiple PDB files where at least one PDB file had a single PDB chain and at least one 
PDB file had more than one associated PDB chain. Mult. Files Complexes refers to PDB chains obtained 
from multiple files that all had more than one PDB chain. Same File Complex refers to PDB chains 
obtained from a single file. 
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Figure 16 The amino acid composition of missing regions relative to the observed residues. DisProt 
vs. PDB select 25 is provided as a reference. 
 
We drew the following conclusions from the results reported in this section:  
 Different missing region types have different secondary structure characteristics 
and different amino acid compositions, and reside in different locations along the 
primary sequence.  
 Missing residues between PDB files show greater variation when there is 
experimental variation between PDB files.  
 The contained pattern appears to be a common result when PDB chains are 
crystallized under different contexts.  
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2.2.4 Disorder prediction correlates with missing residue conservation 
 We measured the fraction of predicted disorder for observed regions, uncharacterized 
regions, and each missing region type using the predictors IUPred-short, ESpritz X-ray, and 
DynaMine, displayed in Table 3. Further information on these predictors is available Chapter 
4, Materials and Methods. The disorder, MoRF and binding site predictors, despite using 
different training sets and prediction methods, were in close agreement, both in the overall 
percentages, and by a per-residue pairwise comparison of prediction scores, which yielded 
agreement between 84% and 96% (Table 4, Table 5). As expected, the highest prediction of 
disorder was within the conserved regions. However, predictions for contained regions were 
very close, while conflicting regions had the lowest number of predicted disordered residues 
of the missing region types. Observed regions had very low prediction scores, further 
validating the sequence-based differences between observed and missing regions. The MoRF 
and binding predictors followed a similar trend, which would be expected, given these 
predictors are geared towards binding residues within disordered regions. Uncharacterized 
regions were also predicted to be significantly more disordered than observed regions. One 
surprising result is that uncharacterized residues were predicted to be within a MoRF 15% of 
the time by ANCHOR. This may be because uncharacterized regions are frequently in N and C 
terminal regions. 
 We found that the average of the disorder scores was a misleading calculation, 
however. The majority of the missing regions are predicted to be either 100% ordered or 100% 
disordered, with little in between (Figure 17).  The most dramatic example is the ESpritz X-
ray prediction for conflicting regions: 80% of the regions are predicted to be 100% ordered, 
13% are predicted to be 100% disordered, and only 7% are somewhere in between. Figure 17 
presents an interesting perspective on the differences between each predictor in terms of 
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“spread.” DynaMine tends to show the largest fraction of regions between 0 and 100%, with 
Espritz X-ray showing the smallest fraction, and IUPred between the two. 
 
Table 3 Disorder content and content of disorder-based binding sites in the datasets analyzed in 
this study. 
 Disorder Predictor Morf / Binding Site Predictor 
Region Type IUPred ESpritz  
X-Ray 
DynaMine Anchor DisoRDP 
DNA 
 DispoRDP 
Prot 
DispoRDP 
RNA 
Morf 
Pred 
Conserved 0.43 0.48 0.47 0.06 0.07  0.04 0.07 0.10 
Contained 0.39 0.41 0.41 0.07 0.07  0.05 0.08 0.08 
Overlapping 0.29 0.29 0.29 0.08 0.06  0.05 0.07 0.03 
Conflicting 0.15 0.12 0.19 0.02 0.04  0.01 0.08 0.03 
Observed 0.05 0.03 0.06 0.02 0.02  0.00 0.06 0.01 
Uncharacterized 0.23 0.23 0.23 0.15 0.04  0.07 0.06 0.01 
 
Table 4 Agreement between disorder predictors. 
Region Type DynaMine-
ESpritz X-Ray 
ESpritz X-Ray - 
IUPred 
IUPred - 
DynaMine 
Conserved 0.84 0.84 0.84 
Contained 0.84 0.85 0.84 
Conflicting 0.89 0.92 0.88 
Overlapping  0.84 0.85 0.84 
 
Table 5 Agreement between MoRF/binding site predictors. 
Region Type Anchor-
Disordp DNA 
Anchor- 
Disordp RNA 
Anchor-
Disordp Prot 
Anchor- 
MoRFpred 
Disordp DNA-
Disordp Prot 
Conserved 0.88 0.88 0.93 0.86 0.89 
Contained 0.88 0.86 0.91 0.87 0.89 
Conflicting 0.95 0.91 0.98 0.95 0.96 
Overlapping 0.88 0.86 0.91 0.91 0.89 
 Disordp DNA- 
Disordp RNA 
Disordp DNA- 
MoRFpred 
Disordp RNA-
Disordp Prot 
Disordp RNA- 
MoRFpred 
MoRFpred- 
Disordp Prot 
Conserved 0.87 0.85 0.88 0.85 0.87 
Contained 0.87 0.88 0.87 0.86 0.88 
Conflicting 0.90 0.94 0.91 0.90 0.96 
Overlapping 0.88 0.92 0.88 0.91 0.93 
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Figure 17 The fraction of the set of each missing region type vs. the fraction of predicted disorder 
for a given missing region. A Savitzky-Golay filter was applied to smooth intermediate values for 
clearer viewing. 
 
Therefore, data reported in this section clearly show that:  
 Missing regions, as well as uncharacterized regions, are predicted on average to be 
more disordered than observed regions.  
 The amount of average predicted disorder for each missing region type scales with 
the level of missing residue conservation (with conserved regions being the most 
conserved, and conflicting regions being the least conserved) in the region. 
 In most cases, missing regions in the dataset are predicted to be either 100% 
disordered or 100% ordered, with little in between, and the average disorder 
scores are mostly determined by the relative fractions of each. 
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2.2.5 Static disorder and wobbly domains are rare in the PDB 
 One interpretation for the narrow split between regions predicted to be entirely 
ordered or entirely disordered could be that the line between the two is a rough divider 
between static and dynamic disorder. In order to investigate this, we felt the best candidate 
subset of our data for static disorder was conflicting regions that were predicted to be 100% 
ordered by a 3/3 consensus of IUPred-short, ESpritz X-ray, and DynaMine. This subset was 
composed of 7033 regions, representing 59% of the total conflicting regions. If we start with 
the assumption that static disorder occurs in regions that are still essentially structured, then 
it would make sense that these regions should have the same amino acid composition as the 
observed regions. We compared the amino acid composition to the observed region 
composition, and found that this subset had a composition bias suggestive of flexibility, 
though less so than other missing regions or conflicting regions as a whole (Figure 18(A)). This 
result suggests that static disorder may be uncommon, and that prediction of structure by 
disorder predictors may not be the best indicator of static disorder. Instead, many of these 
conflicting regions may arise from conditionally or partially disordered residues, which are 
difficult to detect by disorder predictors. 
 In order to investigate the probable incidence of wobbling domains, we examined long 
missing regions at least 50 residues in length as a subset. Domain wobble describes the 
movement of a large structured region, typically facilitated by a smaller flexible region at the 
edges of the domain. As a result of this behavior, we expected that domain wobble may have 
a pattern of predicted disorder at one or both of the ends of the domain, and predicted 
structure in the center. Therefore, for this subset of our data containing long missing regions, 
we looked at the pattern of predicted disorder, by a 2/3 consensus of IUPred-short, ESpritz X-
ray, and DynaMine.  
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 We then examined the distribution of the disorder scores across each individual 
missing region (Figure 18(B)). We divided the missing region into three segments, consisting of 
the first 20%, the middle 60%, and the last 20% of the protein. If there were at least five 
disordered residues by consensus, the location along the protein of those residues was 
recorded. If all residues occurred within the first or last 20% of the region, and they all 
occurred at the beginning or end of the protein chain (the starting point and ending point 
were defined as the first and last characterized residue from all the PDB chains), then these 
regions were assigned as Tails. If all disordered residues occurred in the first and last 20% of 
the region and some or all were not on a tail region, then these were assigned as Ends. If all 
disordered residues occurred in the middle 60% of the protein, these were assigned as 
Centered. All others were considered to be Dispersed, which includes 100% disordered 
regions. All those with fewer than five disordered residues were labeled as Ordered.  
 We expected that wobbly domains would have disordered residues concentrated at 
one or both ends (but not in a tail region), therefore indicating a small flexible hinge that 
could move the larger structured region. The incidence of this pattern was low overall, with 
only 43 out of 865 regions displaying a possible hinge and large movable domain pattern.  
Much more common was a dispersed pattern, with 410 regions displaying a spread-out pattern 
of predicted disordered residues, and only 253 regions predicted to be completely ordered. 
This supports the conclusion that domain wobble is probably rare, and it is more likely that 
many of these regions are conditionally or partially disordered.  
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Figure 18 An analysis of possible static disorder. (A) The composition of conflicting missing regions 
predicted to be ordered by a 3/3 consensus of IUPred-short, ESpritz X-ray, and DynaMine. DisProt vs. 
PDB select 25 is provided for reference. (B) The relative fraction of long missing regions (> 49 residues) 
that fall into each disorder distribution. Ends refers to disorder scores only occurring in the last 20% of 
the missing region, when those residues do not occupy a tail position. Tails refers to disorder scores in 
a missing region occurring only at the ends of the PDB chain. Centered refers to disorder scores only 
occurring in the center 60% of the protein. Dispersed refers to all other cases with 5 or more 
disordered residues. If there are fewer than 5 disordered residues, the region is considered Ordered. 
We drew the following conclusions for this section:  
 Conflicting regions that are predicted to be 100% ordered still display composition bias 
towards flexibility.  
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 Long missing regions rarely display a predicted hinge pattern that would be suggestive 
of domain wobble. 
 Static disorder and domain wobble are probably rare in the PDB. 
2.3 Conclusions 
 We have introduced a method for easily creating and categorizing a dataset of missing 
regions when there are multiple PDB chains attached to a single UniProt identifier. This 
classification scheme further divides ambiguous regions, those where PDB structures disagree 
as to whether a given residue is missing or observed, into three categories: conflicting, 
contained, and overlapping. This classification scheme may be useful in the investigation of 
individual proteins, large sets of proteins, and the development and refinement of disorder 
prediction software. Furthermore, we have provided analysis that will help clarify the nature 
of ambiguous missing regions.  
 Our analysis provides further validation that there is a measurable difference between 
missing regions and observed regions, which indicates increased flexibility. Missing regions 
have a greater variation in secondary structure, an amino acid composition biased in favor of 
intrinsic disorder, and a significantly higher fraction of residues that are predicted to be 
disordered. Furthermore, it appears that the extent of these differences roughly scales with 
the level of ambiguity in the region. Fully conserved regions show the strongest indications of 
intrinsic disorder, followed by contained, overlapping, and conflicting patterns. However, our 
analysis also shows that ambiguity is more likely to arise as different PDB chains with the 
same sequence are exposed to greater environmental differences. Our results indicate that 
perfect conservation in a missing region should not necessarily be correlated to higher 
confidence that a region is intrinsically disordered. Variable lengths of the missing region 
between different files may be a very natural result when intrinsically disordered regions are 
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exposed to different environments. Additionally, conflicting regions should not necessarily be 
discarded from IDP sets, as they may simply be an indication of conditional disorder placed 
within different contexts. In other words, whether the missing region displays a pattern of 
conservation, ambiguity, or conflict may in some cases be a function of the differences 
between the source files rather than the extent of the disorder. We found little evidence of 
static disorder and domain wobble, and suspect that the incidence is probably quite low. 
Instead, it is likely that the ambiguous regions in the PDB are a rich source of conditional and 
partial disorder. 
In summary, results reported in our study support the following main conclusions: 
 In the majority of cases, the characteristics of missing regions indicate protein 
intrinsic disorder instead of static disorder, domain wobble, or experimental 
artifacts. 
 The presence of an ambiguous region and the degree of ambiguity in that region is 
more likely to indicate varying levels of conditional or partial disorder, rather than 
static disorder. 
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3. Intrinsic Disorder in Enzymes 
3.1 Background 
3.1.1 Intrinsically disordered enzymes in the literature 
 Enzymes have been central to the development of the structure-function paradigm, 
which tells us that the unique three-dimensional structure of a protein is the key to 
understanding that protein’s function. Therefore, as the widespread prevalence and 
functional relevance of protein intrinsic disorder has been demonstrated throughout the 
years, enzymes have consistently been considered an exception to the rule. This assumption 
has largely gone unchallenged and un-quantified. This is likely due to an eclipsing focus on 
the catalytic region of enzymes, as the story of PTP1B in section 1.10.1 demonstrates. 
However, catalysis alone does not fully describe the complicated life of an enzyme that may 
need to bind many different partners and substrates, be intricately regulated, or have 
inducible multi-functionality.  
 There is an understanding that many enzymes have a certain amount of 
conformational flexibility and that in fact all proteins interconvert to some extent, however 
the relationship of this movement to catalysis is still hotly debated [127-136]. The 
observation of large domain movements via small hinge regions, small local vibrations, and 
ensembles of structures have been regular fixtures in the discussion of enzyme structure and 
function. Therefore, we would like to distinguish our discussion of IDPs and IDPRs by focusing 
specifically on longer regions of protein intrinsic disorder that spend some part of their 
functional life cycle without a fixed three-dimensional structure, and without a specific and 
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defined range of movement. On a practical level, these are frequently the regions that cause 
experimental difficulties, and may be removed before experimentation. 
 Interestingly, some of the earliest examples of IDPRs came from enzymes. In the late 
1970s, trypsinogen [137, 138], the precursor to the serine protease trypsin, provided one of 
the most extensively documented disordered regions. Disorder facilitates the activation and 
regulation of trypsin in two ways. The first is through increased susceptibility to cleavage, 
which converts trypsinogen to trypsin, the active form. The second is through an IDPR which 
remains after cleavage and tethers a small two residue knob, which has the spatial flexibility 
to search for and bind a hole within trypsin, promoting a disorder-order transition and 
activating trypsin. 
 Another early example of an intrinsically disordered enzyme came in 1983, when 
Manalan and Klee showed that the phosphatase calcineurin can be activated by the cleavage 
of an exposed IDPR, which simultaneously prevents calmodulin binding [33]. Later studies 
showed that this happens due to an intrinsically disordered autoinhibitory domain in 
calcineurin that impedes the active site. Upon binding to calmodulin, the autoinhibitory 
domain becomes structured, and moves away from the active site, therefore activating 
calcineurin [139] (Figure 19). Cleavage of the autoinhibitory domain therefore activates the 
enzyme, but also removes a critical regulatory mechanism. 
 Regulation through an IDPR is a common theme in many enzymes. CTP:phosphocholine 
cytidylyltransferase (CCT) has a disordered tail region that acts as an inhibitor of catalysis in 
the unbound form of the enzyme. However, this IDPR also appears to facilitate binding to the 
cell membrane, and upon binding the inhibition is relieved, and the enzyme becomes active. 
Ding et al. performed a number of experiments with chimeric forms of the enzyme and found 
that this regulatory region was able to accommodate significant changes in length and 
sequence while still being functionally viable [140].  
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Figure 19 The activation of calcineurin by calmodulin through a disorder-order transition. In the 
absence of calmodulin, the disordered autoinhibitory domain impedes substrate access by hovering 
near the active site. Upon binding to calmodulin the autoinhibitory domain undergoes a disorder-order 
transition and is displaced from the active site. Reprinted from Ye Q, Feng Y, Yin Y, Faucher F, Currie 
MA, Rahman MN, Jin J, Li S, Wei Q, Jia Z: Structural basis of calcineurin activation by calmodulin. Cell 
Signal 2013, 25(12):2661-2667.), with permission from Elsevier. 
 
 Human glucokinase provides an example of regulation through a small, but critical 
IDPR that regulates the turnover number (kcat) of the enzyme in a glucose sensitive manner. 
Upon binding to glucose the IDPR undergoes a disorder-order transition that causes the 
enzyme to become catalytically active [45]. Therefore, when glucose is low, the small IDPR in 
glucokinase creates a built-in time delay caused by an order-disorder transition (Figure 20).  
 Disordered regions may also be directly involved in catalysis. The critical 
selenocysteine of the selenoprotein VIMP reductase is found in the disordered C-terminal 
region [141] (Figure 21). The disorder in this region may allow the protein to effectively 
interact with a variety of partially unfolded endoplasmic reticulum associated degradation 
(ERAD) substrates. Similarly, the resolving cysteine in Msrb1 is present in the disordered N-
terminal region [142] (Figure 22). The flexibility in this region is critical to catalytic action, as 
it allows the resolving cysteine to fold up into the proper position. Additionally, flexibility in 
this region may enable interaction with diverse substrates.  
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Figure 20 A schematic of kinetic regulation by an order-disorder transition in glucokinase. (A) The 
small domain of unliganded GCK is intrinsically disordered, giving rise to a broad conformational 
ensemble. (B) Glucose binding, activator binding, or an activating PHHI-associated mutation promotes 
folding of the disordered regions in the small domain, narrowing the conformational distribution. Upon 
formation of the GCK–glucose binary complex, ATP binds and catalysis proceeds with little additional 
reorganization. (C) Following product release, ordered unliganded GCK persists until the small domain 
undergoes an order–disorder transition on the millisecond time scale, allowing access to the “time 
delay loop” (red): Under low glucose concentrations, the delay loop is operational, leading to slow 
turnover and kinetic cooperativity. Under high glucose concentrations (or when GCK is activated), the 
delay loop is effectively bypassed, turnover is fast, and cooperativity is eliminated (green). Reprinted 
under the creative commons license from Larion M, Salinas RK, Bruschweiler-Li L, Miller BG, 
Brüschweiler R: Order-disorder transitions govern kinetic cooperativity and allostery of monomeric 
human glucokinase. PLoS Biol 2012, 10(12):e1001452. 
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Figure 21 The intrinsically disordered C-terminal region of the reductase VIMP contains a 
selenocysteine that is critical for catalysis. The disordered region encompasses residues 123-189 
(shown in green). This research was originally published in The Journal of Biological Chemistry. 
Christensen LC, Jensen NW, Vala A, Kamarauskaite J, Johansson L, Winther JR, Hofmann K, Teilum K, 
Ellgaard L: The human selenoprotein VCP-interacting membrane protein (VIMP) is non-globular and 
harbors a reductase function in an intrinsically disordered region. J Biol Chem 2012, 287(31):26388-
26399 © the American Society for Biochemistry and Molecular Biology.  
 
Figure 22 The N terminal region of MsrB1 samples a wide range of dynamic conformations, and 
contains a resolving cysteine. MsrB1 structural family consisting of 20 conformers with the lowest 
target function. This research was originally published in The Journal of Biological Chemistry. 
Aachmann FL, Sal LS, Kim HY, Marino SM, Gladyshev VN, Dikiy A: Insights into function, catalytic 
mechanism, and fold evolution of selenoprotein methionine sulfoxide reductase B1 through structural 
analysis. J Biol Chem 2010, 285(43):33315-33323 © the American Society for Biochemistry and 
Molecular Biology. 
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 Disorder has been shown in some cases to be necessary for substrate recognition, 
binding, and promiscuity. In particular, enzymes involved in ubiquitination and 
deubiquitination that must interact with a large number of unique substrates, appear to be 
enriched in disorder [37]. The disordered regions of the E3 ubiquitin-ligase San1 [143] and the 
deubiquitinase Upb10 [144] are punctuated by small ordered regions that recognize a large 
number of substrates, while the E2 ubiquitin-conjugating enzyme Ube2w uses disorder to 
specifically recognize the disordered N termini of its substrates [145] (Figure 23). 
 
 
Figure 23 The disordered C-terminal region of Ube2w helps bind diverse substrates. A) Side-view of 
the full Ube2w ensemble looking down the helix-3 axis reveals the three clusters. B) In all twenty 
members of the Ube2w ensemble residues N136-W145 occupy positions beneath the active site, C91 
(orange). Residues 119-135 are not shown for clarity. Adapted with permission from Macmillan 
Publishers Ltd: Nature Chemical Biology Vittal V, Shi L, Wenzel DM, Scaglione KM, Duncan ED, Basrur V, 
Elenitoba-Johnson KS, Baker D, Paulson HL, Brzovic PS et al: Intrinsic disorder drives N-terminal 
ubiquitination by Ube2w. Nat Chem Biol 2015, 11(1):83-89, copyright 2015. 
  
 There are a number of examples of enzymes that use disorder as a flexible tether to 
form transient protein complexes and interact with nucleic acids. The DNA helicase Sgs1 has a 
disordered N-terminus that facilitates chromosome stability and binding to Top3/Rmi1 [146]. 
The membrane bound prokaryotic enzyme RNase E has an extended IDPR in the C-terminal 
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region that is punctuated by MoRFs. These small microdomains allow RNase E to use an 
extended region of disorder as a scaffold to form a multi-enzyme RNA degradosome [147] 
(Figure 24). The DNA glycosylase NEIL1 provides an example of disorder that facilitates a large 
number of protein interactions. NEIL1 has a disordered C-terminal region that interacts with a 
large number of base excision repair proteins. It is likely that the flexibility in this IDPR 
enables increased specificity [148]. Interestingly, the disordered C-terminal region in NEIL1 
also exerts a stabilizing influence on the catalytic region. 
 
 
Figure 24 RNase E forms a flexible scaffold for protein interactions. A) The primary binding partners 
of RNase E form the degradosome. B) The disordered C-terminal region forms a flexible scaffold. 
Reprinted under the creative commons license from Aït-Bara S, Carpousis AJ, Quentin Y: RNase E in the 
γ-Proteobacteria: conservation of intrinsically disordered noncatalytic region and molecular evolution 
of microdomains. Mol Genet Genomics 2014. 
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Figure 25  The disordered C-terminus of NEIL1 allows it to engage in multiple molecular 
interactions. (A) The ab initio shape predicted from the experimental data shows not only a compact 
volume consistent with the crystal structure but also a volume extending from the C-terminal portion 
of the protein. (B) BilboMD models and their percentage representation in the population that were 
selected by the MES fit the experimental scattering data as an ensemble. Reprinted from Hegde ML, 
Tsutakawa SE, Hegde PM, Holthauzen LM, Li J, Oezguen N, Hilser VJ, Tainer JA, Mitra S: The disordered 
C-terminal domain of human DNA glycosylase NEIL1 contributes to its stability via intramolecular 
interactions. J Mol Biol 2013, 425(13):2359-2371 with permission from Elsevier. 
 
 IDPs and IDPRs have been extensively linked to signaling pathways [38], therefore it is 
not surprising that IDPRs in enzymes often play a critical role in signaling. The sulfhydryl 
oxidase lf-ALR has an IDPR that performs a dual function dependent on its subcellular 
localization. In the cytosol it contains a mitochondrial targeting signal, while in the 
intermembrane space, it provides a recognition site in the disulfide relay system of the 
intermembrane space [40]. The intrinsically disordered juxtamembrane domain in the 
receptor tyrosine kinase EGFR contains multiple signals that are critical for receptor 
trafficking and are modulated by interaction with the membrane [149]. Peptidylglycine alpha-
amidating monooxygenase (PAM) is a secretory granule membrane protein that has many 
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phosphorylation sites in its intrinsically disordered cytosolic domain that may help relay 
information to the cytosol and nucleus  [150]. 
 IDPRs in enzymes may also help attenuate or contribute to disease states. The stress 
induced variant of the hydrolase ACHE-R has an IDPR at the C terminal [102]. Interestingly, 
this variant attenuates Alzhemier’s disease in the mouse, while the variant without the 
disordered region does not. Alternatively, we see disorder in the enzymes of multiple 
pathogens, such as adenylate cyclase toxin in b. pertussis [101], alphavirus capsid protease 
[151], and the HIV-1 protease [152]. 
 A survey of the literature documenting IDPRs in enzymes suggests that protein intrinsic 
disorder fulfills many of the same functions in enzymes as it does in non-enzymes, such as 
facilitating DNA binding and protein-protein interactions, and participating in regulation and 
signaling. However, there are also more puzzling cases of enzymes that do not take on 
significant structure. The disordered DNA endonuclease anhydrin [153] remains “fuzzy” when 
bound to DNA and the GTPases TPPP/p25 [154] and UreG [155] are both catalytically active in 
an extended molten globule form.  
 Table 6 summarizes just a few of the many examples of enzymes with functional IDPRs 
found in the literature. A more extensive list of enzymes with experimentally identified IDPRs 
is provided in Appendix D.  
Table 6 Selected enzymes with experimental evidence of functionally relevant regions of protein 
intrinsic disorder. 
Name Enzyme Type Organism Disordered Region References 
Regulation of Catalysis 
calcineurin phosphatase Human central domain 372-467,  
18% disordered 
[33, 139, 
156, 157] 
glucokinase kinase Human inner loop 151-179,  
6% disordered 
[45] 
CCT choline-phosphate 
cytidylyltransferase 
Various N/C terminal [140, 158-
160] 
Participation in Catalysis 
VIMP reductase, 
peroxidase 
Human C terminal 123-189,  
35% disordered 
[141, 161, 
162]  
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Table 6 (Continued) 
 
Name Enzyme Type Organism Disordered Region References 
Msrb1 methionine sulfoxide 
reductase 
mouse N/C terminal 1-18, 105-116, 
25% disordered 
[142] 
Substrate Recognition, Binding and Promiscuity 
San1 E3 Ub-ligase s. 
cerevisiae 
N/C terminal,  
~60% disordered 
[46, 143]  
Upb10 deubiquitinase s. 
cerevisiae 
N terminal 1-359,  
45% disordered 
[144] 
Ube2w E2 Ub-conjugating human C terminal, ~137-145,  
5% disordered 
[145] 
Protein-protein and protein-nucleic acid interactions 
Sgs1 DNA helicase s. 
cerevisiae 
N terminal 1-125,  
9% disordered 
[146, 163]  
NEIL1 DNA glycosylase human C terminal 290-390,  
26% disordered 
[148, 164] 
RNase E RNase e. coli C terminal [147, 165-
167]  
Signaling 
lf-ALR sulfhydryl oxidase human N terminal, 1-80,  
39% disordered 
[40, 168, 
169]  
EGFR tyrosine kinase human Inter-domain, 645-697,  
4% disordered 
[149, 170] 
PAM monooxygenase, 
lyase 
rat C terminal, 896-976,  
8% disordered 
[150] 
PTP1B  Phosphatase human C terminal 300-393,  
23% disordered 
[110] 
Disease Involvement 
AChE-R acetylcholinesterase  human C terminal 575-603,  
5% disordered 
[102, 171] 
adenylate 
cyclase toxin 
adenylate cyclase b. pertussis C terminal 1000-1706,  
41% disordered 
[101, 172-
175] 
alphavirus 
capsid protease 
protease aura virus C terminal [151] 
HIV-1 protease protease HIV-1 linker 79-82 [152, 176-
178]  
Mostly Disordered 
anhydrin DNA endonuclease a. avenae mostly disordered [153] 
TPPP/p25 GTPase human mostly disordered [154, 179-
181] 
UreG GTPase b. pasteurii mostly disordered [155, 182]  
 
 
3.1.2 Previous studies 
 Multiple proteome-wide investigations of intrinsic disorder have been undertaken using 
various disorder predictors [94, 183]. Some proteomics level disorder studies have done Gene 
Ontology (GO) term analyses that included enzyme related keywords, [84, 95], there are 
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studies focusing specifically on ubiquitination pathways [37] and kinases [39], and there is a 
recent review on protein disorder and catalysis [133], however to our knowledge, no  large-
scale proteome level examination of intrinsic disorder in enzymes vs. non-enzymes has been 
undertaken. 
3.2 Results 
3.2.1 Experimental design  
 In this study, we have used two complementary datasets in order to examine the 
incidence of intrinsic disorder in enzymes. The first dataset was compiled from the protein 
sequences in 66 reference proteomes from the Quest for Orthologs (QFO) project [184]. A 4/7 
binary consensus from seven disorder predictors was obtained in order to assess the amount 
of disorder in this dataset (see section 4.3.3 for more details). Additionally, missing residues 
from the PDB were used as a complementary experimental indication of disorder. Due to the 
difficulty in experimentally identifying IDPRs, missing regions in X-ray crystal structures are 
often used as an indication of IDPRs in order to supplement other experimental datasets. In 
Chapter 2, it is shown that there are several possible causes of a missing region in an X-ray 
crystal structure, however supporting evidence, such as an amino acid composition biased in 
favor of flexibility, and variability in secondary structure between multiple structures with 
ambiguous missing regions, suggests that missing regions are very likely to be intrinsically 
disordered, though these regions may have differing amounts of conditional or residual 
secondary structure that depends on the environment [185]. The reference proteomes dataset 
allows us to examine an unbiased and representative collection of proteins, while the PDB 
dataset allows us to examine experimental indications of disorder.  
 Additionally, we have examined the relationship of disorder to enzyme function as 
defined by the Enzyme Commission (EC) designation [186], as well as Gene Ontology (GO) [92] 
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enrichment. It is our objective to better quantify the incidence of IDPRs in enzymes compared 
to non-enzymes, and to broadly ascertain the functional relevance of these regions. 
Table 7 details the relative amounts of each enzyme type in the reference proteomes, 
sorted by taxon, while Table 8 provides similar statistics for the PDB dataset. Due to the low 
number of archaea in the PDB, these proteins were excluded from this dataset. The majority 
of enzymes in all data subsets are composed of Transferases (EC2) and Hydrolases (EC3), 
followed by Oxidoreductases (EC1). 
Table 7 The number of proteins in the reference proteome dataset assigned to each EC number, 
organized by taxon, and enzyme type (or non-enzyme). 
EC# Description Eukaryotes Prokaryotes Archaea 
EC1 Oxidoreductases 20285 (16%) 5751 (20%) 946 (18%) 
EC2 Transferases 43112 (33%) 8344 (29%) 1591 (31%) 
EC3 Hydrolases 49002 (38%) 8784 (31%) 1521 (29%) 
EC4 Lyases 3278 (3%) 1563 (5%) 297 (6%) 
EC5 Isomerases 2915 (2%) 1059 (4%) 172 (3%) 
EC6 Ligases 4062 (3%) 1385 (5%) 352 (7%) 
Multi Multiple EC# 6860 (5%) 1704 (6%) 314 (6%) 
NE Non-enzymes 428126 48443 10036 
 
Table 8 The number of proteins assigned to each EC number in the PDB dataset, organized by 
taxon, and enzyme type (or non-enzyme) for the set of proteins with at least one continuous 
missing (CM) region of three residues in length. 
 
 
 
 
 
 
 
 
 
 
 
Multi refers to enzymes that have been assigned to multiple top level EC. Percentages show percent 
relative to all enzymes. 
EC# Description Eukaryotes Prokaryotes 
EC1 Oxidoreductases 341 (16%) 416 (18%) 
EC2 Transferases 828 (39%) 750 (33%) 
EC3 Hydrolases 627 (30%) 461 (20%) 
EC4 Lyases 119 (6%) 270 (12%) 
EC5 Isomerases 77 (4%) 148 (7%) 
EC6 Ligases 57 (3%) 174 (8%) 
Multi Multiple EC# 53 (3%) 37 (2%) 
NE Non-Enzymes 5648 7560 
Multi refers to enzymes that have been assigned to multiple top level EC numbers. Percentages show 
percent relative to all enzymes. 
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3.2.2 Enzymes and non-enzymes have a similar incidence of IDPRs. 
 Figure 26 shows the relative composition of the reference proteomes (top) and the 
PDB dataset (bottom) by taxon and then further subdivided into enzyme vs. non-enzyme. Due 
to the larger size of eukaryotic proteomes, eukaryotes were most strongly represented in the 
reference proteomes dataset. 23% of eukaryotic proteins were assigned as enzymes, while 
37% and 34% of prokaryotes and archaea were assigned as enzymes respectively. 92% of 
eukaryotic enzymes and 93% of eukaryotic non-enzymes were predicted to have at least one 
continuously disordered (CD) region of at least three residues in length. Interestingly, while 
the number of proteins with predicted CD regions increases as the taxon becomes more 
complex, there is negligible difference between enzymes and non-enzymes in our dataset in 
terms of the number of proteins with predicted CD regions.  
 Our PDB dataset is composed of unique UniProt IDs that are mapped to one or more X-
ray crystal structures. A single composite missing region is compiled using the method 
outlined in Section 4.1, therefore, we are able to minimize the bias that is introduced by 
overrepresented proteins in the PDB. We have removed viruses, as they are a small portion of 
the PDB and provide a unique case due to the number of polyproteins. There are a large 
number of prokaryotic proteins represented in the PDB (Figure 26, bottom), especially 
considering that prokaryotic proteomes tend to be smaller. The number of structures with at 
least one missing region in the PDB is remarkably similar between different taxa and enzymes 
and non-enzymes, with fractions between 69-75% for eukaryotes and prokaryotes. Archaea 
represent the exception, with only 48% of archaeal enzymes having a missing region, 
compared with 68% for non-enzymes, however the sample size is small for archaea. 
Eukaryotic enzymes have slightly more missing regions than non-enzymes, while the numbers 
are almost identical for prokaryotes 
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Figure 26 The composition of the reference proteome dataset (top) and the PDB dataset (bottom). 
A protein is considered to have a predicted IDPR or missing region if there is a continuous stretch of 
predicted disorder or missing region of at least 3 residues in length 
 
3.2.3 Enzymes and non-enzymes have IDPRs of similar lengths 
 When comparing the fraction of predicted disordered residues per protein, eukaryotic 
non-enzymes in the reference proteomes dataset have an average of 23% predicted disorder, 
while enzymes vary from 7-13% depending on the EC assignment (Figure 27A). However, when 
comparing the average length of the longest CD region between enzymes and non-enzymes, 
the similarity between the groups increases. Transferases, hydrolases, and enzymes with 
multiple EC designations have an average longest CD region of 50, 43 and 47 respectively, 
while non-enzymes have an average longest CD region of 59.  A similar trend is observed in 
the number of CD regions (Figure 27B), with transferases and hydrolases having an average of 
4.5 CD regions, enzymes with multiple EC designations having an average of 4.9, and non-
enzymes having an average of 4.8.  
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Figure 27 Predicted intrinsic disorder calculations for eukaryotes, prokaryotes, and archaea in 
reference proteomes. Box plots are first quartile, second quartile (median), and third quartile. Plot 
whiskers extend to 5% and 95% of the data. A) The fraction predicted disorder. B) The number of 
continuously disordered (CD) regions per protein. C) The longest CD region. 
 
 Overall, there is more variability between enzyme types than between enzymes and 
non-enzymes in regards to the presence and length of missing regions in the PDB dataset. We 
have used the same measurements as in the predicted disorder analysis (Figure 27) however, 
we have only included proteins with a missing region of at least 3 contiguous residues in the 
analyzed dataset. We have also excluded archaea due to an insufficient dataset size. The 
longest continuous missing (CM) region average is between 18 and 24, with non-enzymes 
having an average longest CM length of 22 (Figure 28). The exception is ligases which show an 
average longest missing region length of 39 for eukaryotes. This may not generalize, however 
considering the small sample size of 57 proteins. 
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Figure 28 Missing region calculations for eukaryotes, prokaryotes, and archaea in the PDB dataset. 
Calculations were performed only on those proteins that had at least one continuous missing region 
that was three residues in length. Box plots are first quartile, second quartile (median), and third 
quartile. Plot whiskers extend to 5% and 95% of the data. A) The fraction of missing residues per-
protein. B) The number of continuous missing (CM) regions per protein. C) The longest CM region. 
 
3.2.4 Disorder is specific to enzyme length and type. 
 Prokaryotes and archaea are shorter on average than eukaryotes, and non-enzymes are 
shorter on average than enzymes for all taxa (Figure 29A-C, top). Enzymes with multiple 
assigned EC numbers are longer for all taxa, which is likely due to the presence of multiple 
catalytic domains. Transferases, hydrolases, and ligases are the longest in eukaryotes for 
single EC assignments. We created subsets based on protein length for each EC number, and 
for non-enzymes in order to compare fractional disorder to length (Figure 29A-C, bottom). For 
very short proteins of all types, fractional disorder is higher, and then dips to a lowest point 
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as the protein length is increased. We expect that many of these very short proteins do not 
have sufficient length to form a stable core, and are subunits that must be stabilized in order 
to be functional. Therefore, the correlation between length and fractional disorder for 
eukaryotes can be described as more parabolic than linear, however there is significant 
variety between EC numbers. Prokaryotes and archaea, however, do not show significant 
variation in fractional disorder based on length by enzyme type, once they reach a minimum 
stable length. 
3.2.5 Disorder increases with organismic complexity. 
 In alignment with previous studies [49], we found that eukaryotes are predicted by all 
measures to be the most disordered, followed by prokaryotes, and then archaea (Figure 27, 
Figure 28). though it should be emphasized that there is some proteomic variability within 
each taxon. Eukaryotes showed significant variability in their disorder metrics between EC 
numbers, which was not observed to the same extent in prokaryotes or archaea. Eukaryotes in 
particular showed higher predicted disorder in transferases (EC2) and hydrolases (EC3). 
Additionally, the relative proportion of transferases and hydrolases to other enzymes was 
highest for eukaryotes at 72% of total enzymes, versus 60% in prokaryotes and archaea. 
3.2.6 Eukaryotic proteins in the PDB are highly truncated 
 Proteins are frequently truncated as part of preparation for crystallization. The 
remaining protein region is referred to as the characterized portion, while the removed 
region is the uncharacterized portion. Typically, this is to remove areas that have caused 
problems in crystallization, though this is not always the case. These uncharacterized regions 
are predicted to be more disordered than the observed regions, though not as disordered as 
missing regions (Table 3). 
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Figure 29 Distribution of protein lengths and mean fraction of disorder by protein length in 
reference proteomes. Top plots show the distribution of protein lengths separated by enzyme type (or 
non-enzyme). Box plots are first quartile, second quartile (median), and third quartile. Plot whiskers 
extend to 5% and 95% of the data. Bottom plots display the mean fraction of predicted disorder by 
protein length interval, separated by enzyme type. Colors of mean fractions correspond to box plot 
coloring. Sorted into A) Eukaryotes, B) Prokaryotes, and C) Archaea. 
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 When examining the length distributions for the characterized portion of the protein in 
the X-ray crystal structure, we found that the average lengths of the characterized portion of 
eukaryotic proteins that are crystallized are remarkably similar to the average lengths for the 
reference prokaryotes (Figure 30). This relationship was observed for all enzyme types and 
non-enzymes. The difference between the average truncated length and the average full 
length of the proteins in eukaryotes was highly variable depending on the enzyme type 
(Figure 31 left, red circle, black circle). Additionally, in most cases, the mean length of the 
eukaryotic proteins was divergent from the average lengths from the reference proteome set. 
In contrast, prokaryotes were minimally truncated, and length averages were similar to the 
prokaryotic reference proteomes length averages (Figure 31, right) 
 
Figure 30 Length distribution of the characterized portion of eukaryotes in the PDB overlaid on top 
of the length distribution of full length prokaryotes. 
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Figure 31 Length distribution of the PDB dataset divided into eukaryotes (left) and prokaryotes 
(right). Box plots are first quartile, second quartile (median), and third quartile. Plot whiskers extend 
to 5% and 95% of the data. 
 
3.2.7 Long IDPRs in enzymes are associated with specific functions 
 We performed Gene Ontology (GO) enrichment on human enzymes in order to 
investigate the relationship between CD regions and function (Figure 32). We found that 
enrichment occurred at the extreme ends of the disorder-order spectrum. Enzymes predicted 
to be very ordered were enriched in small molecule and lipid metabolic processes while 
enzymes predicted to have CD regions greater than one hundred were enriched in proteins 
involved in macromolecular metabolic processes, phosphorylation, DNA binding, and 
chromosome organization (Figure 32). Small molecule catabolic processes showed significant 
enrichment only at CD lengths between 5-10, and deubiquitination activity showed 
enrichment only at lengths between 50-100, suggesting there may be some CD length 
specificity for some functions.  
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Figure 32 Gene Ontology (GO) term enrichment in human enzymes, categorized by longest CD 
length per protein. A dashed line indicates processes enriched in proteins predicted to be mostly 
structured. Solid lines correspond to processes enriched in proteins predicted to have long CD regions. 
Thick lines correspond to top scoring general GO terms. Thin lines correspond to more specific GO 
terms with high enrichment. Only terms that had a P value of less than or equal to 10-10 are displayed, 
and highly redundant terms have been removed. The plots have been divided into A) Biological 
Processes and B) Molecular Functions. 
 
3.2.8 Promiscuity is not correlated with disorder in enzymes 
 We performed an analysis of the protein-protein interaction properties of enzymes, 
and did not find any strong correlation between the number of binding partners and the 
amount of predicted disorder using interaction data from IntAct [187] and String [188]. We 
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also did not find any compelling relationships between the amount of predicted disorder in 
enzymes and measures of multi-functionality such as the number of GO terms, the keyword 
multifunctional enzyme in UniProt, or experimentally identified moonlighting enzymes in 
MoonProt [189]. While the literature supports a role for IDPRs in promiscuous binding and 
multi-functionality, a bioinformatics analysis suggests that this relationship may be subtle at 
the proteome level or the currently available datasets are incomplete. 
3.3 Conclusions 
 Experimental evidence (Table 6) clearly demonstrates that the existence of an IDPR or 
multiple IDPRs in an enzyme does not preclude catalysis, and in fact an enzyme may be highly 
disordered, while still being catalytically active. Our disorder prediction measurements 
(Figure 27) support the conclusion that enzymes are rarely entirely disordered, and are 
therefore more structured than non-enzymes on the whole. While there are counter examples 
that beg a closer look, our results are in line with the scientific paradigm that catalysis is 
facilitated by a structured core. 
 However, our results also demonstrate the existence of CD regions in enzymes at a 
similar frequency and length as non-enzymes (Figure 27C). Additionally, CM regions in X-ray 
crystal structures in the PDB show more difference between enzyme types than between 
enzymes and non-enzymes, and show a high frequency for both (Figure 28). While it is 
difficult to directly compare prediction scores in representative proteomes to CM regions in 
the PDB, due to the large proportion of uncharacterized residues in the PDB, we feel the two 
measurements still provide consistent support for the common occurrence of IDPRs in 
enzymes and non-enzymes as well as the minimal difference between the two.  
 While it is difficult to capture the diversity of enzyme structural and related 
functional behaviors at this level, there are still some clear trends. Broadly speaking, 
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enzymes with long CD regions are enriched in macromolecular metabolic processes, such as 
those involving DNA, RNA, and glycoproteins, while proteins predicted to be completely or 
almost completely structured are enriched in small molecule and lipid metabolic processes. 
Transferases and hydrolases are not only enriched in disorder in eukaryotes, but they also 
represent a much larger portion of total enzymes in eukaryotes than in prokaryotes/archaea. 
GO term enrichment analysis highlights deubiquitination processes, histone modification, and 
serine/threonine kinase activity in enzymes with long CD regions. We feel these findings 
demonstrate parallels to commonly accepted functional enrichments in intrinsically 
disordered non-enzymes, such as DNA/RNA binding, regulation, and, signaling processes.   
It should be noted that there are many disorder-related functions that are not well 
represented in currently available ontologies, such as scaffolding protein complexes, 
promiscuity, and various flavors of entropically driven allosteric regulation. Furthermore, 
there are IDPRs that have been shown to be very impactful at very short lengths, and so 
relating quantities of disorder to function, will be necessarily incomplete. A lack of GO 
enrichment for intermediate lengths of CD does not necessarily imply that these regions are 
not functionally relevant, instead it only conveys a lack of overrepresentation for any 
particular function or process 
Additionally, it is clear that disorder does not increase randomly as a function of 
length (Figure 29). For instance, the isomerases (EC5), which are overall predicted to be short 
and structured, increase dramatically in their predicted fraction of disorder in eukaryotes for 
protein lengths between 400-800 and enzymes with multiple assigned EC numbers, peak in 
their fraction of predicted disorder at a length of 1600-800, but then become more structured 
at longer lengths. Rather than accumulating stretches of ‘junk’ sequence, it is more likely 
that protein evolution employs both protein length and protein disorder to cope with changing 
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functional needs. Further studies focusing on the evolution of protein intrinsic disorder in 
specific enzyme families will be necessary to shed further light on this. 
 The minimal action an enzyme must perform to be considered functionally viable is 
catalysis. The reduced length of prokaryotic enzymes compared to eukaryotic enzymes, 
suggests that in some cases of functionally similar enzymes, the prokaryotic version 
represents a minimum length for catalytic viability. The overrepresentation of prokaryotes in 
the PDB (Figure 26) and the truncation of eukaryotic proteins to prokaryotic lengths before 
crystallization (Figure 30, Figure 31), suggests that enzymes are often being studied at this 
minimum viable length. The critical question then, is whether IDPRs that extend beyond the 
catalytic core, are important, and this study answers that question with a resounding yes. 
Broadly speaking, IDPRs are likely to be important in regulatory mechanisms, signaling, 
recognition, and interaction with other proteins and biological molecules and may be useful 
targets for intervention. Furthermore, in cases where the IDPR is mediating different 
substrate interactions, targeting these areas creates the possibility of substrate specific 
inhibition or activation.  
 It is a generally agreed upon theory that protein intrinsic disorder increases in 
proteomes as an evolutionarily directed response to complexity. Our results support and 
extend this hypothesis to include IDPRs in enzymes. Our results provide striking parallels to 
(primarily) non-enzyme studies of protein intrinsic disorder that show enrichment in protein 
signaling and regulation [38]. 
 It has typically been assumed that enzymes represent the structured portion of the 
protein kingdom, and when IDPRs are present, they are functionally neutral. However, our 
analysis does not support this assumption. Instead, structure and disorder are more tightly 
coupled to the complexity of the organism, and in more complex organisms, both enzymes 
and non-enzymes show a marked increase in protein intrinsic disorder. Disorder at the 
78 
 
proteome level appears to emerge in response to organismic and functional complexity, and 
enzymes are not an exception to this rule.  
In summary, the results from this study clearly show the following: 
 The presence of an IDPR in an enzyme does not preclude catalysis. 
 IDPRs are common in enzymes and occur at similar lengths and with similar 
frequencies to non-enzymes. 
 IDPRs in enzymes are functionally important and specific. 
 The experimental emphasis on the structured, catalytic portion of enzymes may 
exclude functionally important regions. 
 Protein intrinsic disorder is a response to complexity in both enzymes and non-
enzymes. 
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4. Materials and Methods 
Note to Reader 
Portions of this chapter have been previously published in RSC Advances, 2016 
6(14):11513-11521 and Protein Sci 2016, 25(3):676-688, and have been reproduced with 
permission from the Royal Society of Chemistry and John Wiley & Sons publishing 
4.1 PubMed Data and Analysis 
4.1.1 IDP terminology in PubMed 
 IDPs in the literature can be referred to by a number of different terms. In order to 
try to maximize coverage while minimizing irrelevant results, we used the search term 
(intrinsically OR natively OR naturally OR inherently) AND (disordered OR unfolded OR 
unstructured OR denatured OR flexible) AND (protein OR region OR peptide OR domain) 
AND (1978/1/1:2014/10/15[dp]) in PubMed at http://www.ncbi. 
nlm.nih.gov/pubmed/. This search covers the date ranges from 1/1/1978 through 
10/15/2014. This search yielded 3343 results. 
 From the initial 3343 results, we manually examined each article to try to ascertain 
which proteins were referred to as an IDP or indicated to have an IDPR. We recorded 
these names using the same language used in the corresponding literature. We 
discarded review, theory, proteomic, and method papers, as well as irrelevant results. 
This filtering resulted in 2278 PubMed articles attached to 1127 search terms, each 
corresponding to a protein or protein domain. These search terms and their 
corresponding PubMed IDs can be found in Appendix B. 
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 Our emphasis was primarily on the language used in the literature for the initial 
search, therefore we did not evaluate the experimental evidence when compiling the 
initial list. For each of the 1127 identified proteins and protein domains, we created a 
search term and attempted to maximize relevant results by adding qualifiers as 
necessary. For instance, the search term we created for tau was “tau AND (protein OR 
Alzheimer’s OR tauopathies OR neuronal),” because a search for “tau” alone would 
return many irrelevant results. Similarly, the search term for p53 was “p53 AND (CTD 
or C-terminal or C-terminus),” because we wanted to specifically target our search 
towards the region that had been identified as intrinsically disordered. We attached 
DisProt and UniProt IDs to each protein search term, however in many cases, this 
required an educated guess due to variations in naming conventions. In some cases, 
more than one UniProt and/or DisProt ID was attached when multiple organisms were 
referred to in the paper(s). In cases where only a domain was mentioned, a UniProt ID 
was not assigned. There were 630 proteins in our set that could be attached to DisProt 
IDs. For each UniProt ID assigned to a protein, a disorder prediction was obtained by 
the disorder predictor RAPID [85] at http://biomine-
ws.ece.ualberta.ca/RAPID/index.php.  
 In order to get the number of both IDP and non-IDP papers per year, PubMed was 
automatically queried for each PubMed ID using the Biopython suite of tools [190] and 
custom Python scripts. The fraction of IDP papers is calculated as the number of IDP 
papers divided by the entire set of papers for that protein search query.  
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4.2 PDB Data and Analysis 
4.2.1 Parsing and preparation of the PDB dataset 
 The initial PDB dataset and enzyme designations were obtained from the structure 
integration with function, taxonomy and sequence (SIFTS) project, which provides a mapping 
between PDB chains and UniProt identifiers [191]. This mapping allows us to match sequence 
regions between multiple PDB files with different residue numbering schemes. The missing 
residues and secondary structure assignments for each PDB file are available in a precompiled 
text file provided by the PDB (available at http://www.rcsb.org/pdb/files/ss_dis.txt). By 
using this precompiled information, we were able to avoid directly parsing the PDB files, thus 
greatly simplifying the method. From this starting point, we performed the following filtering: 
1. Remove obsolete PDB files and obsolete UniProt entries, and retain only X-ray 
crystallography files of individual proteins, protein complexes, or proteins and nucleic 
acid complexes.  
2. Remove any entries with unclear mappings between the UniProt and PDB files, or 
where the mapping spanned fewer than four residues. 
3. Remove any PDB files that do not have any secondary structure information available. 
4. Remove any PDB chain that was not a 100% match with the corresponding region of the 
mapped UniProt entry.   
5. Remove any UniProt ID that had a sequence longer than 10000 residues or that 
contained non-standard amino acids (for consistency with disorder prediction). 
 By removing all crystal structures that did not exactly match their corresponding 
UniProt entry, we hope to minimize any confounding effects from sequence variation. We did 
not filter our dataset to remove homologs or fragments, nor did we filter based on date or 
resolution, as our primary objective was to provide a comprehensive survey of missing regions 
in the PDB. Additionally, for all analysis involving ambiguous regions, covered in Chapter 2, all 
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UniProt IDs with only one associated PDB chain were removed. However, for the analysis 
performed in Chapter 3, these UniProt IDs were retained.  
4.2.2 The assignment of missing residues from PDB files 
 We created a representative sequence of secondary structure assignments, 
uncharacterized residues, and missing residues for each PDB chain. Where a residue was not 
characterized, we used a dash character, where the residue was missing, we used an X 
character, and where the residue was observed but not assigned a secondary structure 
designation, we used a P character. The remaining secondary structure designations were 
from DSSP [83, 125]. The PDB chains could then be directly aligned to compare the missing 
regions. 
 In our analysis, we have considered both the individual residues in each PDB chain, as 
well as a single composite of the PDB chains that is attached to a residue position on the 
UniProt sequence. We distinguish these two by referring to a position in the UniProt entry 
that spans all associated PDB chains as a residue column or a residue position.  
4.2.3 The creation of PDB composite data in Python 
 An implementation of this method was written in the programming language Python 
using the Pandas data analysis library [111].  It is available on GitHub at 
https://github.com/shellydeforte/PDB. 
4.2.4 Amino acid composition 
 The amino acid composition analysis in Chapter 2 was performed by composition 
profiler [192] using 10,000 bootstrap iterations. It is displayed using the flexibility index 
proposed by Vihinen et al. [68]. 
4.2.5 Disorder, binding, and MoRF predictions 
 We used ESpritz X-ray [79], IUPred-short [80, 81], and DynaMine [55, 86] to predict 
intrinsic disorder in the PDB dataset for analysis in Chapter 2. We chose these predictors 
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because they are all fast, perform well on short regions, and do not use multiple sequence 
alignments. Furthermore, each predictor used a different training set in its development, 
including a dataset based on missing regions in X-ray crystal structures (ESpritz X-ray), purely 
globular regions (IUPred Short), and NMR chemical shifts (DynaMine). We chose these 
predictors because we felt they would be best at highlighting distinct physicochemical 
features and would not be biased by specific sequence patterns that may be present in the 
PDB. However, because the ESpritz X-ray training set was most likely to have crossover with 
our dataset, we compared the ESpritz X-ray training set to our dataset and found that there 
were 2029 PDB chains in common, representing only 1.4% of our total dataset. Therefore, 
ESpritz X-ray should not be overly biased towards the PDB dataset. 
 In order to predict binding propensity and the presence of MoRFs, we used the DNA, 
RNA, and protein binding predictor DisoRDPbind [193], as well as the MoRF predictors ANCHOR 
[194, 195] and a new fast version of MoRFpred (unpublished work). All disorder and binding 
scores were treated as binary (either ordered or disordered), with the threshold set based on 
published materials of the predictor in question.  
4.3 Reference Proteomes Data and Analysis 
4.3.1 Parsing and preparation of the Reference QFO dataset 
 66 reference proteomes composing the primary proteome set for the Quest for 
Orthologs (QFO) project [184], corresponding to UniProt release 2014_04, were obtained  
from the EMBL-EBI website at http://www.ebi.ac.uk/reference_proteomes. The sequences 
were loaded into a MongoDB database. Before analysis was performed, protein fragments (as 
defined by UniProt), proteins with non-standard amino acids, and proteins of length 10,000 or 
greater where removed. After filtering, our dataset consisted of 649,902 proteins. 
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4.3.2 Enzyme Commission (EC) designations 
 EC numbers are assigned based on the chemical reaction that is catalyzed by the 
enzyme. On a per protein basis, these designations are assigned based on experimental 
evidence, as well as evidence from homology. We obtained these designations from two 
sources. The first was provided by ExPASy at ftp://ftp.expasy.org/databases/enzyme 
(released 2/4/15). These designations appeared to cover primarily the Swiss-Prot portion of 
the Uniprot Knowledgebase, and therefore did not provide complete coverage for our 
reference proteome set. The second source of EC assignments was obtained from QuickGO at 
http://www.ebi.ac.uk/QuickGO/ on 2/20/15 using the EC to GO mapping.  
4.3.3 Disorder prediction 
 We used a 4/7 per-residue, binary (each residue is assigned by each predictor as 
ordered or disordered) consensus of seven different disorder predictors for disorder prediction 
on the reference proteomes, used in the analysis in Chapter 3. The predictors we used were 
the three flavors of Espritz  (Espritz Disprot, Espritz NMR, and Espritz X-ray) [79] and the 
three flavors of IUPred (IUPred Glob, IUPred Long, and IUPred Short) [80, 81], as well as the 
consensus predictor PONDR-fit [87]. Due to the size of our dataset, our first criteria for 
choosing disorder predictors was that they needed to be fast and to perform reasonably well 
against other predictors via a published benchmark. The three Espritz methods and the three 
IUPred predictors use various biophysical methods obtained from unique training sets, while 
PONDR-fit is itself a meta predictor using the output of 6 methods. The rationale for using a 
large number of predictors was to reduce bias towards one kind of disordered region over 
another.  
 We examined the Matthews correlation coefficient (MCC) for the output of the seven 
predictors and consensus score, for the 166 sequences in our dataset that overlapped with the 
MxD dataset [196], which contains experimentally verified disordered and structured regions. 
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The MCC, introduced in section 1.8.2.2, provides a score that combines information from true 
positives and negatives as well as false positives and negatives, and is one of the metrics used 
for evaluating disorder predictor performance in the CASP competition [75]. Our goal was to 
balance the strengths of proven predictors through consensus, as well as produce a high MCC. 
Only IUPred Glob performed better by the MCC measurement, and this was through a high 
true negative rate, but low true positive rate, which we better balanced through our 4/7 
consensus score (Table 9). 
 Figure 33 shows box plots for the fraction of predicted disorder per protein in the 
human proteome, for each of the seven disorder predictors and the 4/7 consensus. This plot 
demonstrates some of the differences between each predictor at the proteome level. In 
particular, Espritz Disprot and IUPred Glob tend to predict more proteins to be 100% 
structured, and have high true negative rates, while predictors such as PONDR-Fit and Espritz 
NMR predict that most proteins will have some disorder, and have high true positive rates. 
Our consensus score finds a balance between these while maintaining a high MCC. 
Table 9 Matthew correlation coefficient comparison for each disorder predictor and a consensus. 
 
 
 
 
 
Disorder Predictor MCC 
Espritz Disprot 0.486 
Espritz NMR 0.415 
Espritz X-ray 0.419 
IUPred Glob 0.491 
IUPred Long 0.466 
IUPred Short 0.417 
PONDR-fit 0.459 
Consensus 0.487 
86 
 
 
Figure 33 The distribution of disorder scores in the human proteome for seven disorder predictors 
and their consensus scores. Box plots are first quartile, second quartile (median), and third quartile. 
Plot whiskers extend to 5% and 95% of the data. 
4.3.4 Disorder analysis 
4.3.4.1 Disorder calculations 
 We used three different calculations for each whole protein sequence, which were the 
fraction of predicted disorder, the longest continuously disordered (CD) region, and the 
number of CD regions, based on the binary disorder consensus score. The fraction of disorder 
is calculated as the number of predicted disordered residues divided by the length of the 
protein. A CD region is defined as the length of contiguous predicted disordered residues. 
4.3.4.2 Expectation values 
 Due to the non-normality of the distributions of calculations used in this study 
including disorder calculations, missing region calculations, and protein length calculations, 
we have used kernel density estimation (KDE) to approximate the probability density function 
and have calculated expectation values from this by the method outlined by Vincent et. al 
(submitted). KDE approximations were obtained via the Python package PyQt and integration 
was performed using the SciPy Python package. For fractional calculations with limits 
between 0 and 1, we used the quad integration method in Scipy, and for all other calculations 
we used Simpson’s rule, with the width set to 0.5. In this paper, we have referred to 
87 
 
expectation values as “mean” or “average” values, but in no case were they obtained from an 
assumed normal distribution.  
4.3.4.3 Transmembrane domains 
 Disorder prediction was performed for every residue over the intact protein sequence, 
however before disorder calculations (fraction of disorder, longest CD region, number of CD 
regions) were obtained, the transmembrane (TM) domains were removed, because the 
disorder predictors we used in this study have not been properly calibrated on these regions 
[197]. For the purposes of calculating the CD length, the regions surrounding a TM domain 
were considered to be contiguous. The region spanning the TM domain was obtained from 
UniProt. 20% of the proteins in our dataset had at least one transmembrane domain (20% each 
for eukaryotes, prokaryotes and archaea).  
4.3.5 Gene Ontology enrichment 
 Gene ontology (GO) enrichment was performed using the R library topGO [198]. The 
human proteome was used to examine enrichment, due to its high coverage of GO terms. No 
filtering was done based on the evidence code for the GO terms, as we suspected that 
experimental evidence for ontology assignments might be biased in favor of structured 
enzymes. The ontology file and the gene association files were downloaded from 
http://geneontology.org/page/download-ontology and 
http://geneontology.org/page/download-annotations on 12/29/15 Human enzymes were 
divided into subsets based on their longest CD length, and interval lengths were chosen so 
that the subsets were of approximately equal size. Enrichment analysis was performed on 
each length interval subset against the entire set of human enzymes. Both the classic method, 
which gives the top scoring GO term, and the weight01 method of topGO, which obtains more 
specific GO terms were used. P-values were obtained using Fischer’s exact test.  
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Appendix A: Glossary 
Ambiguous / dual personality region: A missing region that is characterized by conflicting 
information concerning the presence of missing residues, between multiple PDB structures of 
the same sequence. 
CD: A predicted continuously disordered region. 
CM: A continuous missing region in an X-ray crystal structure, formed from a composite of all 
structures that match that sequence  
Conditionally disordered region: An intrinsically disordered region that is structured under 
some circumstances and disordered under others. 
Conflicting region: An ambiguous missing region where at least one crystal structure is fully 
observed in the region and one crystal structure is fully missing in the region. 
Conserved region: A missing region that is identical between all crystal structures.  
Contained region: An ambiguous missing region where at least one crystal structure contains 
the full length of the missing region, and all others are contained within.  
Domain wobble: A missing region that arises from the wholesale movement of a structured 
domain, typically facilitated by a small flexible hinge. 
Dynamic disorder: Disorder that is characterized by missing regions that arise from perpetual 
motion at the backbone level, in a region of the crystallized protein. The presence of dynamic 
disorder does not necessarily indicate that this region is intrinsically disordered in vivo. 
EC (Enzyme Commission) number: A numerical classification scheme for enzymes based on 
the reactions they catalyze. 
Hybrid protein: A protein that contains a mix of ordered and disordered regions. 
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IDP (Intrinsically disordered protein): A protein that does not have a stable three-
dimensional state in vivo, though it may have some small regions of structure. 
IDPR (Intrinsically disordered protein region): A region of a protein that is intrinsically 
disordered. 
Missing Region: Missing residues in a three-dimensional crystal structure that occur due to 
regions of low or poorly defined electron density.  
MoRF: Molecular Recognition Feature. A small region, typically between ten and seventy 
residues, within longer disordered regions, which undergo a disorder-order transition upon 
binding to the correct molecular partner. 
Overlapping region: An ambiguous missing region that is composed of multiple missing 
regions in crystal structures which overlap or are contiguous, where no one crystal structure 
contains a missing region that encompasses all. 
Partially disordered region: An intrinsically disordered protein region that displays significant 
residual secondary structure.  
PDB: Protein Data Bank 
Static disorder: Disorder that is characterized by missing regions that arise for reasons other 
than dynamic disorder. These possibilities include an ensemble of stable structures, wobbling 
domains, and crystal packing imperfections. Static disorder is exclusive from intrinsic 
disorder. 
Transient / cryptic disorder: Conditional intrinsic disorder that arises due to environmental 
triggers, and typically provides a functional advantage. 
QFO: Quest for Orthologs 
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Appendix B: IDP Search Terms and PubMed IDs 
 
Search term PubMed IDs that use IDP terminology 
Aavlea1 12569097, 21909508 
ABL tyrosine kinase 17211892, 22632137 
(“Abscisic acid stress 
ripening” OR “Abscisic acid-, 
stress-, and ripening-induced“)  
17189335, 23470734 
Acetolactate synthase catalytic 
subunit AND mitochondria* 
11902841 
Acetylcholinesterase 10892800 
acetylcholinesterase variant 
AND AChE-R  
20173328, 23908786 
Acetyl-CoA carboxylase 15341732 
("actin-binding protein") 11668184, 16110343, 19590096 
ACTR 11823864, 20556825, 21766125, 21894929, 21898648, 22253588, 
23327569, 23373423, 23586525, 23758617, 23799450, 24449148, 
24811666 
Acylamino-acid-releasing 
enzyme 
15296741 
Acyl carrier protein AND e. coli 12057197 
(“acyl carrier protein” AND 
“Vibrio harveyi“) 
17604643, 18059524, 18060858, 18773978 
acylphosphatase AND Sulfolobus 
solfataricus 
14724277, 16287076 
Ad41 16254343 
Adapter molecule crk  12384576, 17515907 
Adenomatous polyposis coli 
protein 
16293619, 16753179, 21859464, 24130866 
adenovirus early region 1A 23783631 
(“adenylate cyclase” OR CyaA) 
AND bordetella pertussis 
2522624, 19015266, 19860484, 20096704, 21112299, 21416544, 
21454565, 23941183, 24145447 
ADP-ribosylation factor-binding 
protein GGA1 
12668765, 12679809, 12767220 
ADR1 regulatory protein 3515197, 9642072 
AF9 23260655 
aggrecan AND CS-attachment 
region AND chondroitin sulfate 
20806220 
Table B1 IDP search terms and PubMed IDs. 
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
AGR2 23780840 
(AKAP79 OR AKAP5) 16442664 
(AKAP250 OR AKAP12 OR AKAP 
gravin) 
16442664, 16762919 
(Alb3 OR A3CT OR ALBINO3) 20018841 
Aldehyde dehydrogenase AND 
mitochondria* 
15983043 
ALG11 11846551, 12538870, 15653326, 16037492, 19929855 
Alkylmercury lyase 15222745 
alpha4 22194938 
Alpha-adducin 7642559 
alpha/beta AND (SASP OR small 
acid soluble) AND protein 
24029407 
Alpha-crystallin A chain 9650074, 12235146 
Alpha-crystallin B chain 9650074, 12235146 
(alpha hemolysin OR HlyA) AND 
Escherichia coli 
7703231, 17407262 
alpha lactalbumin AND HAMLET 20977665 
(alpha S1 OR alpha s) AND 
casein 
7305393, 18155889, 18700180, 20025277, 21689790, 22155633 
alpha spectrin AND (N-terminal 
or N-terminus) 
23200054, 24055379 
(“alpha synuclein”)  8901511, 9264546, 10942772, 10978144, 11152691, 11425308, 
11560511, 11604526, 11734199, 11734201, 11784308, 11812782, 
12032141, 12062445, 12428728, 12534279, 12586824, 12621030, 
12649428, 12667059, 12754258, 12815044, 12834338, 12956606, 
14982446, 15005622, 15096050, 15103328, 15643843, 15671169, 
15744056, 15790533, 15925383, 15939304, 16081040, 16092089, 
16162499, 16197548, 16223878, 16305213, 16343531, 16366524, 
16452621, 16464864, 16489768, 16519533, 16571022, 16981679, 
16981712, 17088319, 17209570, 17279794, 17315997, 17391701, 
17605001, 17623039, 17681539, 17893145, 17904099, 18167451, 
18198943, 18282005, 18419123, 18423664, 18436957, 18511942, 
18541383, 18665616, 18691903, 18692132, 18855701, 18948383, 
18976814, 19081538, 19099437, 19208933, 19293380, 19481090, 
19538146, 19554627, 19555081, 19576220, 19634918, 19645507, 
19655784, 19759002, 19763886, 19847913, 19891973, 19910228, 
20026206, 20028147, 20121219, 20141569, 20199073, 20209636, 
20359221, 20385841, 20490633, 20499903, 20522010, 20580965, 
20620148, 20714568, 20828147, 20847048, 20858207, 20872101, 
20923645, 20947801, 21044603, 21108951, 21120859, 21163351, 
21237164, 21280118, 21297620, 21348834, 21376144, 21570984, 
21641618, 21686180, 21819966, 21841800, 21880361, 22009045, 
22024360, 22147495, 22153624, 22155643, 22166445, 22267729, 
22274962, 22308332, 22315227, 22355530, 22438319, 22560500, 
22573613, 22620680, 22662273, 22760321, 22760334, 22767608, 
22771474, 22820150, 22826265, 22927976, 22947936, 22960996, 
22988846, 23123341, 23162382, 23185649, 23189168, 23199922,  
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
 23214618, 23295967, 23314729, 23349712, 23374074, 23398174, 
23398399, 23477540, 23526115, 23557146, 23567152, 23583776, 
23607785, 23648364, 23775688, 23813793, 23817832, 23927048, 
23941114, 23964651, 23978162, 24003031, 24010662, 24018100, 
24058647, 24066973, 24072065, 24099487, 24140056, 24144701, 
24192542, 24338013, 24360766, 24361273, 24367999, 24374342, 
24383916, 24397337, 24474217, 24475132, 24489820, 24507596, 
24551051, 24552879, 24634806, 24725464, 24739028, 24785077, 
24817693, 24947141, 24970188, 24976112, 25079425, 25081642, 
25129622, 25135664, 25139280, 25209675, 25210774, 25224747, 
25246573, 25264250 
alpha tropomyosin AND (N-
terminal OR N-terminus)  
11575936, 21584876, 22754618, 23052974 
alpha Tubulin 24835459, 25307498 
alphavirus capsid protease AND 
(C-terminal or C-terminus) 
25100849 
ameloblastin 18353005, 22243255, 23782691 
amelogenin 19081741, 19086270, 19236004, 20304108, 21351181, 24114119, 
25298002 
Amidophosphoribosyltransferase 9914248 
(amyloid beta OR Abeta OR APP 
OR “amyloid precursor 
protein”)  
12149256, 15925383, 16197548, 17534931, 18059284, 18511942, 
18625543, 19208933, 19260715, 19540204, 20036826, 20306540, 
20336261, 20385841, 20483339, 20598937, 20709081, 21056574, 
21209058, 21354340, 21376731, 21797254, 21985427, 22155633, 
22270944, 22674434, 22828513, 22952038, 23145167, 23421682, 
23484883, 23561531, 23640306, 23679641, 23798407, 23811057, 
23883055, 24028075, 24077017, 24131107, 24410358, 24871565, 
25018569, 25080056, 25260075 
Andes virus Gn tail 22203819 
androgen receptor AND NH2  11896058, 15023052, 15107424, 23722902 
Ankyrin-2 16368689 
Antibacterial protein LL-37 9452503 
Antitermination protein N 9659923 
AP7 AND nacre  19159266, 24837160, 24977921 
AP-2 complex subunit mu 12086608 
(Aplysia nucleolar protein OR 
ApLLP) 
18078811 
apolipoprotein A-I 12062424, 15476409 
Apolipoprotein E 2063194, 10850798 
(apo-parvalbumin OR (“apo 
form” AND parvalbumin))  
18260106, 19651438 
Arabidopsis phototropin 2 21222437 
aragonite associated 
biomineralization proteins 
23060620 
Aragonite protein AP24 14648763, 15222016 
ARG tyrosine kinase 17211892 
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
arrestin2 19710023 
Aryl hydrocarbon receptor 15641800, 22653727 
ASPP2 18448430 
ataxin-3 15265035, 23891935 
At3g04780 15741346 
Atg13  23670046, 25139988 
Atg29 23858448 
Atg3 24879155 
Atg1 25139988 
ATP synthase-coupling factor 6 
AND mitochondria* 
15327958 
Atrial natriuretic peptide 8043577, 16870210, 21508037, 23110718 
auxilin phosphatase  12732633 
(axin OR axin1) 16293619, 21087614, 23603389 
7B2 22947085 
bacillus lipase 25001212 
bacterial luciferase AND mobile 
loop 
11827516, 19435287, 19710008, 21156144 
bacteriophage p22 coat protein 15784254 
bacteriophage T4 tail lysozyme 15701513 
Bag3 21767525 
Bag6 23665563 
(basic region leucine zipper OR 
bZIP) 
22226835 
(Basic salivary proline-rich 
protein 4 OR IB5 salivary 
protein)  
4093242, 16529944, 17503833, 19402144, 19838685, 20643086, 
20665010, 21524106 
BASP1 23520002, 23821606 
BBK32 15292204 
B cell receptor AND Igalpha 14967045, 17176095, 21487502, 24769851 
B cell receptor AND Igbeta 14967045, 17176095, 21487502, 24769851 
Bcl-2 AND apoptosis 15733859, 23272207 
bcl2 antagonist of cell death 11206074, 16645638 
(bcl-2-like protein 11 OR 
BCL2L11) 
16645638 
Bcl-2-modifying factor 16645638 
(Bcl-xL OR "Bcl-2-like protein 
1") AND human 
8692274, 9346936, 14534311 
(Bcl-xL OR "Bcl-2-like protein 
1") AND rat  
9346936 
(BDNF OR "brain derived 
neurotrophic factor") 
24048383 
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
BECN1 24115198 
Beta-adducin 7642559 
Beta-arrestin-1 11566136, 19710023 
Beta casein 2387396, 7305393, 7979373, 8373815, 11784308, 18155889, 
18303844, 18327957, 18336901, 18700180, 19322774, 21689790, 
24918971, 25144497, 25227946 
Beta-defensin 12 7577957 
beta dystroglycan  14622018, 15295116 
Betagamma-crystallin  15536081, 20929244, 21549498, 22836948, 24671380 
Beta-lactoglobulin 9141136 
beta spectrin AND (C-terminal 
or C-terminus) 
23200054, 24055379 
(“beta synuclein”)  10942772, 11812782, 12667059, 15966733, 17681539, 18436957, 
19081538, 23526115, 24489820 
BimC 14530265 
BimL 16645638, 21378313, 24974286 
Biotin carboxyl carrier protein 
of acetyl-CoA carboxylase 
11956202 
BirA bifunctional protein 1409631, 10497026, 11124029, 20169168 
2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase 
15735341 
(BMFP OR Brucella abortus MFP 
) 
18616282 
BN28a 9046590 
Bone sialoprotein 2 11162539 
Borealin 19146389 
(B23 OR Nucleophosmin OR 
NPM1) AND RNA  
24106084, 24576674, 24952945 
Botulinum neurotoxin  15157097 
bovine dentin phosphophoryn 15892946, 16000119 
(bovine viral diarrhea virus core 
OR (BVDV AND bovine)) 
18032507, 18033802 
bovine viral diarrhea virus poly 
protein 
18033802 
(15b protein OR COR15b) 20510170, 25096979 
BQP35 22317784 
bradykinin OR kininogen domain 
5 
19272336, 21355573, 24810540 
BRCA1  15571721, 15609993, 24303310 
(Brinker OR apo-brinker) 21088782 
BSP-30 10377061, 20331968 
(BTPC OR bacterial type 
phosphoenolypyruvate  
21524275, 22404138, 22569262, 24266766 
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
carboxylase)  
Bud13p 18809678 
bunyavirus nucleocapsid protein 16428606 
bZIP28 23624714 
Cadherin-1 11121423 
CagA AND (C-terminal OR C-
terminus)  
22817985, 24223932, 25116152 
Calcineurin AND (subunit B type 
1 OR regulatory subunit) 
7498455, 8142351, 8524402, 12357034, 17498738, 22100452 
calcitonin AND salmon  23208874 
calcium-dependent protein 
kinase SK5 
15568805 
Calcyclin-binding protein 15996101 
caldesmon 14635127 
Calmodulin 1606151, 1909892, 15099569, 19190183 
Calmodulin-sensitive adenylate 
cyclase 
11807546 
Calpastatin  2407243, 9366272, 14500891, 15751971, 18519038, 18537264, 
19020623, 19378261 
calponin AND (“regulatory 
region” OR (N-terminus OR N-
terminal))  
21463585, 22424482 
Calreticulin 11101311 
Calsenilin 15746104 
Calsequestrin 4472093, 6480588, 6725251, 9628486, 25091206 
cAMP-dependent protein kinase 
inhibitor alpha 
1862343, 2040607 
cAMP-dependent protein kinase 
type I-alpha regulatory subunit 
6487597, 15692043 
Canavalin 8310056 
Carbonic anhydrase 10924115 
Carbon monoxide 
dehydrogenase 
11593006 
(carbon monoxide oxidation 
activator OR CooA) 
22544803 
Carnitine O-acetyltransferase  12562770 
carnobacteriocin-B2 immunity 
protein 
15362858 
(CASK-interactive protein1 OR 
Caskin-1) 
19523119 
Catenin beta-1 9298899, 15629534 
cathepsin F 23684953 
(Cby OR Chibby) 21182262 
CcdA AND antitoxin AND (C-
terminal OR C-terminus)  
17007877, 19647513, 23289531 
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
ccl26 11425309 
C4 Cotton leaf curl Kokhran 
virus 
23500017 
(CCT OR phosphocholine 
cytidylyltransferase) AND alpha 
21303909 
(CCT OR phosphocholine 
cytidylyltransferase) AND beta 
21303909 
CDK2AP1 22427660 
CDNF 22528768 
(CDSN OR corneodesmosin) 20448140 
(“C/EBP homologous protein”)  18534616, 22496840 
Cel7a 21112302 
Cell invasion protein sipA 14512630 
Cellular retinoic acid-binding 
protein 1 
15907702 
(C/EPB OR CCAAT enhancer 
binding protein) 
17102635 
CETN1 24252580 
(c-Fos AND (C-terminal OR C-
terminus OR “activation 
domain”))  
10704222, 11749217, 20498278, 22301802 
Chd64 24805353 
Chemotaxis protein cheA  8639521 
Chemotaxis protein cheW 11799399, 12488014 
CHMP3 21220121 
cholera enterotoxin subunit A  7669757, 15049684 
Choriogonadotropin subunit 
beta 
8202136 
chorismate mutase AroQ 9506949, 15322276 
Chromogranin-A 3473966, 8243650 
Chz1 22807669 
Circadian locomoter output 
cycles protein kaput 
22653727 
(CITED2 OR CIT-ED2 OR 
Cbp/p300-interacting 
transactivator 2) 
14594809 
cJun 12437352 
(CLASP2 OR cytoplasmic linker 
associated protein 2) 
22467876 
Clathrin coat assembly protein 
AP180 
11756460 
(CLPH OR casein like 
phosphoprotein) 
19271754 
clusterin  11570883 
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Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
c-Maf 25220806 
C-myb AND “transactivation 
domain”  
23026051, 23875714, 23980173, 24753318 
(CMyBP-C OR cardiac myosin 
binding protein) 
17876814, 22004751 
c-myc AND oncoprotein  8755740, 15663936, 19022175, 19432426, 20598937, 22399317, 
22457068, 22815918, 24098099 
CNBP 24161561 
Col7 24810542 
(“colicin E9” OR colE9)  12054823, 16114886, 16166265, 16894158, 17375930, 18408035, 
19021565, 20687482, 21098297, 22310049, 23176512, 23812713 
("colicin N") 9680221, 9687368, 11099384, 12679333, 15004032, 15465872, 
17375930, 18573254, 19306883, 20687482, 21098297, 23176512, 
23672584 
Collagen adhesin 8218209, 9334749 
Collagen alpha-1(II) chain 15466413 
complexin 21481779 
(connexin43 OR “connexin 43” 
OR cx43) AND cytoplasmic  
18411056, 18649183, 19808665, 23828237 
(connexin45 OR Cx45) 24853747 
(connexin32 OR Cx32) 22718765 
(connexin40 OR Cx40CT) 19808665 
Conotoxin iota-RXIA 17696362 
Consortin 19864490 
Convicilins 18545275 
Copper-transporting ATPase 1 14572476, 15035611 
COR15A 20510170, 25096979 
(cordon-bleu OR Cobl) 24415668 
(C8orf4 OR “Thyroid Cancer 1” 
OR TC-1)  
15087392, 17905836, 23189168, 23880650, 24941347 
Cox17  15465825, 23060071, 23106082 
CP12 AND protein AND calvin 12846565, 15047759, 16427344, 17947231, 19456123, 20224939, 
21271977, 22153507, 22514274, 22955105, 22988853, 24056937, 
24523724, 24863370 
(CPAP OR CENPJ) AND PN2-3   19131341 
c1R AND CUB2 domain 20178990 
(CREB-binding protein OR CBP) 11823864, 18565542, 19278259, 19894758, 20616042, 20949632, 
20969867, 21268115, 21766125, 21892446, 22174264, 22253588, 
22280219, 22506277, 22829760, 23307074, 23327569, 23373423, 
23586525, 23799450, 23822324, 23875714, 23980173, 24253305, 
24446368, 24449148, 24970129, 25002472, 25049401, 25092343, 
25215518 
(CREB-1 OR Cyclic AMP-
responsive element-binding 
protein 1) 
9413984, 19278259, 19894758, 20949632, 21268115, 22506277, 
23822324, 24446368, 24970129, 25215518 
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C21 reductase 20124700 
cryptochrome 2 15751956, 21841916 
cryptochrome 1 16164372 
CsGA 22493266 
CsGB 22493266 
c-Src kinase AND (N-terminal or 
N-terminus)  
19520085, 23744817 
CSTB protein 16155205 
CtBP AND (C-terminal or C-
terminus) 
16597837 
cucumber mosaic virus 
cucumovirus coat 
20056465 
cwf10 24014766 
cyclin B AND G2 12220679 
Cyclin-dependent kinase 
inhibitor 2A  
11718560, 12630860 
(Cyclin-dependent kinase 
inhibitor 1B OR p27(Kip1) OR 
p27) 
8684460, 11749217, 11790096, 12697905, 15024385, 15609350, 
16214166, 16458085, 17426451, 18177895, 18627125, 21715330, 
22080214, 22276948, 22399317, 22721951, 22988851, 23029651, 
23071750, 24278008, 24646893 
cyclin E LMW 24947816 
Cyclin-H 8941715 
Cysteine AND glycine-rich 
protein 2 
9722554 
(Cystic fibrosis transmembrane 
conductance regulator OR 
CTFR) 
10792060, 17660831, 18423665, 22683332, 23052212, 23578801, 
23826884, 24191035, 25120007 
("cytochrome b5") 18398853 
Cytochrome b-c1 complex 
subunit Rieske AND 
mitochondria* 
10971589 
("cytochrome c") 4344990 
Cytochrome c oxidase copper 
chaperone 
18093982 
CytR 24127726 
Dad1 20727855 
DARPP-32 AND PP1  18954090, 20826336 
(DAXX OR Death domain-
associated protein 6) 
17081986, 19106612, 21134643 
Dbp5p 19281819, 21884706 
DcpS 15769464 
ddc1 19464966 
(DEAF1 OR DEAF-1)  23417771, 25310299 
DE-cadherin 7958432, 11121423 
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Decorin 15501918 
Defensin-like protein 10775411 
Defensin-related cryptdin-4 15595831 
Dehydrin AND (TsDHN-1 OR 
TsDHN-2) 
20921991, 20924623, 21970344 
Dehydrin AND (Xero2 OR Lti30) 16565295, 21665998 
Dehydrin CIDhn 18452657 
Dehydrin COR47 16565295, 18849483 
Dehydrin dhn13 15711789 
Dehydrin DHN1 12529538, 12644649, 19439573, 22882870 
Dehydrin ERD14 18359842, 21336827 
Dehydrin ERD10 16565295, 18359842 
Dehydrin K2 19842064, 21031484 
Dehydrin-like protein 12644649 
Dehydrin MpDhn12 21737399 
Dehydrin Rab18 16565295 
Dehydrin YSK2 19842064 
DELLA protein GAI 19037309, 20103592 
Dematin 19241372, 23355471 
(“Dentin phosphoprotein”)  20037676, 20157636 
deoxycytidylate deaminase 15504034 
Deoxyuridine 5'-triphosphate 
nucleotidohydrolase 
1311056, 11257499 
DF31 18484763 
(dHR38 OR hormone receptor 
38) AND drosophila 
21064127 
Dihydrofolate reductase 9012674, 14717591 
(dihydroorotase OR DHO) 19128030 
dihydropyridine receptor AND 
(alpha1 OR II-III) 
18761102, 19076161, 21525002 
Diol dehydrase beta subunit 10467140 
Diol dehydrase gamma subunit 10467140 
Diphtheria toxin repressor 10339551 
DISC1 21853134 
DivlC 11994149 
DNA-binding protein fis 1619650, 1946369, 9362499, 11183780 
DNA-directed RNA polymerase II 
subunit RPB1 
10704311 
DNA-directed RNA polymerase 
subunit RPABC3 
16632472 
DNA fragmentation factor  11371636 
113 
 
Table B1 (Continued) 
Search term PubMed IDs that use IDP terminology 
subunit alpha  
DNA helicase II 17190599, 19762288 
DnaK suppressor protein 15294156 
DNA ligase AND (Enterococcus 
faecalis OR Streptococcus 
faecalis) 
15296738 
DNA lyase AND (apurinic OR 
apyrimidinic) 
9351835, 11286553 
DNA-repair protein 
complementing XP-A cells 
9699634, 10050037 
DNA repair protein XRCC4 11080143, 11702069, 23197791 
DNA topoisomerase 1 AND 
human 
8567649, 8631793, 8631794, 9488644, 9488652, 9611241, 10380229, 
10497031, 11283003, 14654701, 14741206, 21046176 
DNA topoisomerase 2 AND yeast 8538787, 10380229, 12022860 
Dribble nucleolar protein 16542639 
DRM1 23516402, 24442277 
Dss1 19919104, 23094644 
dTIS11 25246635 
duffy binding protein II 24384095 
dynamitin 24829381 
(dynein intermediate chain AND 
(N-terminal OR N-terminus))  
15581372, 16949604, 19759397, 20472935, 20974845, 22988856 
(E7 AND HPV)  8245034, 15035602, 16889404, 17715947, 19553340, 19598264, 
20088881, 21787785, 22590549, 22683353, 23118886, 23504368, 
23864166, 24086265, 24559112 
(E6 AND HPV)  16889404, 19553340 
Early activation antigen CD69 11101293 
Early E2A DNA-binding protein 4040872, 8039495, 9545375 
E1B-55K 21851959 
EBNA2 24675874 
EBNA1 25011696 
4E-BP  21183464, 22977176 
Ebps 24787448 
E1B-93R 21851959 
E-cadherin 16293619 
(Ecdysteroid receptor OR EcR 
OR Ecdysone receptor) AND 
Drosophila melanogaster 
15192079, 19156821, 22628309, 23727127 
Ectodysplasin-A  14656435 
EDEM1 22905195 
E2 enzymes 3R 22507829 
E2F1 16734427 
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EFL1 24406167 
eglin 1505678 
(EhPCTP-L OR 
Phosphatidylcholine transfer 
protein) AND E. histolytica 
25223890 
E1 HPV 22278251 
(eIF-2B OR eIF2beta) 22683627 
Eisenia lombricine kinase  15327979 
EJ97 20385607 
Elongation factor G 8070397, 11054294 
EMB-1 protein 2339072 
EMGAM56 21819990 
EMI1 23708605 
EMILIN1 protein 18463100 
Endonuclease VIII 16145054 
(ENSA OR endosulfine alpha OR 
endosulfine-alpha) 
18973346 
EntI protein 12832790, 15753083 
Eotaxin 9712872, 11425309 
(Epidermal Growth Factor 
Receptor OR EGFR) AND 
(juxtamembrane domain OR 
kinase domain)  
12196540, 15840573, 22579287 
Epsin-1 11756460 
equine lysozyme AND ELOA 20977665 
ERM AND PEA3 20647002 
Er_P1 23665109 
EscJ 15752191 
esculentin 22899362 
EspF(U) 22921828 
Estradiol 17-beta-
dehydrogenase 1 
7663947, 8756321, 8805577, 9525918, 9927655, 10625652, 12223444, 
12490543 
Estrogen receptor AND alpha 
AND (AF1 domain OR N-terminal 
OR DBD)  
9439992, 11595744, 16604168, 22064478, 23792173 
Estrogen receptor AND beta 
AND (N-terminal OR N-
terminus)  
11595744, 16984883 
(Ets-1 OR Ets1) AND (SRR OR 
“serine rich region”) 
18692067, 25017730, 25024220 
Eukaryotic initiation factor 4F 
subunit p150 
10409688 
Eukaryotic peptide chain 
release factor GTP-binding  
15099522 
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Eukaryotic peptide chain 
release factor subunit 1 
10676813 
Eukaryotic translation initiation 
factor 4E-binding protein 1 
9684899, 24122746 
Eukaryotic translation initiation 
factor 4 gamma 1  
16698542 
Ewings Sarcoma AND oncogene 
AND (EWS OR EWS-Fli1) 
17202261, 19584866, 20598937, 22383402, 22399321, 24086122 
Exostosin-like 2 12562774 
ExsE 22138394 
Fab DNA-1 7506692, 15784256 
FACT AND spt16 18698566, 19605348, 23708362 
FACT AND Ssrp1 18698566, 19605348, 23708362 
Fatty acid-binding protein AND 
intestinal 
9063893 
Fatty acid multifunctional 
protein 
20463021 
Fc receptor gamma chain 21487502 
Fc receptor immunoglobulin 
alpha 
12783876 
Fe(3+)-pyochelin receptor 16139844 
Fermitin AND mouse 19804783 
Ferripyoverdine receptor 15733922 
2Fe-2S ferredoxin 21760931 
(FEZ1 OR fasciculation AND 
elongation protein Zeta 1) 
18615714 
fibrinogen  AND (alpha chain OR 
αIIbβ3)  
11601975, 16288455, 20828133, 21044602, 21247890 
fibrinogen AND (gammaC 
peptide OR gamma subunit) 
18710925 
Fibrinogen beta chain 11601975 
Fibrinogen gamma chain 11601975 
(“fibronectin binding protein A” 
OR FnBPA)  
9398523, 18713862 
Fimbrial protein 11294863 
Fip1 18537269 
Flagellin 2810365 
flavocytochrome beta 2 8706682 
FL cytokine receptor 14759363 
FlgB AND salmonella 15136044 
FlgC AND salmonella 15136044 
FlgF AND salmonella 15136044 
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FlgG AND salmonella 15136044 
FlgM 9454599, 12271132, 20298817, 23352839 
FliE AND salmonella 15136044 
formin homology protein OR 
FHOD1 
16361249 
fowlicidin-1 AND cathelicidins  16817888 
FOXO3a 19821614 
Fragile X mental retardation 1 
protein 
10496225 
Frataxin AND mitochondria* 19843162 
FRQ 24316221 
Fst AND par toxin 20677831 
Fth AND SRP 9659905 
FtsL 11994149 
FtsY 21543314 
FtsZ 23692518, 23714328, 25305578 
Gab2 24739176 
Gab1 21935523, 22536782 
GAGA transcription factor 9878427 
GAGE-12I 23029259 
Gal4 15826952 
Gamma-aminobutyric acid type 
B receptor subunit 1 
15304491 
(“gamma synuclein”)  10942772, 11812782, 12667059, 17234772, 17567567, 19081538, 
22620680, 23526115, 23532302, 24489820 
Gap junction alpha-1 protein 12151412, 14699011, 15284189, 15492000 
Gap junction alpha-5 protein 19808665 
GARP 16280326 
General control protein GCN4 2145515, 2204805, 16483603 
Gibberellin receptor GID1A 19037309 
(GIP OR SCP1) 24751520, 24925644 
Gir2 14715270, 15896712 
Gli3 24146948 
Glial cell line-derived 
neurotrophic factor 
9187648, 10545102 
(gliotactin OR Gli-cyt) AND 
Drosophila 
14579366 
globulin cruciferin B 15912356 
glucokinase 23271955 
Glutathione S-transferase 
alpha-1 
11119643 
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Glutenin subunit DX5 12741823 
Glycine amidinotransferase 
mitochondria* 
9165070, 9218780 
Glycine N-methyltransferase 10756111 
Glycogen synthase kinase-3 
beta  
11427888, 11440715, 12554650 
glycolate oxidase 8706682 
Glycyl-tRNA synthetase 7556056, 10064708 
GmPM1 20071374 
GNA1870 16407174 
G3P attachment protein 10329170, 10756036 
gpNU3 21821043 
GRA2 AND “Toxoplasma Gondii”  24327774, 25246715 
GRAS Proteins 21732203, 22280012 
Grb14 AND PIR domain  14623073, 15465854 
GRE1 21420397 
GroEL 8876186, 15238634, 16223749, 24970895 
GroES 21507961, 23583779 
Growth arrest AND DNA 
damage-inducible protein 
GADD45 alpha 
20460379 
Growth factor receptor-bound 
protein 14 
15901248 
Growth factor receptor-bound 
protein 2 
11178911 
Growth hormone-binding 
protein 
1549776, 8943276, 9571026 
GTA AND blood 12198488, 15987364 
GTB AND blood 12198488, 15987364 
G/T mismatch-specific thymine 
DNA glycosylase 
15959518, 16626738, 18512959, 18587051, 21620710 
GTPase HRas 2406906, 8142349, 9230043, 12842038 
GTP-binding protein Rheb 15728574 
Guanine nucleotide-binding 
protein Gt 
9539726 
GW182 protein 24043833 
H/ACA ribonucleoprotein 
complex subunit 3 
16373493 
(HBx OR hepatitis B protein x) 22820921 
HCN1 25142030 
Heat shock factor protein AND 
(Kluyveromyces lactis) 
7849597, 8745404 
Heat shock factor protein AND 
(Saccharomyces cerevisiae OR  
8745404 
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yeast)  
Heat shock protein beta-1 7649277 
Hef 24947516 
Heh2 23357007 
Hemagglutinin 8072525, 21763731 
hemocyanin 16332393 
 (henipavirus OR hendra virus) 
AND (nucleoprotein) 
20657787, 21317293, 22108848, 22881220 
 (henipavirus OR hendra virus) 
AND (phosphoprotein) 
20657787, 21317293, 24086133 
Hepatitis B polymerase 23202419 
(“hepatitis C virus” AND “core 
protein” )  
18992225, 20453932, 24030713 
Hepatitis GB virus B core 
protein 
18033802 
Hepatocyte growth factor 
receptor 
14559966, 15167892 
herpes virus AND VP16 10398682, 15654739, 15826952, 19643037 
Heterogeneous nuclear 
ribonucleoprotein A1 
11917013 
(HEV OR hepatitis E) AND 
polyproline region 
22811526 
Hfq AND (Escherichia coli OR E. 
Coli) AND (C-terminal or C-
terminus)  
21330354, 23396917 
HIF-1 alpha AND (CAD OR N-TAD 
OR ODD)  
11959977, 15629713 
High affinity immunoglobulin 
epsilon receptor subunit gamma 
14967045 
High mobility group protein B1 15379539 
High mobility group protein 
HMG-I/HMG-Y 
7559428, 10372360, 11498590, 11593421, 19732855, 21545188 
High mobility group-T protein 6273163 
Hirudin variant-1 2567183, 3013692 
Histone-binding protein N1/N2 12695505 
Histone H1.0 10794405, 11413144, 11584004, 16006555 
Histone H3 19878690, 21517079, 22212475 
Histone H1 2373370, 9109385, 14654695, 15050829, 15878177, 21464206, 
22021384, 22813934, 24622397, 24906881 
Histone H5 2181148 
histone H1.2 2373370, 9109385 
Histone H2A 21517079, 22212475 
Histone H4 AND N-terminal 
domain 
19395382, 21517079, 22988066 
Histone H2B 21517079 
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HIV AND P6 AND gag 16234236 
HIV-1 AND Vif AND (C-terminal 
OR C-terminus)  
17598142, 19218568, 20450485 
(HIV-1 Integrase OR HIV-1 gag 
OR HIV-1 p24)  
2438988, 9735293, 21134384, 24960591 
HIV-1 Rev 2125482, 7510518, 23972852 
HIV-1 Tat  16423825, 18189286, 19941902, 20034112, 20450479, 21035463, 
21189124, 21303342, 21560167, 23471103, 23557146 
HIV-2 Vpx 24956595 
HMGB1 25190813 
HMGN5 21518955 
(hNopp 140 OR Nopp 140 OR 
human nucleolar 
phosphoprotein p140)  
22906532, 24218616 
hnRNP-u 22902625 
Homeobox protein Nkx-2.1 8282100, 8898894, 9425125 
Homeobox protein Nkx-3.1 19780584 
Homoaconitase small subunit 20170198 
Hop1 23841450 
(h-prune OR human prune 
protein) 
23939913 
hRTN3 19364499 
HSE1 16110343, 17543868 
HSF1 AND (C-terminal OR C-
terminus)  
17323918, 22044151 
hsl protease AND ATP 10693812 
Hsp12 20797624, 21420397, 21998307, 22848679 
Hsp22 17722063, 19783089 
HSP16.9 11702068 
Hsp33 22385960 
Hsp27 22057845 
hsp90 atpase  22660624 
(“human cardiac hormone”) 
AND (N-terminal OR N-
terminus) AND “B-type 
natriuretic peptide”  
17399679, 18440296 
human desmoglein 1 19136012 
human farnesyltransferase 11687658 
human glucocorticoid receptor 
AND (AF1 OR transcription-
activating fragment OR 
activation function subdomain 
OR activation domain)  
10196139, 15545613, 18946767, 19841061, 20184958, 21501657, 
21603604, 21760925, 22003412, 22669939, 22988850, 23132854 
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Humanin 20116397 
human metapneumovirus 
glycoprotein ectodomain  
25031352 
human replication protein A 16060685, 17976647 
(“human respiratory syncytial 
virus”) AND (phosphoprotein OR 
protein) AND (N-terminal OR N-
terminus OR C-terminal OR C-
terminus)  
16361428, 24031640 
(Huntingtin-interacting protein 
1 OR HIP1) 
18155047 
(huntingtin yeast two hybrid 
protein OR hypk)  
18076027, 23272104, 24465598, 25116620 
H5 vaccinia virus 23476017 
(HvNAC013 OR NAC013) 21856750 
HvNAC005 OR NAC005 21856750 
HY5 17001643 
hydrophilin 21420397 
Hypoxanthine-guanine 
phosphoribosyltransferase 
9790669 
I-309 10821677 
(“IA3” OR “IA 3” OR “IA(3)” OR 
"IA₃") AND (Saccharomyces 
cerevisiae OR Yeast) 
15065849, 17087512, 18681437, 19003993, 21080428, 21490720 
IC AND cytoplasmic dynein 25263009 
ICAT AND transcriptional 
inhibitor 
16293619 
(Icln OR pICln) 15905169, 22179008 
Id protein HLH domain 24981796 
IE1 19812155 
(IE62 OR varicella-zoster virus 
major transactivator) 
19357160 
IF1 AND Bovine 25049402 
(IF7 OR IF17) AND “glutamine 
synthetase”  
12824490, 21992216, 22023175 
IgE cepsilonmx 24457896 
IgG heavy chain CH1 11036070, 19524537 
(importin-beta OR Kap95p) 20816072, 25435324 
Inosine-5'-monophosphate 
dehydrogenase 
9271497 
Insulin-like growth factor-
binding protein 6 
15308688 
Integrase p46 20026028 
Interferon-induced guanylate-
binding protein 1 
10676968 
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interferon regulatory factor 1  20947504, 21245151, 23134341 
Involucrin 10601302 
IRF5 22995936 
IRSp53 18417251 
(“islet amyloid polypeptide” OR 
IAPP)  
10191146, 15576552, 16197548, 17123962, 19647750, 20201512, 
20337445, 21215287, 23266002, 23380070, 24009497, 24021023, 
25260075 
Jagged-1 AND human AND 
cytoplasmic tail  
16427310, 17892488 
JARID1A 18270511, 19430464 
JARID1B 19636953, 20403335 
Juxtanodin 23198089 
kappa casein 11784308, 18155889, 18700180, 20025277, 21689790, 21961598, 
22443319, 25035108 
Ki-1/57  18788774, 20436279 
KorB 20200158 
Lactose operon repressor 8638105, 8683581, 9032054 
(Lactotransferrin OR 
lactoferrin) 
19858187, 25245670 
Lamin A/C 12057196, 21635954 
L20 AND ribosomal protein AND 
(extension OR "amino terminal" 
OR N-terminal OR N-terminus)  
16977336, 19399222 
L5 AND xenopus AND ribosome 12860121 
Latent membrane protein 2A 17174309 
(LBH OR limb bud and heart) 
AND (transcription or 
transcriptional) 
20005203 
LC8 21533121, 21777386 
(L1-CAM OR Neural cell 
adhesion molecule L1) 
18321067 
LEA protein 1 AND soybean 11891239 
Lef-1  16293619, 22089506 
Leukotoxin 7703231 
Lhp1p 21212361 
(Lipid A export ATP-binding OR 
permease protein msbA) 
11546864 
Lipoate-protein ligase A subunit 
1 
16384580 
Lipocalin-1 15489503, 19770509 
Listeria monocytogenes ActA 18577520 
LjIDP1 18779323 
LLA23 23317817 
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Lombricine Kinase 21212263 
L-rhamnose isomerase 10891278 
Lupus La protein 12842046, 15004549, 16387655 
luxU Phosphorelay protein  15740742 
Lymphoid enhancer-binding 
factor 1 
7651541 
Lysozyme C 1515108, 15805597 
Lysyl oxidase 20192271 
lytM 16269153 
MA16 22270696 
Macrophage metalloelastase 15809432 
Macrophage scavenger receptor 
types I and II  
11785981 
major prion protein  9132005, 10618385, 11685242, 12890024, 17190613, 17210575, 
17256089, 17299036, 17359979, 19913031, 20356930, 20580965, 
20627399, 20958083, 21091436, 21196244, 21441896, 21726811, 
22339436, 22421432, 22529103, 22676969, 22987112, 23145167, 
24106878, 25034251, 25101991 
(MANF OR mesencephalic 
astrocyte-derived neutrotrophic 
factor) 
19258449 
MAP1B 23339032 
(MAP2c OR “microtubule-
associated protein 2”)  
15751971, 21634433, 23877929 
(MAP4 OR microtubule 
associated protein 4) 
25054624 
MARCKS 8608129, 11829734, 15640140, 18502797, 22427633, 24590112 
Max AND c-myc 16171389, 19022175, 19114306, 22815918, 23106332 
(MaZE OR PemI-like protein 1) 
AND (Escherichia coli OR E. 
coli) AND (C-terminal OR C-
terminus)  
12533537, 12718874, 12743116, 15735309 
MaZF AND (Escherichia coli OR 
E. coli)  
12718874 
MBD1 24810720 
(MCL-1 OR “myeloid cell 
leukemia 1”) AND (N-terminal 
OR N-terminus)  
20392693, 20480043 
MCoCC-1 19711988 
MDM2  11718560, 12630860, 15953616, 18809412, 20303977, 20436290, 
21191186, 22807444, 24127580 
(MDMX OR MDM4) 24127580 
(“measles virus”) AND 
nucleoprotein  
12621042, 14645906, 14749181, 17034249, 18536007, 19198564, 
19445677, 19718689, 20058326, 20303863, 20450481, 20816082, 
20925409, 21533140, 21613569, 21805002, 22399322, 22887965, 
22901047, 23811056, 24043820 
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(“measles virus”) AND 
phosphoprotein 
12069524, 12944395, 14645906, 15479804, 16046624, 20058326, 
20450481, 21805002, 22887965 
mec1 19464966 
(MeCP2 OR Methyl-CpG-binding 
protein 2) 
17371874, 20405910, 21031501, 21278419, 22294343, 24766768 
MEG-14 23746503 
melanophilin 17513864 
Membrane fusion protein p14 15448165 
(mesoderm development 
candidate 2 OR MESD) 
17488095 
Metal-binding protein smbP 15366930 
Metallo beta lactamase 19395380 
metallothionein-2A 24918957 
metapneumovirus 
phosphoprotein 
24224051 
Methane monooxygenase 
component C 
15379538 
Methyl-accepting chemotaxis 
protein I 
15774032 
Methyl-accepting chemotaxis 
protein II 
15774032 
(mfp-1 OR fp1) AND mussel 22915553 
(mfp-3 OR fp3) AND mussel 22915553 
(mfp-2 OR fp2) AND mussel 22915553 
MGM101 23418572 
MHC class I polypeptide-related 
sequence A 
10367903 
(minichromosome maintenance 
protein OR MCM OR N-mtMCM) 
AND protein 
22208199 
2mit 24098788 
(Mitochondria* fission 1 protein 
OR Fis1) 
14623186 
(“mixed lineage leukemia”) 
AND protein 
20961854, 20969867 
MKL1 24909411 
Modification methylase PvuII 9207015 
Mothers against 
decapentaplegic homolog 4 
10647180 
MpAsr 21327389 
Msh6 17531814 
Msn2 22505609 
MSP2 AND “Plasmodium 
Falciparum”  
17883245, 18440022, 19450733, 20545323, 20865513, 21784057, 
22304430, 22749949, 22966050 
MST1 SARAH Domain 22112013 
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mSYD1A 23791195 
Multidrug resistance protein 
mexA 
15226509 
Mu-type opioid receptor 15680247 
(“myelin basic protein”)  12372316, 12605403, 14695288, 15219899, 16420483, 16794783, 
17131428, 17676872, 18284662, 18326633, 18449534, 19134474, 
19519451, 19636827, 19642704, 19855925, 19856323, 19903451, 
20169373, 20453917, 20593886, 20831157, 21044600, 21887699, 
21889463, 22249765, 22405011, 22728818, 22947219, 23618134, 
23861868, 24516125, 24758710, 24956930 
Myelin transcription factor 1-
like protein 
10606515 
MyoD 1327135 
Myoglobin or apomyoglobin 8844864, 12079388, 21640124 
Myomesin-1 15890201 
myosin 5a 25312846 
(myosin II heavy chain kinase B 
OR MHCK-B) 
20199682 
Myosin light chain 1 3233216 
("myosin motor domain") 9147986, 9741621 
n16.3 24720254 
Nab3 24100036 
NACHT LRR PYD domains-
containing protein 1 
14527388 
Naked2 17045239 
(NCoR OR NCoR-1 OR SMRT) 21925568 
Negative regulator of flagellin 
synthesis 
9095196 
NEIL1 AND (C-terminal or C-
terminus)  
22902625, 23542007 
Neurofilament heavy 
polypeptide 
3220257, 9424114, 9714161 
Neurofilament light polypeptide 3920075, 8634266 
neurogranin 23462742, 24713697 
(“neuroligin 3”)  18456828, 19898942, 21481779, 21647611 
neuromodulin 23462742 
neurotensin 15994900 
NF-kappa-B inhibitor alpha OR 
IkappaBalpha 
7891711, 9872404, 18565540, 21628581, 24605363 
NGF AND neurotrophin 20923662 
(NGN1 OR neurogenin 1) 20102160 
NHE1 AND (C-terminal OR C-
terminus)  
20556825, 21425832 
(Nipah virus OR NiV) AND  18815311 
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glycoprotein  
(Nipah virus OR NIV) AND 
nucleoprotein 
20657787 
(Nipah virus OR NIV) AND 
phosphoprotein 
20657787 
NIPP1 22866172, 22940584, 22988849 
NleH 24373767 
(NMDAR2B OR GluN2B) 18197970, 21481779, 21712388, 23782697 
(NMII OR non muscle myosin II) 19959848 
Nogo-B AND (N-terminal OR N-
terminus OR C-terminal OR C-
terminus)  
17397058, 17437522, 17585875, 19508346 
Non-histone chromosomal 
protein 6A 
10228169 
Non-histone chromosomal 
protein H6 
6273163 
Non-histone chromosomal 
protein HMG-14 
6273163 
Non-histone chromosomal 
protein HMG-17 
565710 
(n16 OR n16N) 21473588 
Nrf2 AND Neh2 domain  16581765, 18762866 
(NRSF OR neural restrictive 
silencer factor) 
21627111, 24446368 
(NS5A OR Non structural protein 
5A) AND hepatitis  
15247283, 15339921, 15902263, 17880107, 18032500, 19244328, 
19249289, 19297321, 20450484, 21489988, 21516467, 22543239, 
22720086, 23740998, 23947833, 25031324 
(NS5B OR Non structural protein 
5B) AND hepatitis 
22815741 
NS1-2 norovirus 22347381 
(NS3 OR non structural protein 
3) AND hepatitis C virus 
23803659 
(Nsp OR nucleoskeletal-like 
protein) AND bacillus subtilis 
23358668 
NT4 AND neurotrophin 20923662 
NtGR-RBP1 24957607 
(NTL9 OR N terminal domain of 
the ribosomal protein L9) 
12416980 
Ntrc1 16169010 
Nuclear cap-binding protein 
subunit 1 
11545740 
Nuclear cap-binding protein 
subunit 2  
11545740 
Nuclear pore complex protein 
Nup133 
15557116, 17360435 
Nuclear receptor coactivator 3  11823864 
Nucleocapsid protein p7 1304355, 1639074 
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Nucleoplasmin 11248694, 24121686 
nudix hydrolase 20657662 
Nup214 24739174 
Nup159 23223634, 24037535, 25263009 
Nup107 17360435, 24739174 
Nup62 24739174 
Nup153 17446086, 21961597, 22665783, 24739174, 24898547 
Nup116 AND (Saccharomyces 
cerevisiae OR yeast) 
18688269 
Nup96 OR Nup98 17360435, 24739174 
NUP2P nucleoporin AND 
(Saccharomyces cerevisiae OR 
yeast) 
12065587 
(Nupr1 OR p8 nucleoprotein) 
AND human 
23929272, 24205110 
("ole e 6") 15247256 
Olfactory marker protein 16008352 
Omega gliadin storage protein 12741823 
Oncomodulin 8487302, 17766386 
Opaque 2 15096055 
(OPN OR osteopontin)  11162539, 15892946, 19636917, 20152802, 20174473, 21609000, 
22342723, 22730383, 24327307, 24928493 
Opy2p 19846660 
Ornithine decarboxylase 10563800, 10985770 
OS-9 25193139 
Osteocalcin 8101026, 8218200 
OVOL2 22737237 
OVOL3 22737237 
OVOL1 22737237 
p300 acetyltransferase  17438265, 23133622, 23307074, 24253305 
(PAGE5 OR Prostate associated 
gene 5)  
19768387, 22073178 
(PAGE4 OR “Prostate associated 
gene 4”)  
21357425, 22078626, 24263171, 24559171 
Paired box 6 10346815 
PAK4 23876315 
Pan1 23801378 
pan3 23340509 
Pancreatic trypsin inhibitor 11320305 
p53 AND (CTD or C-terminal or 
C-terminus)  
7559631, 8875929, 9169453, 9405613, 12110597, 12351827, 
12681938, 14499615, 14534297, 15837201, 16118206, 16461914, 
17335006, 17438265, 17620598, 17972286, 18189286, 18366598,  
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 18391200, 18410249, 18809412, 18812399, 18824006, 19162020, 
19216110, 19557012, 19819244, 19847292, 19933326, 20516128, 
20873738, 20876941, 20961098, 21457718, 21528875, 21541066, 
21686180, 21943426, 21979461, 22046250, 22176582, 22280219, 
22777995, 22807444, 22915551, 22972749, 23028280, 23145047, 
23205890, 23313430, 23352836, 23606624, 23609977, 23807285, 
23836939, 24150971, 24303310, 25075982, 25099811, 25185827, 
25244701 
p8 AND human AND 
nucleoprotein 
11056169, 11350901 
PAP AND protein 25267253 
Par-4 AND (C-terminal or C-
terminus)  
11714921, 12538889, 19490121, 25195896 
Parathyroid Hormone AND 
human 
10837469, 11604398 
Parathyroid hormone-related 
protein 
8138348, 10050767 
ParB 21839743 
parG AND (N-terminal OR N-
terminus)  
14622405, 15951570 
PCaP1 18664522, 20448467 
P130Cas AND CasSD  23827411, 24722239 
PCC6 OR Dsp16 9067253 
(p21(Cip1) OR p21 OR Cyclin-
dependent kinase inhibitor 1)  
8876165, 12964161, 16270364, 18627125, 19165719, 21358637, 
21634433, 22399317, 22988851, 23029651 
pdtaR 15341725 
Pectate lyase 11717490 
(PELPK1 OR At5g09530) 21559969 
Penaeidin-3a 12842879 
PEP-19  19106096, 20973509, 23204517 
peptidylglycine alpha-amidating 
monooxygenase 
19635792 
Peptidyl-prolyl cis-trans 
isomerase 
17125854 
Perfringolysin O 10555145, 15797734 
Peripherin-2 16522184 
Periplasmic hydrogenase large 
subunit 
10368269 
peroxiredoxin AND Aeropyrum 
pernix 
16214169 
Peroxisome proliferator-
activated receptor gamma 
19043829, 21620710 
Pex19 25062251 
(Pex5p OR peroxisomal cycling 
receptor)  
16403517 
(PfAMA1 OR (plasmodium 
falciparum AND "apical  
12270711 
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membrane antigen 1"))  
PfEMP1 18773118 
PFMG1 23865482 
(PfTIM OR triosephosphate 
isomerase) AND plasmodium 
falciparum 
19914198 
PGC-1alpha AND “activation 
domain”  
22049338, 23648480, 23884631 
PhaF 23457638 
phasin AND "Novosphingobium 
nitrogenifigens" 
22582058 
Phenylalanyl-tRNA synthetase 
alpha chain 
7664121, 9016717 
phob 17313959 
phosphatase 2B subunit alpha 8524402 
1-phosphatidylinositol-4,5-
bisphosphate phosphodiesterase 
delta-1 
8602259, 8784353 
Phosphatidylinositol-4-
phosphate 5-kinase type II beta 
9753329 
(Phospholamban OR PLN)  25251363 
((photosystem II OR PSII) AND 
manganese stabilizing protein 
OR "Oxygen-evolving enhancer 
protein 1") 
9890923, 10569936, 10675525, 12146968, 16049787, 16170637, 
16228381, 16503666, 21316983, 23940038, 24437616 
Phytanoyl-CoA dioxygenase 16186124 
Pih1 23139418 
Pilosulin-1 15639237 
pin1 17892493 
PIPKIgamma661 19287005 
p57Kip2 11746698 
(PKR OR protein kinase R) 19232355 
(PKS OR modular polyketide 
synthase)  
22282160 
Plasminogen 15299951 
Plasminogen activator inhibitor 
1 
7664104 
PLK1 14592974 
PMLII 19088278 
Pml1p 18809678, 19010333 
(PM28 OR GmPM28) 20071374 
(pNGF OR pro-Nerve Growth 
Factor OR proNGF)  
16856872, 19089979, 21818348 
PNUTS 24591642 
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poliovirus 3AB 23908350 
polyprotein  foot-and-mouth 
disease virus 
2537470, 6194313 
(positive cofactor 4 OR PC4) 
AND Human 
16605275 
Potassium voltage-gated 
channel protein Shaker 
2122519 
POU domain AND class 2 AND 
transcription factor 
11380252 
POU domain class 2-associating 
factor 1 
10329190, 10541551, 11380252 
PPARgamma 16823031 
P1 protease 24603811 
PPYR1 OR CG15031 16631104 
(PQBP-1 OR “polyglutamine 
tract binding protein 1”)  
19303059, 22500761, 23649393 
precol-NG AND "mussel byssus" 23947342 
preS1 17766372, 23851574 
prestin 24453323 
Prevent host death protein 9915794, 18757857, 20603017 
prickle AND PET domain  19053268 
progesterone receptor AND CTE  19553667, 21803119, 23995840 
(“prokaryotic ubiquitin-like 
protein”)  
19580545, 19607839, 20636328, 20953180, 23198822, 23557784, 
23601177 
ProP effector 15476391 
Prostaglandin E synthase 3 10543959, 10811660 
("prostatic acid phosphatase")  10639192, 19995078 
Protease A Inhibitor 3 10655612 
Protein-arginine deiminase 
type-4 
15247907 
Protein argonaute-2 22539551 
Protein B-Myc 16893186 
Protein C-ets-1 9770451, 15994560 
Protein grpE 9103205 
("protein kinase A") 17222345, 23946424, 24192038 
Protein kinase C alpha V5 
domain 
23762412 
Protein L precursor 9007989 
Protein Nef 10339411 
(Protein phosphatase inhibitor 2 
OR PP1 I-2) 
6245879, 10807923, 17636256, 18954090, 20826336 
Protein phosphatase 1 
regulatory subunit 11 
9843442 
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Protein phosphatase 1 
regulatory subunit 1A 
208844 
(Protein phosphatase 1 
regulatory subunit 12A OR 
MYPT1) 
15164081, 21142030 
Protein phosphatase 1 
regulatory subunit 1B 
6319628 
Protein transport protein SEC9 9326367, 10048921 
Protein transport protein Sec61 
subunit gamma 
8942632 
Protein tyrosine phosphatase 
type IVA 1 
15213447 
Protein tyrosine phosphatase 
type IVA 3 
14704153 
proteoglycans syndecans 24956062 
prothymosin alpha  7548085, 10555983, 10631119, 12062405, 12582818, 16628001, 
17355803, 17929838, 17949994, 22125611, 23050820, 23189168, 
23318954, 23359453 
Proto-oncogene 
serine/threonine-protein kinase 
Pim-1 
15525646 
Prp8 24643059 
(PSC OR posterior sex combs) 22517748 
(PSD-95 OR Post Synaptic 
Density 95) 
16601002, 17666528 
PsHSP18.1 19717454 
PTEN 23783762, 24056727 
PTP1B 24845231 
PulS 21878629 
PUMA 23301700, 24654952, 25313042 
(Purkinje cell protein 4 OR 
PEP19) 
19106096, 20973509, 23204517 
(PvAMA-1 OR Plasmodium Vivax 
Apical Membrane Antigen 1) 
21713006 
PVY AND potato virus 17971447 
PWL2 OR PWL2D 20438845 
PXR receptor AND human 11408620 
Pyridoxine-5'-phosphate oxidase 12824491 
Pyridoxine/pyridoxamine 5'-
phosphate oxidase 
15858270 
pyrrhocoricin  15478127 
Pyruvate dehydrogenase E1 11955070 
quaking-A protein 15811367 
rabies virus phosphoprotein 19341745 
Rab proteins  11886217, 12620235 
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geranylgeranyltransferase 
component A 1 
 
RAC-beta serine/threonine-
protein kinase 
12086620, 12517337 
RAD52 homolog DNA repair 
protein 
12370410 
RAF kinase 7766599, 7791872, 8710867, 8756332 
Rap-2a 9312017, 10591105 
RAP1 AND DNA 8620531 
RAR gamma AND (N-terminal OR 
N-terminus) 
24333369 
Ras-related C3 botulinum toxin 
substrate 1 
14625275 
Ras-related protein Ral-A 15530367 
RcdA 19747489 
recA intein AND Mycobacterium 
tuberculosis 
16288917 
Regulator of chromosome 
condensation 
9510255, 20347844 
Regulator of G-protein signaling 
4 
9108480 
Regulatory protein cro 2146682, 6452580, 7500341, 9653036, 9653037 
(RelA OR SPoT) AND (C-terminus 
OR C-terminal) 
24717772 
Replication protein A AND 70 10526407 
(Reticulon-4 OR RTN 4B) 17397058 
(retinal OR cGMP) AND 
phosphodiesterase AND “gamma 
subunit”  
12643535, 18230733, 19075750, 21393250, 21978030, 22514270 
Retinoic acid receptor RXR-
alpha 
9698548, 9826495 
(RGS9-2 OR Regulator of G-
protein signaling 9) 
20095651 
Rhabdoviridae AND 
nucleoprotein 
20450482 
Rhabdoviridae AND 
phosphoprotein 
20450482 
rhodopsin 10926528, 23883288 
Rho GTPase 9009196 
Ribonuclease P protein 
component 1 
15518563 
Ribonucleoside-diphosphate 
reductase M2 subunit 
7589490, 8130196, 8876648 
Ribonucleoside-diphosphate 
reductase small chain 2 
11526233 
Ribonucleoside-diphosphate 
reductase small chain 1 
11526233 
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Ribonucleoside-diphosphate 
reductase 1 subunit beta 
8805591 
ribosomal protein L2 21592750 
ribosomal protein L4 1618378, 19399222 
ribosomal protein L11 8989327, 9398519 
ribosomal protein L33 3297162 
ribosomal protein P1-alpha 10913306 
ribosomal protein P1-B 15182941 
ribosomal protein P2-beta 9236009, 10913306 
ribosomal protein S4 21156135, 22458631 
ribosomal protein S17 6751823 
ribosomal protein SA AND 
human  
22640394, 23137297 
Ribosyldihydronicotinamide 
dehydrogenase 
16302811 
RIC-3 19899809 
Rif1 24634216 
RNA Polymerase AND  
Escherichia coli 
25261014 
RNA polymerase II subunit A C-
terminal domain phosphatase 
OR FCP1 
12732728, 19888685, 21672523, 21988473 
("Rnase E" AND caulobacter 
crescentus) 
20952404 
(“RNase E” AND (escherichia 
coli OR e. coli))  
15236960, 16516921, 17447862 
(“RNase P” OR “ribonuclease P” 
) AND bacillus subtilis  
11258888, 20476778 
("RNase Y") AND Bacillus subtilis 21803996 
RNF4 ubiquitin ligase  24844634 
ROP6 24993791 
(4.1R OR "Protein 4.1") 20109190 
RPM1-interacting protein 4 25039985 
Rpn4 22349505 
Rv2377c 20434955 
Rv3221c  18004752 
(Rwdd1 OR RWD domain-
conatining protein 1) 
18954556 
RYBP 19170609 
RyR1 22937102 
S12 24442609 
S100A4 24098542 
S100A3 24098542 
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S100A12 24098542 
S100A2 24098542 
S100A6 24098542 
(SAA OR serum amyloid A)  22448726 
San1 21211726, 23363599 
(S100A8 OR S100A9) 24098542 
Saposin-C 14674747, 15713488, 16823039, 18462685 
(“SARS coronavirus” AND 
(“nucleocapsid protein” OR 
“nucleocapsid 
phosphoprotein”)) 
16228284, 23717688 
SAS-5 24778935 
S100B 24098542 
(SbASR-1 OR Abscisic acid stress 
ripening protein) 
22639284 
(SBDS OR TcSBDS) AND 
Trypanosoma cruzi 
19121363 
Sbi-III 18550524 
(SBP2 OR SECIS binding protein 
2) 
11238886, 19467292 
Secretogranin-1 9136897 
(securin OR PTTG1 OR pituitary 
transforming gene 1 product) 
AND (N-terminal OR N-
terminus)  
12220679, 15929994, 19053469 
Selenocysteine lyase 20164179 
(“selenoprotein s” OR SelS OR 
VIMP)  
22700979, 23566202, 23914919 
Sem1 24412063 
(Seminal vesicle protein 
number 4 OR SV-IV)  
18215165, 19851073 
(SeMV OR "sesbania mosaic 
virus") AND polyprotein 2a 
19995563 
(“sendai virus”) AND 
nucleoprotein  
17459940, 20450486 
(“sendai virus”) AND 
phosphoprotein  
14980481, 16284250, 17459940, 17586564, 20450486 
sept4 21949740 
SEPT4 AND septins 17105210 
SERF1a 22854022 
Serine-aspartate repeat-
containing protein D 
9813018 
Serine protease HTRA2 AND 
mitochondria* 
11967569 
Serine/threonine protein 
phosphatase 5 
15713458 
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(SERT OR serotonin transporter) 21129485 
("serum albumin") AND human  10388840 
serum response factor 11406578 
Seryl-tRNA synthetase 8128220, 8230201, 8654381 
SF3b155 24795046 
Sfbl-5 21840989 
sfr1 23324799 
S-Gi alpha 1 8073283 
Sgs1 helicase 24038467 
SHC-transforming protein 1 12906822 
shematrin 25001481 
Sialidase-2 15501818 
Sic1 AND CDK  11734834, 17522259, 17660831, 19008353, 19280601, 20399178, 
20399186, 20589454, 21053335, 21539793, 22356687, 23189058, 
24673507 
Sigma-E factor negative 
regulatory protein 
18421143 
Simian virus Major capsid 
protein VP1 
1659663, 8805523 
SIMPL 17233114 
sindbis virus AND capsid protein 1944569 
SIP18 21420397 
(Sir3p OR silent information 
regulator 3 protein OR SIR3) 
AND saccharomyces cerevisiae  
2121770, 16581798, 16641491, 17176117, 22096199 
sirt1 AND (N-terminal OR N-
terminus OR C-terminal OR C-
terminus) 
23497088, 23811471, 24020004 
Sis1 AND yeast 23227221 
(SKIP OR Ski interaction 
protein) AND SNW 
20007319 
skp1 24506136 
SLBP OR (Histone RNA hairpin-
binding protein) 
15260482, 23286197, 25002523 
Small heat shock protein 
HSP16.5 
9707123 
(small molecule reductase 
regulatory protein OR SmI1 OR 
knr4) 
19086274 
Small proline-rich protein 2E 3133554, 9722562 
SMARCA2  15368101 
SMG-9 20817927 
SMK toxin 9089808 
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(Smoothelin-like protein 1 OR 
SMTNL1) 
18310078, 18477568, 22424482, 24905744 
snurportin 19619473 
Somatoliberin 9375414 
SopB 24075929 
sortase  11371637, 15117963, 22468560 
Sortilin 18191449 
Sorting nexin-3 14514667 
Sos1 23528987 
southern bean mosaic virus 
capsid protein 
6854633 
Sp1 15609997, 19292861 
(SPA OR septal pore associated 
proteins) 
22955885 
SPARC 3427055 
Spatzle 12872120 
spd2 24652833 
spd1 20516199, 20556825, 24652833 
Sperm histone 2243113, 2738040 
spinophilin 18028445 
split intein 24236406 
SpoIISB 21147767 
src family kinase 25071818 
50S ribosomal protein L27 3297162, 11673426 
30S ribosomal protein S12 6751823 
30S ribosomal protein S18 6751823 
30S ribosomal protein S19 6751823 
SRP19 17434535 
SSB AND (escherichia coli OR e. 
coli) AND (C-terminal OR C-
terminus)  
15169953, 20360609, 24021816 
(SseJ OR SseJ-H OR SseJ-L) AND 
salmonella 
20877914 
Sso Acp 24893801 
Stannin 16246365 
starmaker  18636772, 19635593, 22821534 
statherin 15892946 
stathmin 10675326, 12860982, 16554300, 17029844, 17034249 
STIL 24022511 
Stim1 24650897 
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stringent starvation protein A 15735307 
(stringent starvation protein B  14536075 
OR SspB)  
subtilisin AND (propeptide OR 
pro-peptide)  
11519747, 15740747, 23009354 
SUFU 24311597 
sulfhydryl oxidase ALR 23207295 
("sulfite reductase") AND NADPH 10860732 
Sulfotransferase 1A3/1A4 10543947 
(SULT2B1 OR SULT2B1b OR 
Sulfotransferase family 
cytosolic 2B member 1) 
12923182 
SUMO-activating enzyme 
subunit 1 
15660128 
SUMO-activating enzyme 
subunit 2 
15660128 
("Superoxide dismutase") 19800308 
superoxide dismutase-like yojM 15897454 
supervillin 23075227 
Suppressor of cytokine signaling 
3 
16302975 
SVIP 24055875 
Swallow AND cytoplasmic 
dynein 
25263009 
Synaptobrevin homolog 1 9326367 
(synaptobrevin OR Vesicle-
associated membrane protein 
2) 
9346956, 19918058, 21481779 
Synaptopodin 2 variant OR 
Fesselin 
17676886, 18457655 
Synaptosomal-associated 
protein 25 
9671503 
syndecan-1 23888783 
Syntaxin-1A 12680753 
Talin-1 19804783 
Tau AND (protein OR 
alzheimer’s OR tauopathies OR 
neuronal)  
10995239, 11606569, 11807946, 12358741, 14769047, 15615633, 
15628855, 15855160, 15925383, 16464864, 16475817, 16515451, 
16908029, 17047358, 17081491, 17241479, 17262987, 17385861, 
17493042, 18061582, 18495933, 18725412, 18725924, 18771286, 
18783251, 18834853, 18953106, 19075586, 19149675, 19214739, 
19226187, 19549281, 19625749, 19769346, 19826005, 20160453, 
20184958, 20678071, 20687558, 21056617, 21498513, 21560166, 
21677644, 21910444, 21931162, 22083130, 22291015, 22401494, 
22528085, 22762014, 22891813, 22901047, 22998648, 23027743, 
23027744, 23199922, 23515417, 24018100, 24361273, 24559475, 
24581495, 24733915, 24945760, 25206938, 25284680 
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Tax AND HTLV transcriptional 
activator 
14580193 
TB1-C-Grx1 24830542 
TBPL2 17570761 
T-cell surface glycoprotein CD4 9622505 
T-cell surface glycoprotein CD3 
delta chain 
14967045, 17176095 
T-cell surface glycoprotein CD3 
epsilon chain 
14967045, 17176095 
T-cell surface glycoprotein CD3 
gamma chain 
14967045, 17176095 
T-cell surface glycoprotein CD3 
zeta chain  
14967045, 17174464, 17176095, 17410622, 19012413, 19733547, 
21487502, 24120941 
TCP8 23760157 
(TDH OR thermostable direct 
hemolysin) AND Vibrio 
parahaemolyticus 
20335168 
TDP-43  23962724, 24497973 
Teg12 20361791 
Telomere-binding protein 
subunit beta 
9201953, 17082188 
(Tex1 OR Trophozoite exported 
protein 1) 
23056243 
TGBp1 19675186, 22349738 
TgDRE 16605254 
TgGCN5 AND "toxoplasma 
gondii" 
21055425 
THAP11 15368101 
thioredoxin AND (escherichia 
coli OR e. coli) 
12641467, 16113108, 16542678, 16787768 
thioredoxin AND human 17611012 
thioredoxin-glutathione 
reductase AND Schistosoma 
mansoni 
19710012 
thrombopoietin receptor MPL 21858098 
Thylakoid soluble 
phosphoprotein 
17176085 
Thylakoid-soluble 
phosphoprotein AND Arabidopsis 
thaliana 
19113838 
Thymidine kinase 7628623, 9336833 
thymidylate synthase 8845352 
Thymosin beta-4 8269922, 15039431 
TIM23 20718036 
Tir AND "Escherichia coli" 17449672 
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titin AND (SH3 OR PEVK)  7569978, 9472037, 16766517, 16949547, 22910563, 23062340, 
23063534 
Tma46 23002146 
tnrc6c 23340509 
Tob2 23340509 
Toc159 20042108, 21057194 
Tom70 15316022 
tomato aspermy virus 
cucumovirus coat 
20056465 
tonB 15644214 
(Tppp3 OR tubulin 
polymerization-promoting 
protein family member 3) 
19235716 
TPPP/p25 15474353, 15567525, 15883183, 17105200, 23166627 
TRAF3IP2 24021976 
Transcriptional activator 
protein traR 
11171981 
("Transcription factor 4") AND 
human 
11237626, 23821606 
("Transcription factor 7-like 2") 11237626, 11713476 
(Transcription factor p65 OR 
NF-kappab p65) 
9384558, 12686541, 21220295 
Transcription initiation factor 
IIA large subunit 
8610010 
Transcription initiation factor 
IIA small subunit 
8610010 
Transcription initiation factor 
TFIID subunit 1 
9741622 
(transient receptor potential 
OR TRPV1) 
22575650 
Transitional endoplasmic 
reticulum ATPase 
15740751 
Translation initiation factor IF-3 9054966 
translocase of chloroplast 132 20042108 
(translocated promoter region 
protein OR Traf3ip2) 
21216290 
Transthyretin 15477096 
Tricorn protease 11719810 
triosephosphate isomerase 
yeast 
2402636, 3430618 
Trisk 95 22937102 
(tropoelastin OR elastin)  19501564, 24550393, 25142785 
tropomodulin AND (N-terminal 
OR N-terminus)  
11423419, 17706248, 21584876 
Troponin C AND (slow skeletal 
OR cardiac muscles) 
2933134 
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Troponin I cardiac muscle 12840750, 18433059, 20889975, 21322033 
TRP channel AND (C-terminal or 
C-terminus)  
23553631, 24723374 
TRPV6 21664972 
TRPV5 21664972 
TRTK-12 23028280 
Trypsin inhibitor 2 11292835, 11434766 
Tryptophan synthase alpha 
chain 
15667212 
(TTN-1 OR 2MDa_1) 20346955 
Tubulin beta-4 chain 10211825, 24835459, 25307498 
Tubulin beta-2 chain 10211825 
Tumor protein p73  11264583 
Type II secretion system protein 
M 
15081815 
Tyrosine 3-monooxygenase 8104613 
Tyrosine-tRNA ligase 17855524 
Tyrosyl-tRNA synthetase 2504923, 12005430 
U1A 15476390 
U2AF65 24734879 
Ubiquinol oxidase subunit 2 1324168, 8433374, 8618822, 11017202 
Ubiquinol oxidase subunit 1 2162835, 11017202 
UDP-N-acetylhexosamine 
pyrophosphorylase 
11707391 
ULK1 21853163 
Ultrabithorax AND (N-terminal 
OR N-terminus OR C-terminal 
OR C-terminus)  
18508761, 22399320, 25286318 
ultraspiracle AND "aedes 
aegypti" 
24704038 
Ump1 24065419, 24688736 
UmuD 18216271 
Undecaprenyl pyrophosphate 
synthetase 
11581264 
UPF2 19556969 
URE2 10224139, 11327838, 15628874 
(UreG OR urease accessory 
protein) 
15542602, 16846235, 17309280, 21922108, 22271305, 23560717, 
25200810 
Uroporphyrinogen 
decarboxylase 
9564029, 11719352 
UV excision repair protein 
RAD23 homolog A 
14557549 
vanilla mosaic virus coat 
protein 
16421638 
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VapD 25084333 
Vinculin 15642262 
VIP1 25212215 
Viral macrophage inflammatory 
protein 2 
10595530 
("Vitamin D3 receptor") 10678179 
Voltage-dependent L-type 
calcium channel subunit alpha-
1S 
12620094 
Voltage-gated potassium 
channel subunit beta-1 
10585425 
Von Hippel-Lindau disease 
tumor suppressor  
14963040 
VP30 17567691 
VP16 AND transcription factor 
activator 
15826952 
VP2 foot-and-mouth disease 
virus 
2537470 
VP1 foot-and-mouth disease 
virus 
2537470 
VP3 foot-and-mouth disease 
virus 
2537470 
VPg AND “potato virus”  18533220, 19800647 
VP4 protein 2537470 
Vpr AND "Bacillus cereus" 19383694 
(VSVP OR vesicular stomatitis 
virus phosphoprotein) 
22789567 
(WASP interacting protein OR 
WIP(C)) 
23060071, 23870269 
(WASP OR Wiskott-Aldrich 
syndrome) AND protein AND (C-
terminus or C-terminal) 
10724160, 15235593, 18650809, 19260013, 20536449, 21875562 
WDR46 23848194 
Wee1 19858290 
Werner syndrome ATP-
dependent helicase 
16339893 
west nile virus AND (capsid 
protein C OR polyprotein) 
18033802 
WSK3 18948596 
Xanthine AND (dehydrogenase 
OR oxidase) 
11005854 
XO lethal protein 1 12672694 
XPA AND DNA 11344324 
yacG 12211008 
(YB-1 OR “Y Box binding protein 
1” OR YBX1)  
22590640, 24217978 
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Yck2 kinase 21653825 
YefM 14672926, 15980067, 18793646 
Yersinia crystallin 15536081, 16470515 
YopE 18502763 
(Yorkie homolog OR YAP1) 20123905, 20368466 
(zetacyt OR T-cell surface 
glycoprotein CD3 zeta chain) 
18311971 
Zinc finger FYVE domain 
containing protein 9 
15231848 
Zinc finger protein 593 18287285 
Zinc finger protein Eos 15491138 
ZipA 12107152, 23660966 
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UniProt RAPID 
score(s) 
Disprot Search Term num IDP 
PMIDs 
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Q95V77 97.2 DP00186 Aavlea1 2 6 
P00519 30.8 x ABL tyrosine kinase 2 9588 
Q08655 90.43 DP00531 (“Abscisic acid stress 
ripening” OR “Abscisic acid-, 
stress-, and ripening-induced“)  
2 11 
P07342 12.95 DP00398 Acetolactate synthase catalytic 
subunit AND mitochondria* 
1 3 
P07140 2.62 DP00346 Acetylcholinesterase 1 22467 
P22303 3.42 x acetylcholinesterase variant AND 
AChE-R  
2 60 
Q00955 4.93 DP00557 Acetyl-CoA carboxylase 1 3789 
P15891 58.11 DP00634 ("actin-binding protein") 3 2248 
Q9Y6Q9 36.94 x ACTR 13 283 
Q9YBQ2 4.47 DP00248 Acylamino-acid-releasing enzyme 1 115 
P0A6A8 55.13 DP00416 Acyl carrier protein AND e. coli 1 1139 
P55336 3.69 x (“acyl carrier protein” AND 
“Vibrio harveyi“) 
4 32 
Q97ZL0 15.84 DP00513 acylphosphatase AND Sulfolobus 
solfataricus 
2 17 
E2IJZ8 2.58 x Ad41 1 132 
P46108 28.29 DP00748, 
DP00748_A002 
Adapter molecule crk  2 27 
P25054 37.88 DP00519 Adenomatous polyposis coli 
protein 
1 2839 
P03255 43.94 x adenovirus early region 1A 1 249 
P0DKX7 6.74 DP00591 (“adenylate cyclase” OR CyaA) 
AND bordetella pertussis 
10 1798 
Q9UJY5 29.11 DP00314 ADP-ribosylation factor-binding 
protein GGA1 
3 17 
P07248 9.07 DP00077 ADR1 regulatory protein 2 52 
P42568 52.82 x AF9 1 286 
P16112 23.85 x aggrecan AND CS-attachment 
region AND chondroitin sulfate 
1 5 
O95994 18.86 x AGR2 1 159 
Table C1 IDP Search Terms, Search Results, and Disorder Scores 
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P24588 60.42 x (AKAP79 OR AKAP5) 1 230 
Q02952 60.44 x (AKAP250 OR AKAP12 OR AKAP 
gravin) 
2 186 
Q8LBP4 17.97 DP00662 (Alb3 OR A3CT OR ALBINO3) 1 91 
P05091 11.03 DP00383 Aldehyde dehydrogenase AND 
mitochondria* 
1 1226 
P53954 0.73 DP00618 ALG11 5 19 
P77072 8.96 DP00575 Alkylmercury lyase 1 29 
P78318 35.4 x alpha4 1 3804 
P35611 33.65 DP00240 Alpha-adducin 1 583 
P02959 37.1 x alpha/beta AND (SASP OR small 
acid soluble) AND protein 
1 103 
P02489 10.4 DP00444 Alpha-crystallin A chain 2 240 
P02511 18.86 DP00445 Alpha-crystallin B chain 2 700 
P09983 9.48 DP00389 (alpha hemolysin OR HlyA) AND 
Escherichia coli 
2 1085 
P00709 16.9 x alpha lactalbumin AND HAMLET 1 77 
P02662 32.71 DP00330 (alpha S1 OR alpha s) AND casein 6 625 
P02549 17.98 x alpha spectrin AND (N-terminal 
or N-terminus) 
2 212 
P37840 43.57 DP00070 (“alpha synuclein”)  218 6160 
P09493 57.39 x alpha tropomyosin AND (N-
terminal OR N-terminus)  
4 324 
Q71U36 9.76 x alpha Tubulin 2 25523 
Q86925 8.28 x alphavirus capsid protease AND 
(C-terminal or C-terminus) 
1 12 
Q9NP70 38.03 x ameloblastin 3 217 
P63277, 
P45561 
48.57, 
53.97 
DP00692, 
DP00692_A001, 
DP00692_A002, 
DP00693 
amelogenin 7 1577 
P0AG16 6.73 DP00578 Amidophosphoribosyltransferase 1 237 
P05067 18.57 x (amyloid beta OR Abeta OR APP 
OR “amyloid precursor protein”)  
45 47039 
Q99BV0 2.28 x Andes virus Gn tail 1 13 
P10275 21.65 DP00492 androgen receptor AND NH2  4 87 
Q01484 34.24 DP00467 Ankyrin-2 1 21 
P49913 11.18 DP00004, 
DP00004_C002 
Antibacterial protein LL-37 1 223 
P03045 67.29 DP00005 Antitermination protein N 1 230 
Q9BP37 10.23 DP00714 AP7 AND nacre  3 8 
P84092 5.75 DP00455 AP-2 complex subunit mu 1 67 
B0FRH7 100.0 DP00544 (Aplysia nucleolar protein OR 
ApLLP) 
1 5 
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P02647 20.97 DP00386, 
DP00386_C001 
apolipoprotein A-I 2 9783 
P02649 25.87 DP00355 Apolipoprotein E 2 19057 
P02628 32.41 DP00550 (apo-parvalbumin OR (“apo 
form” AND parvalbumin))  
2 17 
P93025 26.23 x Arabidopsis phototropin 2 1 112 
x x x aragonite associated 
biomineralization proteins 
1 35 
Q9BP38 14.04 DP00715 Aragonite protein AP24 2 3 
P42684 21.91 x ARG tyrosine kinase 1 88 
P32120 18.1 x arrestin2 1 330 
P35869, 
Q9WTL8 
10.73, 
25.0 
DP00381, 
DP00735_A004 
Aryl hydrocarbon receptor 2 6732 
Q13625 35.02 x ASPP2 1 83 
P54252 37.09 DP00576 ataxin-3 2 355 
Q9SQZ9 14.77 DP00434 At3g04780 1 1 
Q06628 34.82 x Atg13  2 95 
Q12092 33.8 x Atg29 1 16 
P40344 21.94 x Atg3 1 142 
P53104 17.5 x Atg1 1 235 
P02721 31.48 DP00201 ATP synthase-coupling factor 6 
AND mitochondria* 
1 4 
P01160 29.41 DP00747, 
DP00747_C002 
Atrial natriuretic peptide 4 18856 
Q27974 25.05 DP00351 auxilin phosphatase  1 21 
O15169 31.32 x (axin OR axin1) 3 1100 
P05408 39.15 x 7B2 1 288 
P37957 2.36 x bacillus lipase 1 459 
P07740 9.58 x bacterial luciferase AND mobile 
loop 
4 4 
P26747 8.37 DP00268 bacteriophage p22 coat protein 1 113 
P16009 8.17 DP00284 bacteriophage T4 tail lysozyme 1 15 
O95817 51.83 x Bag3 1 219 
P46379 27.92 x Bag6 1 81 
x x x (basic region leucine zipper OR 
bZIP) 
1 2952 
P10163 100.0 DP00119 (Basic salivary proline-rich 
protein 4 OR IB5 salivary protein)  
8 42 
P80723 100.0 x BASP1 2 98 
O50835 37.85 DP00354 BBK32 1 39 
P11912 4.87 DP00502 B cell receptor AND Igalpha 4 106 
P40259 10.92 DP00503 B cell receptor AND Igbeta 4 101 
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P10415 17.15 DP00297 Bcl-2 AND apoptosis 2 37605 
Q61337 63.73 DP00563 bcl2 antagonist of cell death 2 1472 
O43521, 
O43521-2 
35.86, 
57.97 
DP00643, 
DP00643_A002 
(bcl-2-like protein 11 OR 
BCL2L11) 
1 1327 
Q91ZE9 34.59 DP00645 Bcl-2-modifying factor 1 22 
Q07817 15.88 DP00298 (Bcl-xL OR "Bcl-2-like protein 1") 
AND human 
3 4497 
P53563 26.18 DP00449 (Bcl-xL OR "Bcl-2-like protein 1") 
AND rat  
1 926 
P23560 13.77 x (BDNF OR "brain derived 
neurotrophic factor") 
1 14751 
Q14457 18.22 x BECN1 1 1231 
P35612 38.98 DP00241 Beta-adducin 1 583 
P17870 20.33 DP00390 Beta-arrestin-1 2 1906 
P02666, 
P05814 
30.36, 
25.66 
DP00329, 
DP00199 
Beta casein 15 12216 
P46170 13.16 DP00209 Beta-defensin 12 1 338 
Q62165 27.21 DP00491, 
DP00491_C002 
beta dystroglycan  2 1363 
A0A0E1V051, 
Q2SHN6 
3.85, 
13.78 
x Betagamma-crystallin  5 75 
P02754 15.73 DP00193 Beta-lactoglobulin 1 8488 
P11277 17.36 x beta spectrin AND (C-terminal or 
C-terminus) 
2 248 
Q16143 56.72 DP00555 (“beta synuclein”)  9 1276 
P17120 25.08 DP00636 BimC 1 81 
O54918 44.9 DP00518 BimL 3 47 
P0ABE0 25.64 DP00415 Biotin carboxyl carrier protein of 
acetyl-CoA carboxylase 
1 146 
P96884, 
P06709 
8.65, 
5.61 
DP00695, 
DP00349 
BirA bifunctional protein 4 18 
P9WIC8 12.85 DP00295 2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase 
1 9 
Q2YPE7 14.61 x (BMFP OR Brucella abortus MFP ) 1 4 
Q9FUM5 69.23 DP00216 BN28a 1 2 
P21815 60.25 DP00332 Bone sialoprotein 2 1 971 
Q53HL2 39.29 x Borealin 1 79 
P06748 53.4 x (B23 OR Nucleophosmin OR 
NPM1) AND RNA  
3 614 
Q00496 1.36 DP00732_C001 Botulinum neurotoxin  1 12550 
A0JNH0 57.54 x bovine dentin phosphophoryn 2 38 
P19711 0.65 DP00675_C002 (bovine viral diarrhea virus core 
OR (BVDV AND bovine)) 
2 1937 
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P19711 0.65 DP00675 bovine viral diarrhea virus poly 
protein 
1 17 
Q9SIN5 43.97 DP00743 (15b protein OR COR15b) 2 350 
D0V3W5 37.94 x BQP35 1 1 
P01042 22.67 x bradykinin OR kininogen domain 
5 
3 16948 
P38398 38.06 DP00238 BRCA1  3 11054 
Q9XTN4 40.34 x (Brinker OR apo-brinker) 1 975 
P81019 21.31 DP00669 BSP-30 2 36 
P00864 12.46 x (BTPC OR bacterial type 
phosphoenolypyruvate 
carboxylase) 
4 25 
G2WDT1 80.08 x Bud13p 1 8 
P04873 13.19 x bunyavirus nucleocapsid protein 1 127 
Q9SG86 19.56 x bZIP28 1 25 
P09803 10.86 DP00159 Cadherin-1 1 17095 
Q9JP55 20.55 x CagA AND (C-terminal OR C-
terminus)  
3 64 
P63098 8.82 DP00565 Calcineurin AND (subunit B type 
1 OR regulatory subunit) 
6 296 
P01263 31.62 x calcitonin AND salmon  1 1841 
P28583 15.55 DP00561 calcium-dependent protein 
kinase SK5 
1 1 
Q9CXW3 33.62 DP00226 Calcyclin-binding protein 1 59 
P12957 91.7 DP00120 caldesmon 1 5222 
P62152 36.24 DP00344 Calmodulin 4 38337 
P40136 21.5 DP00395 Calmodulin-sensitive adenylate 
cyclase 
1 94 
P20810 78.39 DP00196 Calpastatin  8 1258 
P51911 26.94 x calponin AND (“regulatory 
region” OR (N-terminus OR N-
terminal))  
2 171 
P27797 35.01 DP00333 Calreticulin 1 2412 
Q9QXT8 21.48 DP00291 Calsenilin 1 395 
P07221 19.75 DP00132 Calsequestrin 5 1038 
P61926 48.68 DP00015 cAMP-dependent protein kinase 
inhibitor alpha 
2 1334 
P00514 16.05 DP00245 cAMP-dependent protein kinase 
type I-alpha regulatory subunit 
2 38 
P50477 10.11 DP00436 Canavalin 1 55 
P40881 6.07 DP00110 Carbonic anhydrase 1 10911 
P31896 5.48 DP00239 Carbon monoxide dehydrogenase 1 444 
Q3AB29 4.15 x (carbon monoxide oxidation 
activator OR CooA) 
1 110 
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P43155 6.55 DP00305 Carnitine O-acetyltransferase  1 373 
P38582 9.01 DP00380 carnobacteriocin-B2 immunity 
protein 
1 10 
Q8WXD9 43.12 x (CASK-interactive protein1 OR 
Caskin-1) 
1 2 
Q02248 16.39 DP00341 Catenin beta-1 2 122 
Q9UBX1 6.82 x cathepsin F 1 59 
Q9Y3M2 30.95 DP00709 (Cby OR Chibby) 1 257 
P62552 25.0 x CcdA AND antitoxin AND (C-
terminal OR C-terminus)  
3 4 
Q9Y258 8.51 DP00696 ccl26 1 216 
C1K010 69.0 x C4 Cotton leaf curl Kokhran virus 1 2 
P49585 29.7 x (CCT OR phosphocholine 
cytidylyltransferase) AND alpha 
1 325 
Q9Y5K3 31.44 x (CCT OR phosphocholine 
cytidylyltransferase) AND beta 
1 328 
O14519 33.91 x CDK2AP1 1 62 
Q49AH0 12.3 x CDNF 1 39 
Q15517 52.36 DP00706 (CDSN OR corneodesmosin) 1 141 
P35638 73.37 DP00624 (“C/EBP homologous protein”)  2 2273 
G0RVK1 19.07 x Cel7a 1 163 
E1WAC6 23.8 DP00157 Cell invasion protein sipA 1 54 
P29762 11.68 x Cellular retinoic acid-binding 
protein 1 
1 551 
Q03701 27.8 x (C/EPB OR CCAAT enhancer 
binding protein) 
1 9824 
Q12798 44.19 x CETN1 1 9 
P01100 44.21 DP00078 (c-Fos AND (C-terminal OR C-
terminus OR “activation 
domain”))  
4 832 
Q9VZI1 18.09 x Chd64 1 3 
P07363 7.65 DP00407 Chemotaxis protein cheA  1 421 
Q56311 5.96 DP00350 Chemotaxis protein cheW 2 244 
Q9Y3E7 53.15 x CHMP3 1 44 
P01555 6.2 DP00250 cholera enterotoxin subunit A  2 51 
P01233 23.03 DP00013 Choriogonadotropin subunit beta 1 4569 
Q57696 23.23 DP00465 chorismate mutase AroQ 2 25 
P05059 67.48 DP00118 Chromogranin-A 2 4460 
P40019 88.24 x Chz1 1 11 
O08785 23.39 DP00734 Circadian locomoter output 
cycles protein kaput 
1 3 
Q99967 39.63 DP00356 (CITED2 OR CIT-ED2 OR 
Cbp/p300-interacting  
1 169 
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   transactivator 2)   
P05412 33.23 x cJun 1 398 
O75122 17.23 x (CLASP2 OR cytoplasmic linker 
associated protein 2) 
1 291 
Q05140 36.72 DP00225 Clathrin coat assembly protein 
AP180 
1 174 
Q68FX6 55.13 x (CLPH OR casein like 
phosphoprotein) 
1 770 
P05371 25.28 DP00014 clusterin  1 2078 
O75444 23.06 x c-Maf 1 397 
Q708E1 45.42 x C-myb AND “transactivation 
domain”  
4 210 
Q14896 15.93 x (CMyBP-C OR cardiac myosin 
binding protein) 
2 2450 
P01106 42.14 DP00260 c-myc AND oncoprotein  9 12286 
P62633 11.3 x CNBP 1 166 
Q02388 37.02 x Col7 1 22 
P09883 36.94 DP00342 (“colicin E9” OR colE9)  12 111 
P08083 21.71 DP00461 ("colicin N") 13 51 
Q53654 49.11 DP00098 Collagen adhesin 2 397 
P02458 57.7 DP00274 Collagen alpha-1(II) chain 1 367 
O14810 90.3 x complexin 1 238 
P17302 20.16 x (connexin43 OR “connexin 43” 
OR cx43) AND cytoplasmic  
4 728 
P36383 30.56 x (connexin45 OR Cx45) 1 461 
P08034 10.95 x (connexin32 OR Cx32) 1 986 
P36382 20.67 x (connexin40 OR Cx40CT) 1 239 
Q7Z094 15.22 x Conotoxin iota-RXIA 1 3 
Q6PJW8 34.48 x Consortin 1 2 
x x x Convicilins 1 4 
Q04656 7.0 DP00282 Copper-transporting ATPase 1 2 107 
Q42512 45.32 DP00536 COR15A 2 83 
Q53SF7 45.18 x (cordon-bleu OR Cobl) 1 57 
Q9NR00 30.19 DP00372 (C8orf4 OR “Thyroid Cancer 1” 
OR TC-1)  
5 21820 
Q12287 47.83 DP00277 Cox17  3 103 
Q9LZP9, 
A6Q0K5 
47.33, 
24.3 
DP00534, 
DP00359 
CP12 AND protein AND calvin 14 39 
Q9HC77 48.95 x (CPAP OR CENPJ) AND PN2-3   1 2 
P00736 3.26 DP00621 c1R AND CUB2 domain 1 8 
P45481 32.28 DP00348 (CREB-binding protein OR CBP) 31 12497 
P15337 33.72 DP00682,  (CREB-1 OR Cyclic AMP-  10 5167 
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  DP00080 responsive element-binding 
protein 1) 
  
Q91WR5 4.33 DP00690 C21 reductase 1 215 
Q49AN0 17.37 DP00473 cryptochrome 2 2 548 
Q43125 18.94 DP00474 cryptochrome 1 1 665 
B2CY49 50.0 x CsGA 1 246 
Q548S0 11.26 x CsGB 1 49 
P41240 4.89 x c-Src kinase AND (N-terminal or 
N-terminus)  
2 73 
Q76LA1 28.57 DP00511 CSTB protein 1 245 
Q9Z2F5 12.79 DP00499 CtBP AND (C-terminal or C-
terminus) 
1 269 
Q6Q4B0 18.81 x cucumber mosaic virus 
cucumovirus coat 
1 141 
O94316 8.74 x cwf10 1 1 
P14635 26.79 DP00223 cyclin B AND G2 1 1466 
Q64364, 
Q8N726 
27.81, 
69.7 
DP00335, 
DP00336 
Cyclin-dependent kinase inhibitor 
2A  
2 6615 
P46527 54.55 DP00018 (Cyclin-dependent kinase 
inhibitor 1B OR p27(Kip1) OR 
p27) 
21 10136 
P24941 5.7 x cyclin E LMW 1 39 
P51946 9.6 DP00307 Cyclin-H 1 210 
Q05158 24.23 DP00438 Cysteine AND glycine-rich protein 
2 
1 125 
P13569 1.89 DP00012 (Cystic fibrosis transmembrane 
conductance regulator OR CTFR) 
9 8214 
P20070 4.65 x ("cytochrome b5") 1 2494 
P08067 11.63 DP00687 Cytochrome b-c1 complex 
subunit Rieske AND 
mitochondria* 
1 4 
P00004 54.29 DP00006 ("cytochrome c") 1 38417 
Q14061 52.38 DP00543 Cytochrome c oxidase copper 
chaperone 
1 93 
P0ACN7 11.73 x CytR 1 101 
Q12248 24.47 x Dad1 1 123 
Q9UD71 85.78 x DARPP-32 AND PP1  2 52 
Q9UER7, 
O35613 
40.81, 
38.29 
DP00707, 
DP00708 
(DAXX OR Death domain-
associated protein 6) 
3 471 
P20449, 
Q09747 
13.9, 
16.7 
x Dbp5p 2 17 
Q96C86 10.09 x DcpS 1 200 
Q08949 22.55 x ddc1 1 66 
O75398 24.96 x (DEAF1 OR DEAF-1)  2 76 
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Q24298 5.37 DP00269 DE-cadherin 2 132 
P21793 6.11 DP00489 Decorin 1 2244 
P56552 25.93 DP00582 Defensin-like protein 1 188 
P28311 44.57 DP00388 Defensin-related cryptdin-4 1 3 
E2GK57 95.51 x Dehydrin AND (TsDHN-1 OR 
TsDHN-2) 
3 5 
P42758 100.0 DP00658 Dehydrin AND (Xero2 OR Lti30) 2 10 
Q6L8H6 97.48 x Dehydrin CIDhn 1 2 
P31168 83.77 DP00657 Dehydrin COR47 2 9 
A1IVM4 100.0 x Dehydrin dhn13 1 1 
P12950 83.93 DP00530 Dehydrin DHN1 4 14 
P42763 100.0 DP00667 Dehydrin ERD14 2 7 
P42759 93.85 DP00606 Dehydrin ERD10 2 7 
Q4VT48 100.0 x Dehydrin K2 2 3 
Q39805 59.73 DP00170 Dehydrin-like protein 1 37 
F5CAF0 100.0 x Dehydrin MpDhn12 1 1 
P30185 74.73 DP00689 Dehydrin Rab18 1 5 
Q3ZNL4 100.0 x Dehydrin YSK2 1 4 
Q9LQT8 6.94 DP00724 DELLA protein GAI 2 79 
Q08495 55.56 x Dematin 2 54 
Q9NZW4 62.64 x (“Dentin phosphoprotein”)  2 622 
P16006 5.7 DP00583 deoxycytidylate deaminase 1 191 
P06968 7.95 DP00337 Deoxyuridine 5'-triphosphate 
nucleotidohydrolase 
2 30 
O16042 83.7 x DF31 1 7 
P49869 25.91 DP00594, 
DP00594_A002 
(dHR38 OR hormone receptor 38) 
AND drosophila 
1 43 
P0ABQ4 12.58 DP00301 Dihydrofolate reductase 2 6752 
O66990 3.55 x (dihydroorotase OR DHO) 1 693 
Q13062 9.84 x dihydropyridine receptor AND 
(alpha1 OR II-III) 
3 477 
Q59471 26.79 DP00105 Diol dehydrase beta subunit 1 10 
Q59472 30.06 DP00106 Diol dehydrase gamma subunit 1 7 
H2I233 11.5 DP00374 Diphtheria toxin repressor 1 106 
Q9NRI5 29.16 x DISC1 1 559 
P37471 36.0 x DivlC 1 2 
P0A6R3 16.33 DP00422 DNA-binding protein fis 4 409 
P08775 16.85 DP00181 DNA-directed RNA polymerase II 
subunit RPB1 
1 165 
P52434 14.0 DP00504 DNA-directed RNA polymerase 
subunit RPABC3 
1 4963 
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O00273 18.13 DP00173 DNA fragmentation factor 
subunit alpha 
1 93 
P03018 8.19 DP00684 DNA helicase II 2 12888 
P0ABS1 34.44 DP00414 DnaK suppressor protein 1 44 
Q837V6 8.73 DP00326 DNA ligase AND (Enterococcus 
faecalis OR Streptococcus 
faecalis) 
1 77 
P27695 36.79 DP00007 DNA lyase AND (apurinic OR 
apyrimidinic) 
2 1842 
P23025 30.77 DP00243 DNA-repair protein 
complementing XP-A cells 
2 9 
Q13426 27.38 DP00152 DNA repair protein XRCC4 3 425 
P11387 48.63 DP00075 DNA topoisomerase 1 AND human 12 3961 
P06786 19.4 DP00076 DNA topoisomerase 2 AND yeast 3 292 
Q9VPU8 45.8 DP00540 Dribble nucleolar protein 1 1 
x x x DRM1 2 23 
P60896 84.29 DP00617 Dss1 2 84 
P47980 33.94 x dTIS11 1 6 
C9WHS9 5.18 x duffy binding protein II 1 96 
Q13561 25.69 x dynamitin 1 131 
O14576, 
Q24246 
25.43, 
19.0 
DP00360, 
DP00605 
(dynein intermediate chain AND 
(N-terminal OR N-terminus))  
6 37 
P03129 36.73 DP00024 (E7 AND HPV)  15 3366 
P06463 12.66 x (E6 AND HPV)  2 3507 
Q07108 13.07 DP00306 Early activation antigen CD69 1 1717 
P03265 34.97 DP00003 Early E2A DNA-binding protein 3 193 
P03243 14.31 x E1B-55K 1 118 
P12978 54.41 x EBNA2 1 497 
P03211 50.55 x EBNA1 1 724 
A3KLJ6 59.29 x 4E-BP  2 219 
Q53630 53.7 x Ebps 1 581 
F2YRV4 100.0 x E1B-93R 1 2 
P12830 14.29 x E-cadherin 1 21477 
P34021 14.58 x (Ecdysteroid receptor OR EcR OR 
Ecdysone receptor) AND 
Drosophila melanogaster 
4 279 
Q92838, 
Q92838-3 
35.04, 
35.22 
DP00460, 
DP00460_A003 
Ectodysplasin-A  1 583 
Q92611 4.57 x EDEM1 1 83 
x x x E2 enzymes 3R 1 13 
Q01094 30.21 x E2F1 1 2720 
Q7Z2Z2 20.0 x EFL1 1 9 
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P01051 11.43 x eglin 1 543 
C4LXF1 6.11 x (EhPCTP-L OR 
Phosphatidylcholine transfer 
protein) AND E. histolytica 
1 1 
P17382 9.54 x E1 HPV 1 555 
P32501 16.99 x (eIF-2B OR eIF2beta) 1 509 
O15991 6.47 x Eisenia lombricine kinase  1 6 
Q8KMU4 36.36 x EJ97 1 7 
P13551 18.23 DP00021 Elongation factor G 2 691 
P17639 100.0 DP00022 EMB-1 protein 1 5 
Q8I1K3 21.85 x EMGAM56 1 1 
O00423 10.31 x EMI1 1 90 
Q9Y6C2 19.49 DP00569 EMILIN1 protein 1 26 
P50465 5.7 DP00375 Endonuclease VIII 1 730 
O43768 93.39 x (ENSA OR endosulfine alpha OR 
endosulfine-alpha) 
1 186 
Q47785 10.68 DP00289 EntI protein 2 8 
P51671 25.77 DP00641 Eotaxin 2 2776 
P00533 4.79 DP00309 (Epidermal Growth Factor 
Receptor OR EGFR) AND 
(juxtamembrane domain OR 
kinase domain)  
3 4100 
O88339 45.39 DP00251 Epsin-1 1 237 
x x x equine lysozyme AND ELOA 1 6 
P41161 33.33 x ERM AND PEA3 1 72 
x x x Er_P1 1 1 
Q7DB66 10.0 DP00290 EscJ 1 17 
P86155 32.61 x esculentin 1 67 
Q8X482 60.42 x EspF(U) 1 89 
P14061 11.89 DP00023 Estradiol 17-beta-dehydrogenase 
1 
8 916 
P03372 11.43 DP00074 Estrogen receptor AND alpha AND 
(AF1 domain OR N-terminal OR 
DBD)  
5 254 
Q92731 15.47 DP00079 Estrogen receptor AND beta AND 
(N-terminal OR N-terminus)  
2 111 
P14921 15.42 x (Ets-1 OR Ets1) AND (SRR OR 
“serine rich region”) 
3 10 
P39935 45.27 DP00082 Eukaryotic initiation factor 4F 
subunit p150 
1 2 
O74718 28.7 DP00396 Eukaryotic peptide chain release 
factor GTP-binding subunit 
1 7 
P62495 5.72 DP00310 Eukaryotic peptide chain release 
factor subunit 1 
1 26 
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Q13541 61.86 DP00028 Eukaryotic translation initiation 
factor 4E-binding protein 1 
2 365 
Q04637 33.83 DP00406 Eukaryotic translation initiation 
factor 4 gamma 1  
1 303 
Q01844 41.92 DP00632 Ewings Sarcoma AND oncogene 
AND (EWS OR EWS-Fli1) 
6 484 
Q9ES89 1.82 DP00397 Exostosin-like 2 1 4 
Q9I322 49.38 x ExsE 1 21 
x x DP00270 Fab DNA-1 2 10 
Q8IRG6 28.16 DP00721 FACT AND spt16 3 70 
Q05344 46.89 DP00720 FACT AND Ssrp1 3 75 
P02693 13.64 DP00263 Fatty acid-binding protein AND 
intestinal 
1 1108 
Q9ZPI5 4.41 DP00654 Fatty acid multifunctional 
protein 
1 605 
P12318 11.04 x Fc receptor gamma chain 1 1286 
P24071 4.88 DP00311 Fc receptor immunoglobulin 
alpha 
1 4960 
P42512 9.31 DP00176 Fe(3+)-pyochelin receptor 1 6 
P59113 15.07 DP00655 Fermitin AND mouse 1 5 
P48632 4.29 DP00183 Ferripyoverdine receptor 1 23 
P00250 14.43 x 2Fe-2S ferredoxin 1 223 
Q99689 40.31 x (FEZ1 OR fasciculation AND 
elongation protein Zeta 1) 
1 32 
P14448 20.78 DP00233 fibrinogen  AND (alpha chain OR 
αIIbβ3)  
5 1408 
P02679 10.6 x fibrinogen AND (gammaC peptide 
OR gamma subunit) 
1 153 
Q02020 10.8 DP00234 Fibrinogen beta chain 1 967 
O93568 4.37 DP00235 Fibrinogen gamma chain 1 311 
P14738, 
Q06556 
39.29, 
34.19 
DP00025, 
DP00127 
(“fibronectin binding protein A” 
OR FnBPA)  
2 406 
P17838 12.1 DP00206 Fimbrial protein 1 1793 
P45976 40.06 DP00625 Fip1 1 99 
P06179 11.11 DP00026 Flagellin 1 3902 
P00175 9.98 x flavocytochrome beta 2 1 46 
P36888 4.83 DP00312 FL cytokine receptor 1 973 
P16437 18.84 x FlgB AND salmonella 1 24 
P0A1I7 11.19 x FlgC AND salmonella 1 10 
P16323 29.08 x FlgF AND salmonella 1 13 
P0A1J3 19.23 x FlgG AND salmonella 1 20 
O66683 73.86 DP00701 FlgM 4 141 
P26462 21.15 x FliE AND salmonella 1 20 
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Q9Y613 21.48 DP00448 formin homology protein OR 
FHOD1 
1 278 
Q6QLQ5 10.81 x fowlicidin-1 AND cathelicidins  1 7 
O43524 39.08 x FOXO3a 1 1132 
Q06787 29.43 DP00134 Fragile X mental retardation 1 
protein 
1 2158 
Q16595 18.1 DP00607 Frataxin AND mitochondria* 1 508 
P19970 40.44 x FRQ 1 260 
Q9RLG7 45.45 x Fst AND par toxin 1 10 
x x x Fth AND SRP 1 1 
Q07867 23.93 x FtsL 1 82 
P10121 31.99 x FtsY 1 205 
P0A9A6 12.27 x FtsZ 3 1602 
Q9UQC2 42.16 x Gab2 1 315 
Q13480 40.63 x Gab1 2 413 
Q08605-2 40.66 DP00328 GAGA transcription factor 1 211 
P0CL82 86.32 x GAGE-12I 1 1 
P04386 11.58 x Gal4 1 4292 
Q9Z0U4 4.94 DP00463 Gamma-aminobutyric acid type B 
receptor subunit 1 
1 178 
O76070 53.54 DP00630 (“gamma synuclein”)  10 354 
P08050 19.9 DP00278 Gap junction alpha-1 protein 4 130 
Q01231 23.18 DP00646 Gap junction alpha-5 protein 1 9 
Q28181-4 73.39 DP00441 GARP 1 255 
P03069 51.6 DP00083 General control protein GCN4 3 104 
Q9MAA7 3.77 DP00723 Gibberellin receptor GID1A 1 31 
P58466 13.03 x (GIP OR SCP1) 2 2919 
Q03768 36.98 DP00163 Gir2 2 11 
P10071 33.23 x Gli3 1 681 
Q07731 29.86 DP00029 Glial cell line-derived 
neurotrophic factor 
2 3683 
Q7KT70 8.68 x (gliotactin OR Gli-cyt) AND 
Drosophila 
1 12 
P15456 7.91 x globulin cruciferin B 1 8 
P35557 5.59 x glucokinase 1 3364 
P00502 12.61 DP00731 Glutathione S-transferase alpha-
1 
1 176 
P10388 50.83 DP00285 Glutenin subunit DX5 1 9 
P50440 7.33 DP00099 Glycine amidinotransferase 
mitochondria* 
2 23 
P13255 2.39 DP00031 Glycine N-methyltransferase 1 376 
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P49841 19.29 DP00385 Glycogen synthase kinase-3 beta  3 4189 
F8WQN2 6.77 x glycolate oxidase 1 314 
P56206 6.72 DP00032 Glycyl-tRNA synthetase 2 172 
Q01417 80.35 DP00664 GmPM1 1 2 
Q6QCC2 17.15 DP00471 GNA1870 1 9 
P03661 29.01 DP00034 G3P attachment protein 2 10 
P03712 30.91 x gpNU3 1 5 
P13404 43.78 x GRA2 AND “Toxoplasma Gondii”  2 50 
x x x GRAS Proteins 2 599 
O88900 14.68 DP00490 Grb14 AND PIR domain  2 9 
Q08969 89.88 x GRE1 1 14 
P0A6F5 9.49 x GroEL 4 2724 
P0A6G1 14.43 DP00412 GroES 2 1176 
P24522 20.0 DP00704 Growth arrest AND DNA damage-
inducible protein GADD45 alpha 
1 23 
Q14449 13.15 DP00230 Growth factor receptor-bound 
protein 14 
1 48 
P62993 9.68 DP00210 Growth factor receptor-bound 
protein 2 
1 2094 
P10912 10.34 DP00033, 
DP00033_C001 
Growth hormone-binding protein 3 768 
P16442 4.8 DP00339 GTA AND blood 2 78 
B0B1U2 9.6 DP00338 GTB AND blood 2 175 
Q13569 27.56 DP00719 G/T mismatch-specific thymine 
DNA glycosylase 
5 531 
P01112 3.7 DP00153 GTPase HRas 4 2018 
Q15382 7.07 DP00364 GTP-binding protein Rheb 1 289 
P04695 16.86 DP00273 Guanine nucleotide-binding 
protein Gt 
1 242 
Q8NDV7 41.28 x GW182 protein 1 141 
Q6Q547 81.03 DP00475 H/ACA ribonucleoprotein 
complex subunit 3 
1 5 
P0C686 20.78 x (HBx OR hepatitis B protein x) 1 2716 
O60741 16.63 x HCN1 1 392 
P22121 32.2 DP00036 Heat shock factor protein AND 
(Kluyveromyces lactis) 
2 15 
P10961 33.73 DP00135 Heat shock factor protein AND 
(Saccharomyces cerevisiae OR 
yeast) 
1 930 
P14602 21.05 DP00142 Heat shock protein beta-1 1 2899 
D4GYC2 25.29 x Hef 1 296 
Q03281 41.93 x Heh2 1 23 
P13102 0.18 DP00566 Hemagglutinin 2 18266 
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P80960 9.09 x hemocyanin 1 4981 
O89339 18.42 DP00698  (henipavirus OR hendra virus) 
AND (nucleoprotein) 
4 21 
O55778 30.83 DP00700  (henipavirus OR hendra virus) 
AND (phosphoprotein) 
3 34 
P03159 4.85 x Hepatitis B polymerase 1 6736 
P27958 3.29 DP00588_C002 (“hepatitis C virus” AND “core 
protein” )  
3 3236 
Q69422 3.63 DP00674, 
DP00674_C001 
Hepatitis GB virus B core protein 1 11 
P08581 1.22 DP00317 Hepatocyte growth factor 
receptor 
2 6193 
P06492 22.45 DP00087 herpes virus AND VP16 4 723 
P09651 44.62 DP00324 Heterogeneous nuclear 
ribonucleoprotein A1 
1 545 
A0A075C3Q2 8.19 x (HEV OR hepatitis E) AND 
polyproline region 
1 4 
P0A6X3 27.45 x Hfq AND (Escherichia coli OR E. 
Coli) AND (C-terminal or C-
terminus)  
2 23 
Q16665 25.91 DP00262 HIF-1 alpha AND (CAD OR N-TAD 
OR ODD)  
2 105 
P30273 17.44 DP00509 High affinity immunoglobulin 
epsilon receptor subunit gamma 
1 2 
P63158 80.47 DP00384 High mobility group protein B1 1 2941 
P17096 100.0 DP00040 High mobility group protein HMG-
I/HMG-Y 
6 69 
P07746 80.39 DP00041 High mobility group-T protein 1 6 
P01050 32.31 DP00137 Hirudin variant-1 2 32 
P06180 58.98 DP00213 Histone-binding protein N1/N2 1 12 
P10922 100.0 DP00097 Histone H1.0 4 213 
P68432 36.76 x Histone H3 3 36292 
P53551 92.64 DP00423 Histone H1 10 34935 
P02259 100.0 DP00044 Histone H5 1 33570 
P15865 100.0 DP00136 histone H1.2 2 86 
P04908 37.69 x Histone H2A 2 33886 
P62805 38.83 x Histone H4 AND N-terminal 
domain 
3 463 
P62807 62.7 x Histone H2B 1 33905 
P12493, 
P27958 
32.4, 
3.29 
DP00101, 
DP00101_C006 
HIV AND P6 AND gag 1 312 
P69723 18.75 x HIV-1 AND Vif AND (C-terminal 
OR C-terminus)  
3 74 
P12497 13.52 DP00410_C011, 
DP00410 
(HIV-1 Integrase OR HIV-1 gag OR 
HIV-1 p24)  
4 10585 
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P04325 50.86 DP00424 HIV-1 Rev 3 3075 
Q1PAB4 64.36 DP00650 HIV-1 Tat  11 4193 
P06939 28.57 x HIV-2 Vpx 1 145 
P09429 80.47 x HMGB1 1 3734 
P82970 100.0 x HMGN5 1 16 
Q14978 86.98 x (hNopp 140 OR Nopp 140 OR 
human nucleolar phosphoprotein 
p140)  
2 9 
Q00839 34.18 x hnRNP-u 1 106 
P23441 32.53 DP00071 Homeobox protein Nkx-2.1 3 12 
Q99801 77.35 DP00683 Homeobox protein Nkx-3.1 1 10 
Q58667 7.65 DP00619 Homoaconitase small subunit 1 5 
P20050 12.73 x Hop1 1 128 
Q86TP1 14.35 x (h-prune OR human prune 
protein) 
1 101 
O95197 30.52 x hRTN3 1 2 
P38753 32.74 DP00635 HSE1 2 31 
Q00613 32.89 x HSF1 AND (C-terminal OR C-
terminus)  
2 46 
P0A6H5 19.41 DP00100 hsl protease AND ATP 1 5 
P22943 77.06 DP00705 Hsp12 4 103 
Q9UJY1 32.65 x Hsp22 2 147 
P12810 23.84 DP00677 HSP16.9 1 22 
Q08914 3.38 x Hsp33 1 52 
P04792 37.07 x Hsp27 1 3274 
P02829 25.39 x hsp90 atpase  1 815 
P16860 32.09 DP00551 (“human cardiac hormone”) AND 
(N-terminal OR N-terminus) AND 
“B-type natriuretic peptide”  
2 2142 
Q02413 8.1 x human desmoglein 1 1 672 
P49354 21.9 DP00558 human farnesyltransferase 1 1391 
P04150 17.63 DP00030 human glucocorticoid receptor 
AND (AF1 OR transcription-
activating fragment OR 
activation function subdomain 
OR activation domain)  
12 457 
Q8IVG9 66.67 x Humanin 1 173 
Q6WB98 1.67 x human metapneumovirus 
glycoprotein ectodomain  
1 3 
P15927 20.0 x human replication protein A 2 981 
P12579 57.68 DP00447 (“human respiratory syncytial 
virus”) AND (phosphoprotein OR 
protein) AND (N-terminal OR N-  
2 144 
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   terminus OR C-terminal OR C-
terminus) 
  
Q9NX55 72.09 DP00546 (Huntingtin-interacting protein 1 
OR HIP1) 
1 247 
Q9NX55 72.09 x (huntingtin yeast two hybrid 
protein OR hypk)  
4 60 
P07242 50.74 x H5 vaccinia virus 1 32 
F6IAY2 19.08 x (HvNAC013 OR NAC013) 1 2 
K9S1M5 33.33 x HvNAC005 OR NAC005 1 2 
O24646 76.19 DP00469 HY5 1 262 
P38216,  50.78,  x hydrophilin 1 6 
P47009, 
P53872 
74.04, 
84.8 
    
Q27796 8.6 DP00045 Hypoxanthine-guanine 
phosphoribosyltransferase 
1 4495 
P22362 17.71 DP00644 I-309 1 138 
P01094 85.29 DP00586 (“IA3” OR “IA 3” OR “IA(3)” OR 
"IA₃") AND (Saccharomyces 
cerevisiae OR Yeast) 
6 248 
O14576 25.43 x IC AND cytoplasmic dynein 1 39 
Q9NSA3 51.85 x ICAT AND transcriptional 
inhibitor 
1 17 
P35521 45.96 DP00717 (Icln OR pICln) 2 106 
P41134 20.0 x Id protein HLH domain 1 264 
P03169 34.01 x IE1 1 822 
P09310 28.4 x (IE62 OR varicella-zoster virus 
major transactivator) 
1 145 
P01096 71.56 x IF1 AND Bovine 1 49 
P73124 46.15 DP00158 (IF7 OR IF17) AND “glutamine 
synthetase”  
3 8 
x x x IgE cepsilonmx 1 4 
x x DP00710 IgG heavy chain CH1 2 62 
G2WJG6 9.64 x (importin-beta OR Kap95p) 2 1310 
P50097 0.6 DP00399 Inosine-5'-monophosphate 
dehydrogenase 
1 303 
P24592 25.42 DP00211 Insulin-like growth factor-binding 
protein 6 
1 262 
P03355 22.5 DP00651, 
DP00651_C007 
Integrase p46 1 2 
P32455 19.43 DP00313 Interferon-induced guanylate-
binding protein 1 
1 21 
P10914 44.62 x interferon regulatory factor 1  3 1689 
P07476 65.81 DP00221 Involucrin 1 1510 
Q13568 30.52 x IRF5 1 364 
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Q9UQB8 33.7 x IRSp53 1 114 
P10997 7.87 x (“islet amyloid polypeptide” OR 
IAPP)  
13 2321 
P78504 5.17 DP00418 Jagged-1 AND human AND 
cytoplasmic tail  
2 4 
P29375 22.13 DP00713 JARID1A 2 32 
Q9UGL1 17.29 DP00712 JARID1B 2 60 
Q8TAM6 66.2 x Juxtanodin 1 6 
P02668 49.47 DP00192 kappa casein 8 10004 
Q5JVS0 49.88 x Ki-1/57  2 17 
P07674 39.11 DP00656 KorB 1 644 
P03023 8.61 DP00433 Lactose operon repressor 3 949 
P02788 2.96 DP00616 (Lactotransferrin OR lactoferrin) 2 6859 
P02545 34.79 DP00716, 
DP00716_C001 
Lamin A/C 2 1243 
A3MYU7 21.37 x L20 AND ribosomal protein AND 
(extension OR "amino terminal" 
OR N-terminal OR N-terminus)  
2 10 
Q6PBE3 27.03 DP00579 L5 AND xenopus AND ribosome 1 14 
A8CDV5 94.07 DP00538 Latent membrane protein 2A 1 217 
Q9CX60 51.43 DP00661 (LBH OR limb bud and heart) AND 
(transcription or transcriptional) 
1 82 
Q2PEE1 15.73 x LC8 2 133 
P32004 5.33 DP00666 (L1-CAM OR Neural cell adhesion 
molecule L1) 
1 1557 
I1JLC8 100.0 DP00185 LEA protein 1 AND soybean 1 16 
Q9UJU2 51.13 x Lef-1  2 1110 
P16535 7.76 DP00345 Leukotoxin 1 768 
E7Q1N2 43.27 x Lhp1p 1 20 
P60752 2.92 DP00400 (Lipid A export ATP-binding OR 
permease protein msbA) 
1 141 
Q9HKT1 9.92 DP00096 Lipoate-protein ligase A subunit 
1 
1 4 
P31025 11.93 DP00647 Lipocalin-1 2 209 
Q6EAJ7 62.42 x Listeria monocytogenes ActA 1 494 
x x x LjIDP1 1 1 
Q9SEW0 87.32 x LLA23 1 5 
Q8T6T7 6.56 x Lombricine Kinase 1 19 
P32170 9.79 DP00429 L-rhamnose isomerase 1 38 
P05455 41.91 DP00229 Lupus La protein 3 2365 
P0C5S4 16.67 DP00292 luxU Phosphorelay protein  1 9 
Q9QXN1 55.42 DP00046 Lymphoid enhancer-binding 
factor 1 
1 906 
160 
 
Table C1 (Continued) 
UniProt RAPID 
score(s) 
Disprot Search Term num IDP 
PMIDs 
num 
all 
PMIDs 
P00703 0.68 DP00259 Lysozyme C 2 4276 
P16636 22.14 x Lysyl oxidase 1 1537 
O33599 26.58 DP00352 lytM 1 46 
B6TRJ5 29.11 x MA16 1 17 
P39900 4.04 DP00571 Macrophage metalloelastase 1 617 
P21758 28.92 DP00246 Macrophage scavenger receptor 
types I and II  
1 96 
P04156, 
P04925, 
P04273 
32.81, 
31.5, 
36.22 
DP00466, 
DP00265, 
DP00187, 
DP00483 
major prion protein  27 1025 
P55145 13.19 x (MANF OR mesencephalic 
astrocyte-derived neutrotrophic 
factor) 
1 65 
P46821 47.89 x MAP1B 1 515 
P15146 54.0 DP00122 (MAP2c OR “microtubule-
associated protein 2”)  
3 33929 
P27816 63.8 x (MAP4 OR microtubule associated 
protein 4) 
1 291 
P26645 100.0 DP00253 MARCKS 6 742 
P61244, 
P61244-2 
94.38, 
95.36 
DP00084, 
DP00084_A002 
Max AND c-myc 5 868 
P0AE73 21.95 DP00296 (MaZE OR PemI-like protein 1) 
AND (Escherichia coli OR E. coli) 
AND (C-terminal OR C-terminus)  
4 8 
P0AE70 9.91 DP00299 MaZF AND (Escherichia coli OR E. 
coli)  
1 116 
Q9UIS9 37.69 x MBD1 1 205 
Q07820 30.0 x (MCL-1 OR “myeloid cell 
leukemia 1”) AND (N-terminal OR 
N-terminus)  
2 368 
D0VWX1 27.27 DP00681 MCoCC-1 1 2 
Q00987 31.16 DP00334 MDM2  9 6283 
O15151 22.65 x (MDMX OR MDM4) 1 497 
Q89933, 
P04851 
14.1, 
15.11 
DP00160, 
DP00640 
(“measles virus”) AND 
nucleoprotein  
21 360 
P03422 44.77 DP00133 (“measles virus”) AND 
phosphoprotein  
9 229 
P38111 3.55 x mec1 1 515 
P51608 74.49 DP00539 (MeCP2 OR Methyl-CpG-binding 
protein 2) 
6 1977 
G4V6N9 68.38 x MEG-14 1 2 
Q91V27 40.34 DP00541 melanophilin 1 81 
Q80FJ1 34.4 DP00276 Membrane fusion protein p14 1 27 
Q14696 52.56 x (mesoderm development  1 139 
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   candidate 2 OR MESD)   
Q82S91 83.76 DP00205 Metal-binding protein smbP 1 1 
Q9XBN7 7.23 x Metallo beta lactamase 1 2055 
P02795 19.67 x metallothionein-2A 1 75 
Q8B9Q8 69.05 x metapneumovirus 
phosphoprotein 
1 19 
P22868 21.26 DP00379 Methane monooxygenase 
component C 
1 800 
P02942 9.62 DP00300 Methyl-accepting chemotaxis 
protein I 
1 931 
P07017 14.47 DP00294 Methyl-accepting chemotaxis 
protein II 
1 930 
Q25460 64.8 x (mfp-1 OR fp1) AND mussel 1 10 
Q2Q9Z9 10.14 x (mfp-3 OR fp3) AND mussel 1 10 
Q25464 2.75 x (mfp-2 OR fp2) AND mussel 1 3 
P32787 17.1 x MGM101 1 13 
Q29983 7.57 DP00670 MHC class I polypeptide-related 
sequence A 
1 30 
O27798 11.11 x (minichromosome maintenance 
protein OR MCM OR N-mtMCM) 
AND protein 
1 2175 
Q9VFY9 23.49 x 2mit 1 1 
Q9Y3D6 9.87 DP00457 (Mitochondria* fission 1 protein 
OR Fis1) 
1 829 
Q03164 38.47 x (“mixed lineage leukemia”) AND 
protein 
2 825 
Q969V6 46.29 x MKL1 1 178 
P11409 11.01 DP00060 Modification methylase PvuII 1 49 
Q13485 17.03 DP00464 Mothers against decapentaplegic 
homolog 4 
1 2781 
x x x MpAsr 1 2 
Q03834 19.57 x Msh6 1 1146 
P33748 37.22 x Msn2 1 248 
B7SX18 83.2 x MSP2 AND “Plasmodium 
Falciparum”  
9 204 
Q13043 31.62 x MST1 SARAH Domain 1 14 
Q9DBZ9 29.99 x mSYD1A 1 1 
P52477 22.19 DP00401 Multidrug resistance protein 
mexA 
1 101 
P35372 8.5 DP00272 Mu-type opioid receptor 1 114 
P02687, 
P02686, 
P04370, 
P81558 
57.4, 
50.0, 
57.6, 
76.61 
DP00047, 
DP00236, 
DP00237, 
DP00663 
(“myelin basic protein”)  34 9697 
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P70475 46.67 DP00049 Myelin transcription factor 1-like 
protein 
1 6 
P15172 35.94 x MyoD 1 3390 
P02185 16.88 DP00303 Myoglobin or apomyoglobin 3 11645 
P52179 18.87 DP00517 Myomesin-1 1 11 
Q9Y4I1 14.56 x myosin 5a 1 49 
P90648 15.3 x (myosin II heavy chain kinase B 
OR MHCK-B) 
1 69 
P24844 37.21 x Myosin light chain 1 1 5351 
P10587 34.66 DP00102 ("myosin motor domain") 2 117 
Q9TW98 11.45 x n16.3 1 1 
P38996 42.39 x Nab3 1 57 
Q9C000 11.34 DP00554 NACHT LRR PYD domains-
containing protein 1 
1 15 
Q969F2 51.66 DP00520 Naked2 1 8 
O75376 48.85 x (NCoR OR NCoR-1 OR SMRT) 1 896 
P26477 56.7 DP00027 Negative regulator of flagellin 
synthesis 
1 47 
Q96FI4 37.18 x NEIL1 AND (C-terminal or C-
terminus)  
2 14 
P19246 74.22 DP00050 Neurofilament heavy polypeptide 3 139 
P02547 36.98 DP00151 Neurofilament light polypeptide 2 317 
Q92686 69.23 x neurogranin 2 290 
Q9NZ94 8.84 DP00553 (“neuroligin 3”)  4 105 
P17677 100.0 x neuromodulin 1 2519 
P30990 14.71 x neurotensin 1 5218 
P25963 25.55 DP00468 NF-kappa-B inhibitor alpha OR 
IkappaBalpha 
5 7656 
P01138 14.94 x NGF AND neurotrophin 1 2287 
Q92886 40.08 DP00672 (NGN1 OR neurogenin 1) 1 430 
P19634 4.66 x NHE1 AND (C-terminal OR C-
terminus)  
2 50 
Q9IH62 1.83 DP00686 (Nipah virus OR NiV) AND 
glycoprotein 
1 177 
Q9IK92 15.79 DP00697 (Nipah virus OR NIV) AND 
nucleoprotein 
1 18 
Q9IK91 35.26 DP00699 (Nipah virus OR NIV) AND 
phosphoprotein 
1 39 
Q12972 33.9 x NIPP1 3 39 
A0A023YU88 7.85 x NleH 1 22 
Q13224 7.35 x (NMDAR2B OR GluN2B) 4 459 
Q7Z406 34.54 x (NMII OR non muscle myosin II) 1 2413 
Q96E22 13.31 x Nogo-B AND (N-terminal OR N-  4 17 
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P11632 94.62 DP00432 Non-histone chromosomal 
protein 6A 
1 4 
P02315 100.0 DP00042 Non-histone chromosomal 
protein H6 
1 14 
P02316 100.0 DP00038 Non-histone chromosomal 
protein HMG-14 
1 71 
P05204, 
P02313 
100.0, 
100.0 
DP00039, 
DP00195 
Non-histone chromosomal 
protein HMG-17 
1 75 
I7GQ94 22.48 x (n16 OR n16N) 1 185 
Q61985 29.82 DP00671 Nrf2 AND Neh2 domain  2 27 
Q13127 50.23 x (NRSF OR neural restrictive 
silencer factor) 
2 317 
Q9WMX2, 
P27958 
3.32, 
3.29 
DP00588_C010, 
DP00615_C010, 
DP00615 
(NS5A OR Non structural protein 
5A) AND hepatitis  
16 1342 
P26662 2.96 x (NS5B OR Non structural protein 
5B) AND hepatitis 
1 1446 
Q80J95 16.6 x NS1-2 norovirus 1 8 
P26662 2.96 x (NS3 OR non structural protein 3) 
AND hepatitis C virus 
1 2768 
x x x (Nsp OR nucleoskeletal-like 
protein) AND bacillus subtilis 
1 2 
P34130 15.24 x NT4 AND neurotrophin 1 146 
Q9SQ56 66.56 x NtGR-RBP1 1 1 
Q9BYD2 12.36 x (NTL9 OR N terminal domain of 
the ribosomal protein L9) 
1 66 
O67198 9.34 x Ntrc1 1 13 
Q09161 19.11 DP00392 Nuclear cap-binding protein 
subunit 1 
1 39 
P52298 20.51 DP00393 Nuclear cap-binding protein 
subunit 2  
1 37 
Q8WUM0 8.04 DP00318 Nuclear pore complex protein 
Nup133 
2 39 
Q9Y6Q9-3 36.75 DP00343 Nuclear receptor coactivator 3  1 506 
P03347 32.62 DP00148, 
DP00148_C004 
Nucleocapsid protein p7 2 164 
P05221 66.5 DP00217 Nucleoplasmin 2 335 
Q9RY71 16.37 x nudix hydrolase 1 214 
P35658 30.96 x Nup214 1 182 
P40477 29.66 x Nup159 3 43 
P57740 11.24 x Nup107 2 82 
P37198 26.44 x Nup62 1 70 
P49790 40.41 x Nup153 5 181 
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Q02630 37.11 x Nup116 AND (Saccharomyces 
cerevisiae OR yeast) 
1 37 
P52948 19.15 x Nup96 OR Nup98 2 389 
P32499 67.22 DP00222 NUP2P nucleoporin AND 
(Saccharomyces cerevisiae OR 
yeast) 
1 19 
O60356 100.0 x (Nupr1 OR p8 nucleoprotein) AND 
human 
2 58 
O24172 36.0 DP00580 ("ole e 6") 1 9 
P08523 28.22 DP00279 Olfactory marker protein 1 845 
Q9FUW7 100.0 DP00227 Omega gliadin storage protein 1 24 
P02631 32.11 DP00730 Oncomodulin 2 143 
Q39532 44.36 DP00470 Opaque 2 1 2868 
P10451 45.86 DP00214 (OPN OR osteopontin)  10 7702 
E7QAI1 42.5 x Opy2p 1 2 
P07805 2.84 DP00051 Ornithine decarboxylase 2 7562 
Q13438 37.03 x OS-9 1 124 
P81455 38.78 DP00116 Osteocalcin 2 14028 
Q9BRP0 26.91 x OVOL2 1 15 
O00110 25.23 x OVOL3 1 1 
Q86XL8 14.75 x OVOL1 1 26 
Q09472 28.38 DP00633 p300 acetyltransferase  4 930 
Q96GU1 72.31 x (PAGE5 OR Prostate associated 
gene 5)  
2 2001 
O60829 100.0 x (PAGE4 OR “Prostate associated 
gene 4”)  
4 2014 
Q66SS1 35.07 DP00568 Paired box 6 1 1305 
O96013 31.64 x PAK4 1 160 
P32521 37.3 x Pan1 1 77 
Q58A45 12.97 x pan3 1 39 
P00974 5.0 DP00729 Pancreatic trypsin inhibitor 1 4801 
P04637 39.69 DP00086 p53 AND (CTD or C-terminal or C-
terminus)  
61 1240 
O60356 100.0 DP00510 p8 AND human AND 
nucleoprotein 
2 21 
P15309 6.22 x PAP AND protein 1 5439 
Q96IZ0 68.24 x Par-4 AND (C-terminal or C-
terminus)  
4 17 
P01270 49.57 DP00637 Parathyroid Hormone AND human 2 24877 
P12272 76.84 DP00138 Parathyroid hormone-related 
protein 
2 4240 
P9WIJ9 18.6 x ParB 1 279 
Q9KJ82 34.21 DP00529 parG AND (N-terminal OR N-  2 16 
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Q96262 71.11 x PCaP1 2 8 
Q61140 36.16 x P130Cas AND CasSD  2 6 
P22239 100.0 DP00112 PCC6 OR Dsp16 1 7 
P38936 44.51 DP00016 (p21(Cip1) OR p21 OR Cyclin-
dependent kinase inhibitor 1)  
10 29902 
P9WGM2 20.0 DP00247 pdtaR 1 3 
Q9RHW0 5.36 DP00738 Pectate lyase 1 638 
Q9LXB8 95.41 x (PELPK1 OR At5g09530) 1 2 
P81058 4.88 DP00373 Penaeidin-3a 1 2 
P48539 91.94 x PEP-19  3 64 
P19021 8.74 x peptidylglycine alpha-amidating 
monooxygenase 
1 484 
Q7RSH5 7.14 DP00745 Peptidyl-prolyl cis-trans 
isomerase 
1 6121 
P0C2E9 4.8 DP00280 Perfringolysin O 2 233 
P17810 4.64 DP00220 Peripherin-2 1 32 
P07598 8.31 DP00108 Periplasmic hydrogenase large 
subunit 
1 23 
Q9Y9L0 11.2 DP00037 peroxiredoxin AND Aeropyrum 
pernix 
1 8 
P37231-2 6.92 DP00718, 
DP00718_A001 
Peroxisome proliferator-
activated receptor gamma 
2 15469 
P40855 48.83 x Pex19 1 95 
P50542-3 24.56 DP00472 (Pex5p OR peroxisomal cycling 
receptor)  
1 182 
P22621 10.29 x (PfAMA1 OR (plasmodium 
falciparum AND "apical 
membrane antigen 1")) 
1 248 
Q25733 28.56 DP00746 PfEMP1 1 404 
Q3YL59 21.32 x PFMG1 1 2 
Q07412 2.82 DP00614 (PfTIM OR triosephosphate 
isomerase) AND plasmodium 
falciparum 
1 31 
Q9UBK2 32.08 x PGC-1alpha AND “activation 
domain”  
3 44 
Q88HS5 15.81 x PhaF 1 64 
F1ZCA0 71.26 x phasin AND "Novosphingobium 
nitrogenifigens" 
1 1 
P27001 10.29 DP00053 Phenylalanyl-tRNA synthetase 
alpha chain 
2 12 
P0AFJ5 12.23 x phob 1 354 
Q08209 20.35 DP00092 phosphatase 2B subunit alpha 1 62 
P10688 10.85 DP00055 1-phosphatidylinositol-4,5-
bisphosphate phosphodiesterase  
2 86 
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P78356 15.87 DP00054 Phosphatidylinositol-4-phosphate 
5-kinase type II beta 
1 9 
P26678 38.46 x (Phospholamban OR PLN)  1 2847 
P12359 21.99 DP00188 ((photosystem II OR PSII) AND 
manganese stabilizing protein OR 
"Oxygen-evolving enhancer 
protein 1") 
11 160 
O14832 6.51 DP00327 Phytanoyl-CoA dioxygenase 1 7 
Q9NWS0 27.59 x Pih1 1 26 
Q07932 22.32 DP00567 Pilosulin-1 1 7 
Q13526 49.69 x pin1 1 1054 
O70161 26.48 x PIPKIgamma661 1 6 
P49918 45.25 DP00017 p57Kip2 1 292 
P19525 21.23 x (PKR OR protein kinase R) 1 21830 
Q03133 9.21 x (PKS OR modular polyketide 
synthase)  
1 2214 
P00747 8.89 DP00191 Plasminogen 1 47732 
P05121 6.72 DP00320 Plasminogen activator inhibitor 1 1 10218 
P53350 10.12 DP00428 PLK1 1 1171 
P29590 24.94 x PMLII 1 3 
E7Q6S2 12.25 x Pml1p 2 6 
Q9XES8 66.29 DP00665 (PM28 OR GmPM28) 1 4 
P01139 46.06 x (pNGF OR pro-Nerve Growth 
Factor OR proNGF)  
3 219 
Q96QC0 45.96 x PNUTS 1 33 
P03300 2.26 x poliovirus 3AB 1 59 
P03305 11.41 DP00573 polyprotein  foot-and-mouth 
disease virus 
2 140 
Q6IBA2 74.8 DP00501 (positive cofactor 4 OR PC4) AND 
Human 
1 498 
P08510 14.5 DP00267 Potassium voltage-gated channel 
protein Shaker 
1 631 
P14859 26.38 DP00231 POU domain AND class 2 AND 
transcription factor 
1 99 
Q64693, 
Q16633 
33.98, 
33.98 
DP00008, 
DP00172 
POU domain class 2-associating 
factor 1 
3 3 
P37231 8.51 x PPARgamma 1 15073 
P17767 8.44 x P1 protease 1 3149 
Q9VXX1 55.66 x PPYR1 OR CG15031 1 7 
O60828 56.23 x (PQBP-1 OR “polyglutamine tract 
binding protein 1”)  
3 162 
U5Y3Y2 74.66 x precol-NG AND "mussel byssus" 1 2 
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Q6VBP1 7.25 x preS1 2 365 
P58743 2.55 x prestin 1 290 
Q06253 24.66 DP00288 Prevent host death protein 3 373 
A1Z6W3 30.64 x prickle AND PET domain  1 6 
P06401 23.9 x progesterone receptor AND CTE  3 6 
P9WHN4 90.62 DP00293 (“prokaryotic ubiquitin-like 
protein”)  
7 69 
P45577 53.88 DP00377 ProP effector 1 4 
Q15185 45.62 DP00358 Prostaglandin E synthase 3 2 1038 
P15309 6.22 DP00628 ("prostatic acid phosphatase")  2 1647 
P01094 85.29 DP00179 Protease A Inhibitor 3 1 38105 
Q9UM07 7.69 DP00321 Protein-arginine deiminase type-
4 
1 10 
Q9UKV8 15.13 DP00736 Protein argonaute-2 1 255 
Q6P8Z1 51.18 DP00564 Protein B-Myc 1 15 
P27577 14.32 DP00111 Protein C-ets-1 2 1114 
P09372 32.99 DP00103 Protein grpE 1 561 
P10644 13.91 x ("protein kinase A") 3 14902 
P17252 8.04 x Protein kinase C alpha V5 domain 1 5 
Q51912 47.84 DP00121 Protein L precursor 1 7035 
P04324, 
P03406 
22.82, 
27.18 
DP00189, 
DP00048 
Protein Nef 1 3009 
P11845, 
P41236, 
Q8R3G1 
60.98, 
72.2, 
30.2 
DP00232 (Protein phosphatase inhibitor 2 
OR PP1 I-2) 
5 180 
O60927 69.05 DP00219 Protein phosphatase 1 regulatory 
subunit 11 
1 36 
P01099 100.0 DP00325 Protein phosphatase 1 regulatory 
subunit 1A 
1 7 
Q90623-2 45.38 DP00218 (Protein phosphatase 1 
regulatory subunit 12A OR 
MYPT1) 
2 370 
P07516 85.15 DP00421 Protein phosphatase 1 regulatory 
subunit 1B 
1 7 
P40357 43.16 DP00128 Protein transport protein SEC9 2 32 
P60058 13.24 DP00117 Protein transport protein Sec61 
subunit gamma 
1 8 
Q93096 8.09 DP00255 Protein tyrosine phosphatase 
type IVA 1 
1 6 
O75365 10.4 DP00254 Protein tyrosine phosphatase 
type IVA 3 
1 4 
x x x proteoglycans syndecans 1 2090 
P06302 100.0 DP00058 prothymosin alpha  14 377 
P11309-2 8.63 DP00322 Proto-oncogene  1 538 
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Q6P2Q9 5.35 x Prp8 1 153 
P35820 45.03 x (PSC OR posterior sex combs) 1 4066 
P78352 8.84 x (PSD-95 OR Post Synaptic Density 
95) 
2 1744 
P19243 29.11 DP00676 PsHSP18.1 1 3 
P60484 19.85 x PTEN 2 9534 
P18031 24.6 x PTP1B 1 1232 
H0USY9 24.73 x PulS 1 516 
Q9BXH1 53.89 x PUMA 3 1997 
P48539 91.94 DP00592 (Purkinje cell protein 4 OR 
PEP19) 
3 2220 
Q9N607 12.32 x (PvAMA-1 OR Plasmodium Vivax 
Apical Membrane Antigen 1) 
1 68 
Q02597 6.04 DP00560, 
DP00560_C007 
PVY AND potato virus 1 365 
Q01144 63.45 x PWL2 OR PWL2D 1 9 
O75469 12.44 DP00323 PXR receptor AND human 1 1030 
P0AFI7 11.93 DP00165 Pyridoxine-5'-phosphate oxidase 1 78 
Q9NVS9 16.09 DP00168 Pyridoxine/pyridoxamine 5'-
phosphate oxidase 
1 3 
P37362 90.0 x pyrrhocoricin  1 24 
P0AFG8 4.96 DP00427 Pyruvate dehydrogenase E1 1 1159 
Q32NN2 22.58 DP00286 quaking-A protein 1 258 
P22363 30.3 x rabies virus phosphoprotein 1 164 
P37727 16.92 DP00458 Rab proteins 
geranylgeranyltransferase 
component A 1 
2 8 
P31751 9.98 DP00304 RAC-beta serine/threonine-
protein kinase 
2 5 
P43351 32.54 DP00437 RAD52 homolog DNA repair 
protein 
1 63 
P04049 15.28 DP00171 RAF kinase 4 11589 
P10114 12.02 DP00167 Rap-2a 2 3 
P11938 30.71 DP00020 RAP1 AND DNA 1 539 
P51449 20.85 x RAR gamma AND (N-terminal OR 
N-terminus) 
1 22 
P63000 5.21 DP00408 Ras-related C3 botulinum toxin 
substrate 1 
1 4520 
P11233 34.47 DP00581 Ras-related protein Ral-A 1 6 
Q9A3A9 24.85 x RcdA 1 230 
P9WHJ3 7.22 x recA intein AND Mycobacterium 
tuberculosis 
1 31 
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P18754 9.26 DP00691 Regulator of chromosome 
condensation 
2 140 
P49799 27.32 DP00063 Regulator of G-protein signaling 
4 
1 846 
P03040 30.3 DP00741 Regulatory protein cro 5 330 
P9WHG9 8.54 x (RelA OR SPoT) AND (C-terminus 
OR C-terminal) 
1 375 
P27694 13.8 DP00061 Replication protein A AND 70 1 137 
Q9NQC3-2 31.9 DP00524 (Reticulon-4 OR RTN 4B) 1 600 
P04972 79.31 DP00638, 
DP00347 
(retinal OR cGMP) AND 
phosphodiesterase AND “gamma 
subunit”  
6 287 
P62965 12.41 DP00340 Retinoic acid receptor RXR-alpha 2 1745 
O54828 27.11 x (RGS9-2 OR Regulator of G-
protein signaling 9) 
1 125 
x x x Rhabdoviridae AND nucleoprotein 1 613 
x x x Rhabdoviridae AND 
phosphoprotein 
1 433 
P02699 13.51 DP00271 rhodopsin 2 8760 
Q07960 24.6 DP00459 Rho GTPase 1 11298 
O28362 13.73 DP00382 Ribonuclease P protein 
component 1 
1 53 
P11157 10.51 DP00462 Ribonucleoside-diphosphate 
reductase M2 subunit 
3 74 
P49723 10.72 DP00488 Ribonucleoside-diphosphate 
reductase small chain 2 
1 4 
P09938 18.3 DP00487 Ribonucleoside-diphosphate 
reductase small chain 1 
1 5 
P69924 9.57 DP00107 Ribonucleoside-diphosphate 
reductase 1 subunit beta 
1 9 
B0B899 30.63 x ribosomal protein L2 1 89 
P60723 28.86 DP00600 ribosomal protein L4 2 168 
P56210 27.82 DP00512 ribosomal protein L11 2 277 
P0A7N9 100.0 DP00143 ribosomal protein L33 1 74 
P05318 40.57 DP00164 ribosomal protein P1-alpha 1 3 
Q9HFQ6 46.3 DP00001 ribosomal protein P1-B 1 1 
P02400 54.55 DP00002 ribosomal protein P2-beta 2 8 
B9JVV3 19.02 x ribosomal protein S4 2 205 
P0AG63 16.67 DP00242 ribosomal protein S17 1 45 
P08865 30.85 x ribosomal protein SA AND human  2 58 
P16083 6.49 DP00727 Ribosyldihydronicotinamide 
dehydrogenase 
1 105 
Q22472 56.08 DP00613 RIC-3 1 51 
Q6PR54 22.57 x Rif1 1 170 
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P0AEM6 12.97 x RNA Polymerase AND  Escherichia 
coli 
1 11148 
Q9Y5B0 40.27 DP00177 RNA polymerase II subunit A C-
terminal domain phosphatase OR 
FCP1 
4 121 
Q9A749 26.17 x ("Rnase E" AND caulobacter 
crescentus) 
1 3 
P21513 28.84 DP00207 (“RNase E” AND (escherichia coli 
OR e. coli))  
3 496 
P25814 43.1 DP00387 (“RNase P” OR “ribonuclease P” ) 
AND bacillus subtilis  
2 157 
O31774 17.88 x ("RNase Y") AND Bacillus subtilis 1 16 
P78317 37.89 x RNF4 ubiquitin ligase  1 64 
S8GC24 38.75 x ROP6 1 19 
P11171 37.5 DP00678 (4.1R OR "Protein 4.1") 1 704 
Q8GYN5 69.19 x RPM1-interacting protein 4 1 9 
Q03465 32.02 x Rpn4 1 65 
P9WIP5 21.13 x Rv2377c 1 1 
P9WPQ1 15.49 x Rv3221c  1 1 
Q9CQK7 50.62 DP00587 (Rwdd1 OR RWD domain-
conatining protein 1) 
1 4 
Q8N488 78.51 DP00694 RYBP 1 57 
P21817 11.49 x RyR1 1 5680 
P0AEI4 6.35 x S12 1 2307 
P26447 21.78 x S100A4 1 899 
P33764 19.8 x S100A3 1 45 
P80511 13.04 x S100A12 1 331 
P29034 16.33 x S100A2 1 195 
P06703 14.44 x S100A6 1 410 
P0DJI8 24.59 x (SAA OR serum amyloid A)  1 6478 
P22470 42.46 x San1 2 29 
P05109 16.13 x (S100A8 OR S100A9) 1 1466 
P07602 10.69 DP00733_C004 Saposin-C 4 635 
Q19QV9 23.47 x (“SARS coronavirus” AND 
(“nucleocapsid protein” OR 
“nucleocapsid phosphoprotein”)) 
2 368 
Q20010 60.4 x SAS-5 1 39 
P04271 25.0 x S100B 1 1667 
C4MN95 80.69 x (SbASR-1 OR Abscisic acid stress 
ripening protein) 
1 63 
C0J347 28.88 x (SBDS OR TcSBDS) AND 
Trypanosoma cruzi 
1 1 
Q931F4 40.85 x Sbi-III 1 1 
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Q96T21 37.0 DP00420 (SBP2 OR SECIS binding protein 2) 2 142 
P23389 50.93 DP00124 Secretogranin-1 1 413 
P40316, 
O95997 
69.44, 
71.78 
DP00256, 
DP00521 
(securin OR PTTG1 OR pituitary 
transforming gene 1 product) 
AND (N-terminal OR N-terminus)  
3 25 
Q68FT9 7.64 DP00620 Selenocysteine lyase 1 71 
Q9BQE4 45.5 x (“selenoprotein s” OR SelS OR 
VIMP)  
3 2084 
O94742 47.19 x Sem1 1 33 
P02783 83.93 DP00527 (Seminal vesicle protein number 
4 OR SV-IV)  
2 153 
Q9EB08 20.28 x (SeMV OR "sesbania mosaic 
virus") AND polyprotein 2a 
1 4 
Q07097 16.98 DP00629 (“sendai virus”) AND 
nucleoprotein  
2 191 
P04859 52.11 x (“sendai virus”) AND 
phosphoprotein  
5 308 
O43236 23.01 x sept4 1 79 
O43236 23.01 DP00537 SEPT4 AND septins 1 74 
O75920 65.45 x SERF1a 1 7 
O86488 31.79 DP00065 Serine-aspartate repeat-
containing protein D 
1 2 
O43464 6.99 DP00315 Serine protease HTRA2 AND 
mitochondria* 
1 231 
P53041 10.82 DP00365 Serine/threonine protein 
phosphatase 5 
1 68 
P31645 5.56 x (SERT OR serotonin transporter) 1 8514 
P02768 11.82 DP00515 ("serum albumin") AND human  1 42565 
P11831 36.02 DP00574 serum response factor 1 24776 
P34945 15.91 DP00514 Seryl-tRNA synthetase 3 258 
O75533 12.27 x SF3b155 1 23 
x x x Sfbl-5 1 2 
Q86XK3 35.92 x sfr1 1 35 
P10824 15.82 DP00035 S-Gi alpha 1 1 1 
P35187 26.88 x Sgs1 helicase 1 323 
P29353 30.19 DP00154 SHC-transforming protein 1 1 1430 
U5Y0K9 25.95 x shematrin 1 5 
Q9Y3R4 21.05 DP00261 Sialidase-2 1 5 
P38634 57.75 DP00631 Sic1 AND CDK  13 87 
P0AFX7 43.98 DP00552 Sigma-E factor negative 
regulatory protein 
1 16 
P03087 27.9 DP00182 Simian virus Major capsid protein 
VP1 
2 79 
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Q5VVH5 33.08 x SIMPL 1 23 
P27285 9.96 DP00066, 
DP00066_C001 
sindbis virus AND capsid protein 1 195 
P50263 86.08 x SIP18 1 11 
P06701 15.54 DP00533 (Sir3p OR silent information 
regulator 3 protein OR SIR3) AND 
saccharomyces cerevisiae  
6 385 
Q96EB6 31.06 x sirt1 AND (N-terminal OR N-
terminus OR C-terminal OR C-
terminus) 
3 83 
P25294 53.12 x Sis1 AND yeast 1 80 
Q13573 49.63 DP00608 (SKIP OR Ski interaction protein) 
AND SNW 
1 16 
P52285 27.16 x skp1 1 918 
Q9VAN6 63.41 DP00144 SLBP OR (Histone RNA hairpin-
binding protein) 
3 111 
Q57733 14.29 DP00067 Small heat shock protein HSP16.5 1 28 
P32566 32.87 x (small molecule reductase 
regulatory protein OR SmI1 OR 
knr4) 
1 131 
P22531 59.72 DP00130 Small proline-rich protein 2E 2 249 
Q6DIC0 34.12 x SMARCA2  1 301 
Q9H0W8 31.15 x SMG-9 1 5 
P19972 12.61 DP00180, 
DP00180_C003 
SMK toxin 1 6 
Q99LM3 70.81 DP00742 (Smoothelin-like protein 1 OR 
SMTNL1) 
4 13 
O95149 21.11 x snurportin 1 23 
P63292 21.7 DP00125 Somatoliberin 1 6955 
O30916 12.12 x SopB 1 200 
Q9S446 36.89 DP00208 sortase  3 528 
Q99523 3.85 x Sortilin 1 387 
Q08826 14.2 DP00482 Sorting nexin-3 1 9 
Q07889 20.63 x Sos1 1 515 
P03607 18.28 DP00064 southern bean mosaic virus 
capsid protein 
1 36 
P08047 24.59 DP00378 Sp1 2 9875 
x x x (SPA OR septal pore associated 
proteins) 
1 8059 
P07214 15.23 DP00052 SPARC 1 2696 
A1Z0H7 38.52 x Spatzle 1 127 
G2TRL7 41.18 x spd2 1 22 
Q10585 52.42 x spd1 3 42 
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P15340 96.77 DP00057 Sperm histone 2 1664 
Q96SB3 46.38 x spinophilin 1 256 
x x x split intein 1 171 
O34800 58.93 x SpoIISB 1 5 
x x x src family kinase 1 11278 
P0A7L8 45.88 DP00140 50S ribosomal protein L27 2 6 
P0A7S3 22.58 DP00145 30S ribosomal protein S12 1 17 
P0A7T7 18.67 DP00146 30S ribosomal protein S18 1 7 
P0A7U3 34.78 DP00147 30S ribosomal protein S19 1 10 
P09132 45.83 DP00570 SRP19 1 86 
P0AGE2 38.76 DP00722 SSB AND (escherichia coli OR e. 
coli) AND (C-terminal OR C-
terminus)  
3 66 
Q9FD10 3.92 x (SseJ OR SseJ-H OR SseJ-L) AND 
salmonella 
1 31 
Q9UWU0 0.0 x Sso Acp 1 8 
O75324 12.5 DP00162 Stannin 1 21 
A2VD23 100.0 DP00584 starmaker  3 9 
P02808 43.55 x statherin 1 193 
P16949 100.0 DP00174 stathmin 5 867 
Q7Z626 18.17 x STIL 1 161 
Q2M3R5 5.75 x Stim1 1 876 
Q7CL96 13.62 DP00302 stringent starvation protein A 1 7 
P0AFZ3 42.42 DP00194 (stringent starvation protein B 
OR SspB) 
1 147 
P04189 12.86 DP00394 subtilisin AND (propeptide OR 
pro-peptide)  
3 166 
Q9UMX1 16.74 x SUFU 1 241 
P55789 34.63 x sulfhydryl oxidase ALR 1 33 
P38038 8.35 DP00190 ("sulfite reductase") AND NADPH 1 94 
P0DMM9 9.49 DP00011 Sulfotransferase 1A3/1A4 1 3 
O00204, 
O00204-2 
27.95, 
27.71 
DP00404, 
DP00404_A002 
(SULT2B1 OR SULT2B1b OR 
Sulfotransferase family cytosolic 
2B member 1) 
1 74 
Q9UBE0 19.65 DP00485 SUMO-activating enzyme subunit 
1 
1 5 
Q9UBT2 18.28 DP00486 SUMO-activating enzyme subunit 
2 
1 3 
P00441 29.87 DP00652 ("Superoxide dismutase") 1 58522 
O31851 16.84 DP00257 superoxide dismutase-like yojM 1 158 
O95425 32.79 x supervillin 1 35 
O35718 28.89 DP00446 Suppressor of cytokine signaling  1 3127 
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   3   
Q8NHG7 100.0 x SVIP 1 13 
P40688 33.94 x Swallow AND cytoplasmic dynein 1 5 
P31109 34.19 DP00113 Synaptobrevin homolog 1 1 27 
P63045, 
P63027 
43.1, 
43.97 
DP00622, 
DP00069 
(synaptobrevin OR Vesicle-
associated membrane protein 2) 
3 2159 
A7UMX5 66.67 DP00535 Synaptopodin 2 variant OR 
Fesselin 
2 15 
P60881 29.61 DP00068 Synaptosomal-associated protein 
25 
1 1413 
P18827 50.32 x syndecan-1 1 1484 
P32851 19.44 DP00155 Syntaxin-1A 1 1104 
P26039 20.31 DP00653 Talin-1 1 60 
P10636-8 72.11 DP00126 Tau AND (protein OR alzheimer’s 
OR tauopathies OR neuronal)  
65 20253 
P03409 13.31 x Tax AND HTLV transcriptional 
activator 
1 146 
E7AIJ0 7.37 x TB1-C-Grx1 1 1 
Q6SJ96 29.87 x TBPL2 1 12 
P01730 8.52 DP00123 T-cell surface glycoprotein CD4 1 16415 
P04234 5.85 DP00505 T-cell surface glycoprotein CD3 
delta chain 
2 533 
P07766 21.74 DP00506 T-cell surface glycoprotein CD3 
epsilon chain 
2 321 
P09693 15.93 DP00508 T-cell surface glycoprotein CD3 
gamma chain 
2 1278 
P20963 38.41 DP00200 T-cell surface glycoprotein CD3 
zeta chain  
8 713 
Q9C518 43.14 x TCP8 1 10 
P19250 4.23 DP00668 (TDH OR thermostable direct 
hemolysin) AND Vibrio 
parahaemolyticus 
1 430 
Q13148 18.36 x TDP-43  2 1497 
B7T1D7 15.44 DP00703 Teg12 1 2 
P16458 50.39 DP00659 Telomere-binding protein subunit 
beta 
2 20 
A0A077Y0G0 18.42 x (Tex1 OR Trophozoite exported 
protein 1) 
1 26 
P04867 23.67 x TGBp1 2 53 
Q8MWS6 39.48 DP00500 TgDRE 1 2 
S8F3V2 19.19 x TgGCN5 AND "toxoplasma gondii" 1 6 
Q96EK4 32.48 x THAP11 1 17 
P0AA25 10.09 x thioredoxin AND (escherichia coli 
OR e. coli) 
4 1921 
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Q9BRA2 9.76 x thioredoxin AND human 1 4112 
Q962Y6 7.19 DP00642 thioredoxin-glutathione 
reductase AND Schistosoma 
mansoni 
1 20 
P40238 9.13 x thrombopoietin receptor MPL 1 991 
Q8GT36 82.52 DP00532 Thylakoid soluble phosphoprotein 1 7 
x x x Thylakoid-soluble phosphoprotein 
AND Arabidopsis thaliana 
1 1 
P03176 13.56 DP00419 Thymidine kinase 2 13187 
P04818 11.5 DP00073 thymidylate synthase 1 4845 
P62328 100.0 DP00357 Thymosin beta-4 2 673 
O14925 3.83 x TIM23 1 204 
P0DJ91 29.93 x Tir AND "Escherichia coli" 1 447 
Q8WZ42 17.39 DP00072 titin AND (SH3 OR PEVK)  7 133 
Q12000 52.46 x Tma46 1 3 
Q9HCJ0 36.27 x tnrc6c 1 14 
Q14106 30.52 x Tob2 1 38 
O81283 25.02 DP00609 Toc159 2 72 
O94826 22.04 x Tom70 1 144 
P23627 22.71 x tomato aspermy virus 
cucumovirus coat 
1 19 
P02929 48.95 DP00043 tonB 1 905 
Q9BW30 47.73 x (Tppp3 OR tubulin 
polymerization-promoting 
protein family member 3) 
1 9 
O94811 42.47 x TPPP/p25 5 34 
x x x TRAF3IP2 1 108 
P33905 7.69 DP00198 Transcriptional activator protein 
traR 
1 34 
P15884 48.88 DP00224 ("Transcription factor 4") AND 
human 
2 701 
Q9NQB0 40.06 DP00175 ("Transcription factor 7-like 2") 2 844 
Q04207, 
Q04206 
24.23, 
29.22 
DP00085, 
DP00129 
(Transcription factor p65 OR NF-
kappab p65) 
3 10649 
P32773 40.56 DP00104 Transcription initiation factor IIA 
large subunit 
1 23 
P32774 13.93 DP00009 Transcription initiation factor IIA 
small subunit 
1 32 
P51123 34.62 DP00081 Transcription initiation factor 
TFIID subunit 1 
1 33 
Q8NER1 6.44 x (transient receptor potential OR 
TRPV1) 
1 11105 
Q01853 13.4 DP00435 Transitional endoplasmic 
reticulum ATPase 
1 36 
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P0A707 34.44 DP00197 Translation initiation factor IF-3 1 50 
Q9SLF3 28.28 DP00610 translocase of chloroplast 132 1 2 
Q498R8 30.29 x (translocated promoter region 
protein OR Traf3ip2) 
1 481 
Q53WY6 34.09 x Transthyretin 1 6607 
P96086 2.24 DP00484 Tricorn protease 1 27 
P00942 4.84 DP00430 triosephosphate isomerase yeast 2 186 
Q13061 90.26 x Trisk 95 1 8 
P15502 13.23 x (tropoelastin OR elastin)  3 9861 
Q91006 25.63 DP00131 tropomodulin AND (N-terminal 
OR N-terminus)  
3 35 
P63315 37.89 DP00249 Troponin C AND (slow skeletal OR 
cardiac muscles) 
1 730 
P19429 44.29 DP00166 Troponin I cardiac muscle 4 2759 
I1RJZ4 6.21 x TRP channel AND (C-terminal or 
C-terminus)  
2 129 
Q9H1D0 9.67 x TRPV6 1 423 
Q9NQA5 7.68 x TRPV5 1 343 
P47756 11.55 x TRTK-12 1 27 
P82409 29.41 DP00680 Trypsin inhibitor 2 2 13106 
P0A877 11.94 DP00252 Tryptophan synthase alpha chain 1 84 
x x DP00688 (TTN-1 OR 2MDa_1) 1 3 
P04350 8.33 DP00114 Tubulin beta-4 chain 3 11 
P32882 10.79 DP00169 Tubulin beta-2 chain 1 35 
O15350 17.45 DP00319 Tumor protein p73  1 1283 
P41851 17.58 DP00725 Type II secretion system protein 
M 
1 130 
P04177 14.66 DP00094 Tyrosine 3-monooxygenase 1 13435 
Q5UPJ7 6.94 DP00726 Tyrosine-tRNA ligase 1 427 
P00952 7.4 DP00095 Tyrosyl-tRNA synthetase 2 491 
P09012 36.88 x U1A 1 337 
P26368 19.58 x U2AF65 1 180 
P0ABJ1 13.97 DP00089 Ubiquinol oxidase subunit 2 4 24 
P0ABI8 4.98 DP00088 Ubiquinol oxidase subunit 1 2 38 
Q16222, 
Q16222-2 
7.09, 
6.73 
DP00363, 
DP00363_A002 
UDP-N-acetylhexosamine 
pyrophosphorylase 
1 4 
O75385 26.38 x ULK1 1 276 
P83949 19.54 DP00623 Ultrabithorax AND (N-terminal 
OR N-terminus OR C-terminal OR 
C-terminus)  
3 29 
Q9GSG8 16.53 x ultraspiracle AND "aedes aegypti" 1 20 
P38293 31.08 x Ump1 2 37 
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P0AG11 6.47 DP00626, 
DP00626_C001 
UmuD 1 289 
P60472 9.88 DP00516 Undecaprenyl pyrophosphate 
synthetase 
1 59 
Q9HAU5 34.12 x UPF2 1 137 
P23202 21.75 DP00353 URE2 3 265 
Q9RP19 8.53 DP00367 (UreG OR urease accessory 
protein) 
7 154 
P06132 10.9 DP00308 Uroporphyrinogen decarboxylase 2 613 
P54725 39.12 DP00156 UV excision repair protein RAD23 
homolog A 
1 8 
Q8QXJ6 22.02 x vanilla mosaic virus coat protein 1 5 
B4F3C5 7.93 x VapD 1 29 
P12003-1 28.24 DP00556 Vinculin 1 3131 
Q9MA75 45.75 x VIP1 1 154 
Q98157 9.57 DP00685 Viral macrophage inflammatory 
protein 2 
1 117 
P11473 17.8 DP00184 ("Vitamin D3 receptor") 1 200 
P07293 5.55 DP00228 Voltage-dependent L-type 
calcium channel subunit alpha-1S 
1 9 
Q14722-2 7.48 DP00090 Voltage-gated potassium channel 
subunit beta-1 
1 57 
P40337 34.74 DP00287 Von Hippel-Lindau disease tumor 
suppressor  
1 1064 
Q05323 18.4 DP00627 VP30 1 72 
P51610 25.06 x VP16 AND transcription factor 
activator 
1 439 
P03305 11.41 DP00573_C004 VP2 foot-and-mouth disease virus 1 123 
P03305 11.41 DP00573_C006 VP1 foot-and-mouth disease virus 1 888 
P03305 11.41 DP00573_C005 VP3 foot-and-mouth disease virus 1 140 
Q85197 4.81 x VPg AND “potato virus”  2 57 
P03305 11.41 DP00573_C003 VP4 protein 1 1453 
Q730H9 10.58 x Vpr AND "Bacillus cereus" 1 3 
P03520 31.32 x (VSVP OR vesicular stomatitis 
virus phosphoprotein) 
1 327 
Q9NZQ3 21.05 x (WASP interacting protein OR 
WIP(C)) 
2 87 
P42768 44.42 DP00215 (WASP OR Wiskott-Aldrich 
syndrome) AND protein AND (C-
terminus or C-terminal) 
6 220 
O15213 32.13 x WDR46 1 4 
P30291 33.59 DP00611 Wee1 1 772 
Q14191 15.64 DP00443 Werner syndrome ATP-dependent 
helicase 
1 16 
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P06935 1.75 DP00673, 
DP00673_C001 
west nile virus AND (capsid 
protein C OR polyprotein) 
1 100 
x x x WSK3 1 1 
P80457 5.71 DP00450 Xanthine AND (dehydrogenase OR 
oxidase) 
1 13452 
Q23229 23.02 DP00361 XO lethal protein 1 1 10 
P27088 37.83 DP00091 XPA AND DNA 1 858 
P0A8H9 38.46 DP00202 yacG 1 6 
Q6PKI6 59.02 x (YB-1 OR “Y Box binding protein 
1” OR YBX1)  
2 915 
P23292 28.02 x Yck2 kinase 1 32 
P69346 28.92 x YefM 3 27 
Q7CJN0 3.85 DP00275 Yersinia crystallin 2 3 
P31493 26.48 x YopE 1 250 
P46937 51.59 DP00702 (Yorkie homolog OR YAP1) 2 672 
P20963 38.41 x (zetacyt OR T-cell surface 
glycoprotein CD3 zeta chain) 
1 709 
O95405 17.19 DP00141 Zinc finger FYVE domain 
containing protein 9 
1 1 
O00488 58.96 DP00549 Zinc finger protein 593 1 15 
Q9H2S9 45.47 DP00376 Zinc finger protein Eos 1 19 
P77173 42.07 DP00161 ZipA 2 110 
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Name PMIDs 
2,4-dienoyl-CoA reductase 15531764 
5-Aminolevulinate synthase (ALAS) 25240868 
ABL tyrosine kinase 17211892 
acetylcholinesterase variant, AChE-R 20173328, 23908786 
acylphosphatase 24893801, 20223823, 18832052, 18451804, 16287076, 
14872538, 9790846 
adenylate cyclase toxin 19860484, 20096704, 21416544, 24145447 
alphavirus capsid protease 25100849, 9094737 
aminoglycoside 6'-N-
acetyltransferase type Ii 
16131761 
anhydrin 20805515 
apo-DCpS 15769464 
ARG tyrosine kinase 17211892 
arginine kinase 21075117 
bacillus lipase 25001212 
bacterial luciferase mobile loop 21156144 
BCR-ABL tyrosine kinase 22632137 
calcineurin, CaN 22100452 
cathepsin F 23684953 
CCT, phosphocholine 
cytidylytransferase 
21303909, 24397368, 23238251, 22988242 
Cel7a, Trichoderma reesi family 7 
cellobiohydrolase 
21112302, 23959893 
colicin E9 15004032, 16114886, 16166265, 17375930, 18573254, 
19021565, 22310049, 23672584, 23812713 
c-Src kinase 19520085, 25071818, 23744817 
Dbp5p, DEAD-box protein 5 19281819, 24045937, 21884706 
dihydroorotase, DHO 19128030 
Dnmt1 25533200, 20352123, 19923434 
E2 enzymes sub-family 3R 22507829 
E2-C 10350465 
EcoO109I 19348764 
Table D1 Intrinsically disordered enzymes 
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epidermal growth factor receptor, 
EGFR, EGFR kinase domain 
15840573, 22579287 
ErbB2 receptor tyrosine kinase 24815698 
firefly luciferase 19119851, 19492113, 20221465 
FtsZ 25305578, 23714328, 23692518, 23692518 
glucokinase 23271955 
glycolate oxidase 8706682, 18215067 
hammerhead ribozyme 10802069, 21740954 
HDAC4 18614528 
Hef 24947516 
hepatitis B polymerase 23202419 
HIV-1 protease 10739910, 15572155, 17243183 
hsp90 atpase 22660624 
inteins 16288917, 24236406 
lombricine kinase, phosphagen 
kinase family 
15327979, 21212263, 20121101, 21212263 
Lysyle oxidase  20192271 
Metallo beta lactamase 19395380 
mGIP/SCP1 24751520, 24925644 
multidomain polymerase protein 25297996 
myosin II heavy chaine kinase B 20199682 
NEIL1 22902625, 23542007 
Nickel Superoxide dismutase 25580509 
NS3, non structural protein 3 from 
hepatitis C virus 
23803659, 21112306, 9223519, 24752801 
Ntrc1 16169010 
nuclease colicin 15004032 
nudix hydrolase 20657662 
ornithine decarboxylase 10623504, 23684952 
p1 protease 24603811 
p300 acetyltransferase 17438265, 23133622, 23307074, 24253305 
PAM, peptidylglycine alpha-
amidating monooxygenase 
19635792 
PfTIM, triosephosphate isomerase 19914198, 15465054 
Phototropin 2 21222437 
PKS, modular polyketide synthase 22282160, 9166770 
polyphenol oxidase  16332393 
protein kinase A 17222345, 23946424, 24192038, 25112875 
protein kinase C alpha V5 domain 23762412 
protein kinase R, PKR 19232355 
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PTP1B/PTPN1 17643420, 24845231 
RelA/SPoT 24717772 
retinal phosphodiesterase gamma 
subunit 
12643535, 18230733, 19075750, 21393250, 21978030, 
22514270 
Ribonuclease A 9689069 
Ribonuclease P 11258888, 11749217, 20476778 
RNA polymerase 25261014 
Rnase E 12947103, 15236960, 16094605, 16516921, 17447862, 
19215771, 20952404, 25432321 
Rnase P 11258888, 20476778, 15518563 
Rnase Y 21803996 
San1, PQC ubiquitin ligase  21211726, 23363599, 21551067, 21941105 
selenoprotein k 22963794 
selenoprotein methionine sulfoxide 
reductase B1, MsrB1 
20605785 
selenoprotein s, VIMP reductase 23566202, 23914919, 22700979 
sgs1 helicase 24038467 
sirt1, sirtuin family 23497088, 23811471, 24020004 
sortase 22468560 
src family kinase 25071818 
SRPK1 21600902 
Sso Acp 24893801 
sulfhydryl oxidase ALR 23207295 
TAFI 18722183 
Tbsp1 23192346 
TgGCN5 family histone 
acetyltransferases 
21055425 
thrombin 21782041 
thymidylate synthase 16259621, 14967037, 19797058, 20815815, 21878626, 
23181752, 23684952 
TPPP/p25 21995432 
Type IA topoisomerases 18186484 
Ube2w E2 25436519 
Upb10 26149687 
UreG 15542602, 17309280 
Vpr, feather degrading minor 
extracellullar protease 
19383694 
xylanases 25576604 
yck2 kinase 21653825 
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1. Moral rights, such as the right of integrity, are not licensed under this Public 
License, nor are publicity, privacy, and/or other similar personality rights; 
however, to the extent possible, the Licensor waives and/or agrees not to 
assert any such rights held by the Licensor to the limited extent necessary to 
allow You to exercise the Licensed Rights, but not otherwise. 
2. Patent and trademark rights are not licensed under this Public License. 
3. To the extent possible, the Licensor waives any right to collect royalties from 
You for the exercise of the Licensed Rights, whether directly or through a 
collecting society under any voluntary or waivable statutory or compulsory 
licensing scheme. In all other cases the Licensor expressly reserves any right to 
collect such royalties. 
Section 3 – License Conditions. 
Your exercise of the Licensed Rights is expressly made subject to the following conditions. 
a. Attribution. 
1. If You Share the Licensed Material (including in modified form), You must: 
A. retain the following if it is supplied by the Licensor with the Licensed 
Material: 
i. identification of the creator(s) of the Licensed Material and any 
others designated to receive attribution, in any reasonable 
manner requested by the Licensor (including by pseudonym if 
designated); 
ii. a copyright notice; 
iii. a notice that refers to this Public License; 
iv. a notice that refers to the disclaimer of warranties; 
v. a URI or hyperlink to the Licensed Material to the extent 
reasonably practicable; 
B. indicate if You modified the Licensed Material and retain an indication 
of any previous modifications; and 
C. indicate the Licensed Material is licensed under this Public License, and 
include the text of, or the URI or hyperlink to, this Public License. 
2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner 
based on the medium, means, and context in which You Share the Licensed 
Material. For example, it may be reasonable to satisfy the conditions by 
providing a URI or hyperlink to a resource that includes the required 
information. 
3. If requested by the Licensor, You must remove any of the information required 
by Section 3(a)(1)(A) to the extent reasonably practicable. 
4. If You Share Adapted Material You produce, the Adapter's License You apply 
must not prevent recipients of the Adapted Material from complying with this 
Public License. 
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Section 4 – Sui Generis Database Rights. 
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the 
Licensed Material: 
a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, 
reproduce, and Share all or a substantial portion of the contents of the database; 
b. if You include all or a substantial portion of the database contents in a database in 
which You have Sui Generis Database Rights, then the database in which You have Sui 
Generis Database Rights (but not its individual contents) is Adapted Material; and 
c. You must comply with the conditions in Section 3(a) if You Share all or a substantial 
portion of the contents of the database. 
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations 
under this Public License where the Licensed Rights include other Copyright and Similar 
Rights. 
Section 5 – Disclaimer of Warranties and Limitation of Liability. 
a. Unless otherwise separately undertaken by the Licensor, to the extent possible, 
the Licensor offers the Licensed Material as-is and as-available, and makes no 
representations or warranties of any kind concerning the Licensed Material, 
whether express, implied, statutory, or other. This includes, without limitation, 
warranties of title, merchantability, fitness for a particular purpose, non-
infringement, absence of latent or other defects, accuracy, or the presence or 
absence of errors, whether or not known or discoverable. Where disclaimers of 
warranties are not allowed in full or in part, this disclaimer may not apply to You. 
b. To the extent possible, in no event will the Licensor be liable to You on any legal 
theory (including, without limitation, negligence) or otherwise for any direct, 
special, indirect, incidental, consequential, punitive, exemplary, or other losses, 
costs, expenses, or damages arising out of this Public License or use of the 
Licensed Material, even if the Licensor has been advised of the possibility of such 
losses, costs, expenses, or damages. Where a limitation of liability is not allowed in 
full or in part, this limitation may not apply to You. 
c. The disclaimer of warranties and limitation of liability provided above shall be 
interpreted in a manner that, to the extent possible, most closely approximates an 
absolute disclaimer and waiver of all liability. 
Section 6 – Term and Termination. 
a. This Public License applies for the term of the Copyright and Similar Rights licensed 
here. However, if You fail to comply with this Public License, then Your rights under 
this Public License terminate automatically. 
b. Where Your right to use the Licensed Material has terminated under Section 6(a), it 
reinstates: 
1. automatically as of the date the violation is cured, provided it is cured within 
30 days of Your discovery of the violation; or 
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2. upon express reinstatement by the Licensor. 
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor 
may have to seek remedies for Your violations of this Public License. 
c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under 
separate terms or conditions or stop distributing the Licensed Material at any time; 
however, doing so will not terminate this Public License. 
d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License. 
Section 7 – Other Terms and Conditions. 
a. The Licensor shall not be bound by any additional or different terms or conditions 
communicated by You unless expressly agreed. 
b. Any arrangements, understandings, or agreements regarding the Licensed Material not 
stated herein are separate from and independent of the terms and conditions of this 
Public License. 
Section 8 – Interpretation. 
a. For the avoidance of doubt, this Public License does not, and shall not be interpreted 
to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material 
that could lawfully be made without permission under this Public License. 
b. To the extent possible, if any provision of this Public License is deemed 
unenforceable, it shall be automatically reformed to the minimum extent necessary to 
make it enforceable. If the provision cannot be reformed, it shall be severed from this 
Public License without affecting the enforceability of the remaining terms and 
conditions. 
c. No term or condition of this Public License will be waived and no failure to comply 
consented to unless expressly agreed to by the Licensor. 
d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, 
or waiver of, any privileges and immunities that apply to the Licensor or You, including 
from the legal processes of any jurisdiction or authority. 
Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons 
may elect to apply one of its public licenses to material it publishes and in those instances 
will be considered the “Licensor.” The text of the Creative Commons public licenses is 
dedicated to the public domain under the CC0 Public Domain Dedication. Except for the 
limited purpose of indicating that material is shared under a Creative Commons public license 
or as otherwise permitted by the Creative Commons policies published 
at creativecommons.org/policies, Creative Commons does not authorize the use of the 
trademark “Creative Commons” or any other trademark or logo of Creative Commons without 
its prior written consent including, without limitation, in connection with any unauthorized 
modifications to any of its public licenses or any other arrangements, understandings, or 
agreements concerning use of licensed material. For the avoidance of doubt, this paragraph 
does not form part of the public licenses 
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